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Abstract 
Résumé: Ce travail décrit d'abord l’élaboration de nanogels hydrophiles stimulables, sensibles à 
un changement de pH et à un environnement où les propriétés d’oxydo-réduction peuvent varier. 
Ils ont été synthétisés en milieu dilué, d’une part, et en émulsion inverse, d’autre part; dans les 
deux cas à partir d’un copolymère statistique composé d’unités 2-éthyl-2-oxazoline et éthylène 
imine. Ces nanogels n’ont pas montré d’interactions spécifiques avec des protéines telles que la 
BSA et se sont avérés non-toxiques in vitro. Une plateforme à base d’un copolymère POx 
statistique porteur de fonctions aldéhydes a par ailleurs permis d’accéder à une librairie de POx, 
incluant des structures greffées et réticulées. Enfin, l’auto-assemblage en solution d’un 
copolymère à blocs de type poly(2-methyl-oxazoline)-b-poly(2-isopropyl-2-oxazoline) (PMeOx-
b-PiPrOx), a été étudié en détail. Des micelles ont été observées à des temps courts au-dessus du 
point trouble du PiPrOx. Pour des temps plus longs, la formation de fibres et de micelles 
réticulées physiquement ont été mise en évidence, comportement expliqué par la cristallisation 
des chaines de PiPrOx stabilisées par les blocs PMeOx hydrophiles. 
Mots clés: poly(2-oxazoline), nanogel, hydrogel, stimulable, cristallisation, point trouble, 
aldehyde, cytotoxicité. 
 
Abstract: This PhD work is based on the design of poly(2-oxazoline) (POx) hydrogels and 
nanogels, by chemical or physical cross-linking, aimed to be used for biomedical applications. 
Nanogels were first prepared in dilute media and in inverse emulsion based on a statistical 
copolymer made of 2-ethyl-2-oxazoline and ethylene imine units. These stimuli-responsive 
nanogels were swelling in acidic media and were cleaved in reductive environment. They proved 
to be non-cytotoxic and act as protein repellent. Second, a reactive platform based on a statistical 
POx polymer bearing aldehyde functionalities was engineered, enabling the synthesis of graft and 
cross-linked POx. Last, a block copolymer made of 2-methyl- and 2-isopropyl-2-oxazoline units, 
proved to self-assemble into micelles when heated above its LCST, for a short period of time (< 
1h30). When annealed for a longer time (> 1h30), crystallization-driven self-assembly led to the 
formation of different morphologies (fiber rods and cross-linked micelles). 
Keywords : poly(2-oxazoline), nanogel, hydrogel, responsive, crystallization, LCST, post-
polymerization modification, aldehyde, cytotoxicity, protein repellent. 
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 1 
GENERAL INTRODUCTION 
Hydrogels are a broad class of cross-linked polymeric networks, which often extensively swell in water 
or biological fluids while maintaining their three-dimensional (3D) structure.1 Because of their high water 
content, hydrogels are most of the time biocompatible and have been widely developed and used in 
biomaterial sciences. Since the first biocompatible hydrogel reported in 1960,2 Their use as biomaterials 
has evolved from static implants and devices to dynamic, bio-responsive scaffolds, drug delivery vehicles 
and cell culture platforms for regenerative medicine. As for nanogels, they are defined as soluble polymer 
networks with a dimension smaller than 100 nm,3 and display the same structural features as hydrogels. 
Nanogels have been proposed as robust drug delivery systems (DDS);4 the current trend in the field 
being to introduce both responsiveness and targeting properties in theses nanocarriers.  
Thanks to the increasing knowledge in polymer engineering, environment-stimuli responsive hydrogels 
and nanogels are now accessible.5,6 Depending on the polymer and cross-linker used, hydrogels/nanogels 
can, for example, be made responsive to pH or temperature changes. They can also exhibit an “on and 
off” response, depending on fluctuating properties, in order to answer to more precise and specialized 
needs, as it is the case to glucose concentration.7–10  
In the past decades, the use of polymeric materials has increased dramatically for biomedical applications. 
The main used polymers – polyether,11 polyesters,12 polycarbonates13 and polypeptides14 - are 
biocompatible, the unconditional properties for biomedical applications. Another important feature in 
this field is the will to develop synthetic polymers with chemical structures as close as possible to natural 
polypeptides and proteins, in order to obtain bio-mimicking functional biomaterials. Synthetic peptide-
based polymers are actually not new,15 but one of the current trend is to go towards increasingly 
complex polymer sequences that would display tunable properties, while presenting excellent 
biocompatibility and offering some potential biofunctionalities.  
The major goal of this PhD thesis work was to design responsive hydrogels and nanogels made from a 
specific class of polymers - poly(2-oxazoline)s (POx) - for biomedical applications. POx are, however, still 
relatively new in comparison to other polymers already established for such a use, but they definitely fall 
within this approach. POx are synthesized by living cationic ring opening polymerization, and are 
described as pseudo-polypeptides because of their similar structure. Nevertheless, the presence of 
tertiary amides in POx makes them more chemically and enzymatically stable than polypeptides, while 
having a similar biocompatibility.16  
2 
POx prove fully competitive as biocompatible hydrophilic polymer alternatives of poly(ethylene glycol) 
(PEG), poly(vinyl pyrrolidone) (PVP), and poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA) for 
biomedical uses.17 More especially poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) 
(PEtOx) are often compared to PEG because they present the same stealth behavior towards plasmatic 
protein. 
In addition to their advantageous biological properties, POx are chemically versatile allowing the 
synthesis of tailor-made polymers and copolymers with tunable properties. Finally, POx interests are not 
only recognized by researchers in Academia but also by the chemical industry: a pharmaceutical 
company, Serina therapeutics, is currently creating new pharmaceutical candidates using poly(2-
oxazoline)s for Parkinson’s disease, cancer, inflammation, pain and metabolic disorders.18 
 
In this context, we propose, in this work, to expand the POx toolbox towards the design of functional 
POx-based hydrogels and nanogels that are chemically or physically cross-linked, for possible biomedical 
applications. Different oxazoline monomers will be used, yielding (co)polymers with various chemical 
handles and/or properties.  
This manuscript is composed of five chapters. First, a literature review on engineering of POx and their 
use in biomedical applications is presented. The second chapter will describe the design of dual-stimuli 
responsive hydrogels and nanogels made from partially hydrolyzed POx. The third chapter is devoted to 
the crystallization driven self-assembly of a particular diblock copolymer, namely poly(2-isopropyl-2-
oxazoline)-block-(2-methyl-2-oxazoline) copolymer; the manipulation of which can lead to the formation 
of different nanostructures. In the fourth chapter, the expansion of the POx toolbox by post-
polymerization modification of ketal and aldehyde-functionalized POx, which could be further used to 
3 
prepare hydrogels, so as will be exploited. In the last chapter, the optimization of POx nanogels 
presented in the first chapter to meet the specific needs of a drug delivery system, and their evaluation in 
term of cytotoxicity and interactions with proteins will be discussed.  
 
This PhD work was carried out in the framework of a collaboration between three universities: the 
University of Bordeaux in the Laboratoire de chimie des polymères organiques (LCPO, France), the 
University of Waterloo (Canada) and the University of Liège (Belgium). It was part of the International 
Doctoral Programme in Functional Materials (IDS FunMat), with an Erasmus Mundus scholarship. 
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INTRODUCTION 
The aim of this literature review is to give to the reader the key elements for a critical reading of this 
PhD manuscript. This chapter is dedicated to the scope and applications of engineered poly(2-
oxazoline)s (POx, Scheme 1). The living cationic ring opening polymerization (CROP) leading to POx 
has been discovered more than 50 years ago by 4 different research teams simultaneously and since 
then, this special class of polymers has been studied meticulously, giving rise to versatile polymeric 
materials. However, it is only since 15 years, with the discovery of their remarkable properties for 
biomedical applications and their thermo-responsiveness, that POx arouse increasing interest by the 
scientific community. POx are now considered as smart bioinspired polymers,1 with an ability to 
form functional materials and nanostructures with tunable properties,1–3 leading to numerous 
applications.3 POx are claimed to be used in adhesives,4 coatings5,6 or ink formulations7 as well as in 
drug delivery applications.8,9 The reader should be advised that the former applications are out of the 
scope of this literature review but related information can be found elsewhere.4–9 
 
Scheme 1 Poly(2-oxazoline)s general structure 
First, the remarkable properties of POx making them attractive candidates for biomedical 
applications will be presented. Second, a description of the polymerization mechanism, and potential 
issues which could be encountered, will be discussed. In the third part, the POx versatility in terms of 
chemistry and properties will be illustrated through selected examples. A special focus will also be 
placed on the design of POx-based hydrogels, as this category of materials has been the main topic of 
this PhD thesis. In the last part, the use of POx as polymer therapeutics will be briefly reviewed, with 
a special emphasis on both self-assembled nano-structures (micelles, polymer vesicles and polyplexes) 
and nanogels.  
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I. ADVANTAGEOUS PROPERTIES OF POLY(2-OXAZOLINE)S FOR 
BIOMEDICAL APPLICATIONS 
I.1. BIOCOMPATIBILITY STUDIES 
POx are often viewed as amino-acid analogues3 or as pseudo-polypeptides, where each repeating unit 
contains a peptide bond, albeit on the side instead of the main chain (Scheme 2). One can thus 
expect POx to be biocompatible. In addition, poly(2-ethyl-2-oxazoline) (PEtOx) has been approved 
by the Food and Drug Administration (FDA) as an indirect additive used in food contact substances,10 
which was the case for poly(ethylene glycol) (PEG) before being accepted in pharmaceutical 
formulations. 
 
Scheme 2 Analogy between poly(2-oxazoline)s and synthetic or naturally occurring polypeptides3 
In order to evaluate the biocompatibility of both homopolymers and block copolymers based on 
POx, a series of studies has to be conducted. First, in vitro studies should be carried out, in order to 
check the cytotoxicity of POx on different cell lines as well as their hemocompatibility and cell 
internalization. If in vitro tests are conclusive, in vivo evaluation should be realized with a 
pharmacokinetic study (i.e. the study of the fate of the polymer in the body), and the biodistribution 
evaluation.  
First, an in vitro cytotoxicity study was conducted on a library of homopolymers and block 
copolymers based on POx, showing  that POx were well tolerated at polymer concentrations up to 
20 mg/mL,11  and even up to 80 mg/mL for PEtOx.12 
The POx molar mass also influenced cytotoxicity: the higher the molar mass, the lower the cell 
toxicity.12,13 POx purity matters too, as monomers appeared to be toxic.13 
Hemocompatibility evaluation of PEtOx with molar masses of 5, 10, and 20 kDa, at a polymer 
concentration up to 10 mg/mL, showed no adverse effect on red blood cells.14 Other studies 
reported even better blood compatibility with no damaging effect on red blood cells, regardless of 
the poly(2-methyl-2-oxazoline) (PMeOx) and PEtOx molar mass, and up to a concentration higher 
than that typically used in biomedical application (up to 80 mg/mL).12,15 More recently, zwitterionic 
POx (i.e. a globally neutral POx polymer but with positive and negative electrical charges along the 
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chain) were reported to not only exhibit high hemocompatibility and low cytotoxicity, but also a 
beneficial anticoagulant activity.16 
A cellular uptake study was also conducted on a POx library, at a polymer concentration below the 
critical micellar concentration.11 The results suggested that amphiphilic POx could efficiently enter 
cells. All polymers studied were water-soluble (> 100 g/L), but the more hydrophobic the polymer, 
the more readily it could enter the cell.11,12 PEtOx, which is one of the most water-soluble systems, 
displayed a low endocytosis (molecules absorption by the cells by engulfing them). Moreover, it was 
observed that the length of the hydrophilic block had no influence on cellular uptake, but it depended 
on the polymer concentration and on temperature (cellular uptake decreased when the temperature 
was increased).  
In vivo studies were conducted on PMeOx and PEtOx that were radio-labelled and injected into mice 
and both polymers were rapidly cleared from the body.17,18 PEtOx was safe when administered 
intravenously, and the maximum tolerated dose corresponding to a unique injection (MTD) was 
greater than 2 g/kg.14 However, in case of multiple intravenous injections, 20 kDa PEtOx appeared to 
be safe and non-toxic if injected every 2 days at doses of up to 50 mg/kg over a period of 2 
weeks.19,20 
In terms of biodistribution and cytotoxicity, POx were compared to other commonly used polymers, 
such as poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) or PEG.18,21  
In vivo POx pharmacokinetics have not been studied yet, but some in vitro studies suggested that 
PEtOx was not subjected to enzymatic degradation. First, a biodegradation study of PEtOx by 
Proteinase K, a non-human enzyme, was achieved via incubation.22 A partial hydrolysis reaction 
occurred at the amide bond, leading to the formation of a statistical copolymer made of PEtOx and 
poly(ethylene imine) (PEI, Scheme 3) and ultimately to linear PEI.  
 
Scheme 3 Poly(2-ethyl-2-oxazoline) degradation by Proteinase K 
Nevertheless, in vitro studies showed that the lower the percentage of linear PEI, the lower the 
cationic charge density.23,24  In such cases, a better cell viability was also observed,23,24 and even until 
10% of hydrolysis no cytotoxicity was detected.25 More recently, PEtOx degradation in presence of 
digestive enzymes and in an acidic environment, mimicking physiological conditions, revealed that 
PEtOx did not undergo hydrolysis.25 As a consequence, POx are most often described as non-
biodegradable polymers because only hydrolytic and proteolytic (enzymatic) degradation are 
Chapter 1 
	  
	  12	  
	  	  
 
considered. However, a recent study by Luxenhofer et al. showed that POx were prone to oxidative 
degradation under physiologically relevant conditions.26 The generation of reactive oxygen species 
(ROS) led to a pronounced time and concentration dependent degradation, and in vivo degradability 
seemed feasible. In addition, there is a plethora of ROS in the body (mainly produced in 
mitochondria, a special sub-units found within eukaryotic cells), which could lead to oxidative stimuli 
system. 
I.2. STEALTH BEHAVIOR AND PROTEIN REPELLENT ACTION OF POLY(2-
OXAZOLINE)S  
PMeOx and PEtOx are not only compared to PEG because of their similar properties in the 
therapeutic relevant dosage range (i.e. non-toxicity and hemocompatibility properties), but most 
importantly because all these polymers exhibit a stealth behavior. “Stealth” nanoparticles are defined 
as possessing properties that allow them to evade clearance by the body and remain in circulation for 
extended periods of time. Their extended presence in the bloodstream allows for a greater 
percentage of compound cargo to reach target tissue, as well as to provide more consistent dosing 
of the tissue.  
The stealth behavior of PMeOx and PEtOx was first reported in 1994 by Woodle et al.27 who studied 
the fate of PMeOx or PEtOx coated liposomes injected into rats. The coated liposomes showed 
dramatic reticuloendothelial system (RES)-evasion and prolonged blood circulation effects compared 
to uncoated liposomes, which had a short blood lifetime and accumulated in the RES (Figure 1).  
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Figure 1 A) Blood circulation time and B) Biodistribution of liposomes coated with poly(ethylene glycol) 
(PEG), poly(2-ethyl-2-oxazoline) (PEtOx), poly(2-methyl-2-oxazoline) (PMeOx) and of uncoated liposomes, 
egg phosphatidyglycerol (EPG). Adapted from ref. 27 
Moreover, with the POx coated liposomes, the pharmacokinetics were dose-independent. The blood 
circulation time and biodistribution were compared between POx and PEG coated liposomes. The 
results showed that both systems presented the same stealth behavior, as confirmed by another 
study by Zalipsky et al.28 
The stealth behavior of PEG is due to a steric stabilization effect because PEG chains are mobile, 
present conformational flexibility and water binding ability.28 PMeOx and PEtOx possess similar 
solution properties and flexibility, the chain backbone of both polymers being composed of carbon-
carbon bonds featuring one heteroatom.28  
As a consequence, POx are increasingly regarded as a good alternative to PEG.12,29–31 PEGylated 
systems have been in the market for more than 20 years,20 mainly with protein PEGylation 
applications (i.e. attachment of PEG to a protein), as it enhances the permeability and retention effect, 
increases the biodistribution, the cellular targeting and the solubility of insoluble drugs in water or of 
enzymes in organic solvents due to its amphipatic properties.32 The new challenge is to be able to 
have site-selective PEGylation to increase the degree of homogeneity and to preserve the 
bioactivity.33 However, because of this intensive use of PEG, PEGylated systems lose their function 
when placed in vivo because of specific and nonspecific recognition of PEG by the immune system. 
Specific antibodies were detected in the serum of patients treated with PEG-asparaginase and PEG-
uricane. Anti-PEG antibodies were also identified in the case of patients who never received 
treatment based on PEG, due to the presence of PEG in food products.34 These antibodies have a 
neutralizing effect and cause the loss of therapeutic efficacy.35 
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Similarly to POx, PEG is described as a non-biodegradable (hydrolytic and enzymatic wise) polymer, 
but it is actually more sensitive to oxidative degradation than POx and the products resulting from 
the oxidative degradation of PEG were found to be toxic in humans.20  
Another disadvantage of PEG is its low drug content when used as a bioconjugate, as the only way to 
attach a drug molecule to a PEG chain is through the end functionalities. In contrast, due to the 
versatility of 2-oxazolines, such as in 2-oxazoline monomers bearing a functional group on their side 
chain, several drug molecules can eventually be coupled to the polymer chain. In addition, the end 
functionality can even be used to attach another active compound such as targeting moieties. POx 
functionalization will be discussed in greater details in section III of this chapter.  
Last but not least, POx are less viscous than PEG, which makes the pharmaceutical formulation 
easier.36 
The protein repellent action of POx is a direct consequence of their stealth behavior. It has been 
studied for comb-polymers made from a poly(L-lysine) backbone and PMeOx side chains (PLL-g-
PMeOx),35 deposited on negatively charged surfaces, forming a polymer coating. This coating was 
then exposed to human serum albumin (HSA), and the adsorption of protein was monitored by 
optical spectroscopy that allowed in situ measurement of the surface immobilization of biomolecules 
in an aqueous environment. Even after several exposure cycles to HSA, no mass uptake was 
observed, indicating that protein adsorption was below the detection limit of the instrument (< 2 
ng/cm²). Similar results were obtained for PEG-based systems. These results were corroborated with 
other POx architectures, such as polymer brushes,29 bottle-brush brushes copolymers,37 capsules,38 
hydrogels,39,40 or amphiphilic POx-based block copolymers41 where POx always presented a protein 
repellent character. Some compounds also showed an antimicrobial activity (i.e. bacteria repellent)29 
and were even cell repellent,37,39 leading to low or non-fouling systems. 
POx brushes were compared to the equivalent PEG brushes, and it appeared that the coating made 
of POx brushes had a better stability under physiological conditions, especially in an oxidative 
environment. In addition, the degradation of PEG surfaces under oxidation conditions led to protein 
adsorption.29 
Both POx architecture and composition are also of great importance: PLL-g-PMeOx brushes 
prevented protein adsorption and suppressed bacterial surface adhesion,29 whereas linear PEtOx and 
poly(2-nonyl-2-oxazoline) (PNonOx) showed no antimicrobial activity.42 Concerning the 
composition, it was shown that the more hydrophilic the system (i.e. the POx used), the better the 
non-fouling properties.37 Anti-microbial activities were also increased with the POx percentage of 
hydrolysis.42 
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To summarize, POx, and especially PMeOx and PEtOx, proved non-toxic to cells, hemocompatible 
and internalized by cells. In vivo, they presented the same stealth behavior as PEG and could also be 
used as protein repellent. Last, studies on their in vitro degradation showed that POx were not 
sensitive to hemolytic or enzymatic degradation under physiological conditions, but could be cleaved 
by oxidative degradation under the same conditions leading to a possible degradable polymer. POx 
thus appears as valuable competitors in terms of biological properties compared not only to PEG, but 
also to other hydrophilic polymers used in biomedical applications, such as poly(vinyl pyrrolidone) 
(PVP), or polymethacrylamides.43 
II. SYNTHESIS OF POLY(2-OXAZOLINE)S 
2-Oxazolines represent a special class of 5 membered cyclic imino-ethers. Their “controlled/living” 
polymerization was discovered in 1966 by four different research groups simultaneously.44–47 Since 
then, their ring-opening polymerization (ROP) has been described in several reviews48–50 and book 
chapters.51 Scheme 4 shows the general scheme of such a ROP of 2-substituted-2-oxazolines. 
 
Scheme 4 Polymerization of 2-substitued-2-oxazolines 
The first monomers studied in polymerization reactions were 2-methyl-2-oxazoline (MeOx) and 2-
phenyl-2-oxazoline (PhOx).44 These monomers, now with 2-ethyl-2-oxazoline (EtOx), are still the 
most commonly used because of their commercial availability. However a wide variety of 2-
substituted-2-oxazolines can be synthesized through various reaction schemes, such as the reaction 
of nitrile or isocyanides with amino-alcohols, the cyclization of haloamides, etc (Scheme 5). The 
different synthetic ways to 2-substituted-oxazolines were previously reviewed.48,49 
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Scheme 5 Examples of 2-oxazoline monomer synthesis 
II.1. POLYMERIZATION MECHANISM: INITIATION AND PROPAGATION 
The ROP of 2-oxazolines can be initiated by various reagents including Lewis acids (BF3, AlCl3,), 
strong protic acids (HClO4, HBr, H2SO4,), oxazolinium salts,51 strong cationic Bronsted acids,52 or 
more generally X of an electrophile RX, where the X typically stands for p-toluenesulfonate (OTs), 
trifluoromethanesulfonate (OTf), or Br, Cl or I. Polymerization can be conducted in relatively polar 
aprotic solvents, such as dimethylformamide (DMF), dimethylacetamide (DMAc) or in bulk, but the 
most commonly used solvent is acetonitrile (CH3CN).  
The termination agent has to be a nucleophilic species possessing a greater electron donating 
capacity than that of the monomer. Most common nucleophiles are water, alcohols or secondary 
amines (like piperidine).  
The choice of initiator and termination agent will thus determine the end functionalization of the 
polymer chain and will be discussed in greater detail in section III.  
Depending on the nucleophilic reactivity of the counter anion arising from the initiator, two different 
mechanisms, namely, the cationic and the covalent mechanism, can operate (Scheme 6).49,53 In the 
case of a cationic ROP, an electrophile species initiates the reaction, creating a cationic oxazolinium 
propagating species. The polymerization reaction corresponds to the nucleophilic attack of the 
subsequent monomer resulting in a ring opening step. Termination can be achieved by the addition of 
an external nucleophilic species. However, when an initiator generating a stronger nucleophile is 
used, the polymerization proceeds via covalent-bonded species. In this case, the 2-oxazolinium ring is 
eventually opened by the counter anion that has a higher nucleophilicity than the monomer. Last, 
when the nucleophilicity of the monomer and of the counter anion of the initiator are comparable 
both mechanisms can coexist. 
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Scheme 6 Polymerization mechanisms 
The reaction of the oxazolinium salt with the counter ion in the covalent mechanism is comparable 
to the termination reaction of the cationic mechanism. However, the covalent species proceed to 
react with the monomer and propagation continues. 
Most of the initiators used currently, such as methyl p-toluenesulfonate (MeOTs) and methyl 
trifluoromethanesulfonate (MeOTf), lead to a true cationic polymerization pathway because they give 
rise to stable (less nucleophilic) tosylate and triflate anions, respectively. 
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II.2. POLYMERIZATION MECHANISM: TRANSFER AND TERMINATION BY 
COUPLING 
In the ideal case, the ROP of 2-oxazolines can be controlled, but one has to be aware that some side 
reactions can occur. For instance, a transfer reaction takes place by the abstraction of a proton from 
the R1-carbon atom of the propagating species, by the nitrogen atom of a monomer.54 Consequently, 
a positively charged “activated” monomer and a non-charged polymer with a C=C double-bond are 
formed (Scheme 7). 
 
Scheme 7 Mechanism of chain transfer 
This mechanism has been highlighted by Litt et al. in 1975.54 They demonstrated that the major site of 
chain transfer is the carbon in α-position from the ring. A greater chain transfer is observed for POx 
with activated methylene groups such as 2-benzyl or 2-acetoxymethyl, whereas for polymers such as 
poly(2-isobutyl-2-oxazoline) where the α-methylene group is shielded, the chain transfer is reduced 
(Scheme 8). A greater chain transfer is also observed for PMeOx than for the polymerization of 
other 2-alkyl-2-oxazolines. 
 
Scheme 8 Extent of chain transfer depending on the monomer side-chain 
Once this chain transfer reaction has occurred, the dormant ene-terminated POx chain can act as a 
nucleophilic species via a process called chain coupling, which increases the molecular weight 
(Scheme 9). Nevertheless, the dormant chain being less nucleophilic than the monomer, it reacts 
more slowly, and most of the coupling reaction occurs during the last phase of the polymerization 
reaction.54,55 The mechanism of chain transfer and coupling has been confirmed by Warakomski et 
al.56 
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Scheme 9 Mechanism of chain coupling 
In order to control the polymerization and to avoid such side reactions, specific conditions have to 
be fulfilled, i.e. high purity of monomer, solvent and initiator, low [M]/[I] ratio, a monomer with no α-
hydrogen, and a solvent with no protic hydrogen atoms.56 Another hindrance of the polymerization 
of 2-oxazolines is the rather long reaction time (reactions could last up to several days at 85 °C). 
Consequently, the optimization of the polymerization reaction conditions has been the subject of 
numerous studies, in order to reduce the reaction time. All parameters have to be considered to 
reach the optimum conditions: temperature, solvent, initiator and monomer used, monomer 
concentration, [M]/[I] ratio, and heating process.  
If chain transfer and coupling can be excluded, the polymerization proceeds in a “controlled/living” 
manner, which can be exploited in the design of well-defined systems and for block copolymer 
synthesis as well. In such a case, the concentration of propagating species is constant and the 
polymerization proceeds via a first order kinetic. As a matter of fact, the size exclusion 
chromatography (SEC) trace should be a narrow peak with no shoulder (coupling) or tail (transfer). 
One has to be aware, however, that the nitrogen atoms present on the backbone of the polymer can 
interact with the SEC column materials, and this may also contribute to the tail observed in the SEC 
traces. With the choice of a suitable solvent, such as DMF, most of the interactions with the column 
material can be suppressed.57 
Another interesting parameter that can be used to examine and elucidate the transfer and coupling 
reactions is the color of the reaction medium; it turns from clear to yellowish when chain transfer 
and/or coupling are occurring.58 
II.3. OPTIMIZATION OF THE REACTION PARAMETERS 
In order to study the influence of each parameter, systematic studies (i.e. by varying one parameter at 
a time) have been conducted, mainly by Hoogenboom et al., using an automated synthesizer 
(Chemspeed ASW200)59 allowing to conduct 16 experiments simultaneously and with high 
reproducibility. 
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First, the influence of temperature was studied.58 Sixteen PEtOx were synthesized under the same 
conditions (in DMAc using benzyl bromide as an initiator, with a [M]/[I] ratio of 60 and a reaction 
time of 16h), but the temperature varied between 80 °C to 130 °C. As expected, the reaction rate 
increased with temperature due to the activation energy. The number-average molecular weight 
(𝑀!) obtained from SEC increased linearly at 90 °C and 100 °C. Below 90 °C, no polymerization 
occurred and above 100 °C, it was not well-controlled. 
The influence of temperature was also studied for the CROP of PhOx under the same conditions.60 
Its polymerization was more difficult to initiate than EtOx. With benzyl bromide as the initiator, 
polymerization was observed only at 140 °C and 150 °C and not in a quantitative manner. When 
using MeOTs as the initiator, linear first-order kinetics were obtained with an optimal temperature 
reaction of 130 °C. At lower temperature, the initiation was too slow and not all the polymer chains 
were growing at the same time (dispersity Ð>1.40); at higher temperature, side reactions were 
observed. 
In addition, Park et al. used 2-isopropyl-2-oxazoline (iPrOx) and EtOx to synthesize homopolymers 
and gradient copolymers in acetonitrile, using MeOTs as initiator. They showed that mild 
temperature conditions, i.e. 42 °C, were optimum to avoid chain transfer and coupling (Figure 2).61 
 
 
Figure 2 SEC traces of poly(2-isopropyl-2-oxazoline) prepared at different temperatures. Reprinted from 
ref. 61 
The different POx obtained had a low dispersity (Ð =1.02) showing that the polymerizations were 
well controlled. However, as the temperature was decreased, reaction times were longer: up to 
476.5h to get a PiPrOx with a degree of polymerization (DP) of 86, which represents a severe 
limitation. 
The influence of the initiator was also studied for the CROP of MeOx, EtOx, PhOx and NonOx. The 
polymerization rate matched well with the decrease in nucleophilicity of the counter-ion: methyl 
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triflate (MeOTf) > MeOTs > methyl iodide (MeI) > benzyl bromide (BB).62 However, polymerizations 
initiated with MeOTf or MeOTs exhibited a loss of control, as indicated by a curved first-order 
kinetic behavior. This was ascribed to the fact that more active initiators were more sensitive to 
moisture and other contaminations. 
Monomer concentration was optimized for the CROP of EtOx. The optimal monomer concentration 
was between 4 and 7M when polymerization was conducted at 100°C in DMAc, using BB as the 
initiator, with a [M]/[I] ratio of 60.57 At lower concentration indeed, a deviation from the theoretical 
molecular weight was observed, and the dispersity values were high (between 1.6 and 1.9) with a tail 
at lower molecular weight, due to chain transfer reactions. At higher concentration, a shoulder 
characteristic of chain transfer and coupling was observed on the SEC trace. These differences were 
attributed to differences in the initiation process at low and high monomer concentration, but the 
exact mechanism is still being debated.55 
The reactions were also dependent on the solvent used: polymerization at 80 °C in acetonitrile was 
faster than at 90 °C in DMAc, but lower than at 100 °C in DMAc. This difference could be explained 
by the slightly higher dipole moment of acetonitrile that led to better solvation of the propagating 
oxazolinium rings.62 
The substituent group of the monomer has also a direct influence on the kinetics of the reaction and 
the occurrence of side reactions. The monomer reactivity increases with its nucleophilicity, but it 
also becomes more prone to side reactions.54,63 The higher nucleophilicity of MeOx resulted in a 
slightly faster polymerization rate compared to other monomers (EtOx, PhOx, NonOx). By co-
polymerizing monomers with different reactivities, side reactions could be avoided. For example, 
when MeOx was polymerized at 80 °C in acetonitrile, with MeOTs as an initiator, no polymer with a 
DP superior to 100 could be obtained without the occurrence of chain transfer. When MeOx and 
EtOx were copolymerized, EtOx being less susceptible to side reactions than MeOx, copolymers 
with DP up to 500 were obtained in a controlled manner.64 
Optimal conditions for a better control on the polymerization are thus different from one system to 
another, and the reaction times are still quite long, between 10h and a few days. In 2004, PEtOx was 
synthesized for the first time in a single mode microwave synthesizer, in acetonitrile, using MeOTs as 
the initiator and with a [M]/[I] ratio of 60.65 The reaction rate was significantly increased with 
temperature, as observed in conventional syntheses, but under microwave irradiation the solvent 
boiling point (82 °C for acetonitrile) was no longer a limiting factor as the pressure inside the vial 
also increased (up to 1 bar). Hence, the reaction could be performed even at 200 °C,65 with a 
reaction rate up to 350 faster. Nevertheless, below 100 °C and above 160 °C side reactions were 
still present; the optimal temperature was 140 °C, at which PEtOx synthesis was completed in 10 
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minutes, with a dispersity below 1.10. The living character of the polymerization was also retained at 
all studied temperatures (between 80 and 190°C). A control experiment at 140°C under 
conventional heating in a high pressure vial revealed the same reaction speed, meaning that the 
increase in reaction rate was eventually not linked to any “microwave effect”, the microwave reactor 
being only used as an efficient heating device. The fast and direct heating applied without contact and 
the use of a good microwave absorbing solvent like acetonitrile are thus the keys factors. The 
efficiency of the polymerization under microwave irradiation was later confirmed for other 
homopolymer syntheses (PMeOx, PPhOx, PNonOx), where polymerization was still controlled 
(Ð<1.2) while being up to 400 faster.66 Block copolymer synthesis was also possible under such 
conditions.67 
Thus microwave synthesizers seem to be powerful devices, overcoming the long reaction times 
necessary under conventional heating conditions, while producing polymers in a well-controlled 
manner and yielding products with lower dispersity values.68 This new synthetic approach has 
brought POx to the fore front, and since then, POx research is mainly focused on POx engineering 
and applications. 
III. POLY(2-OXAZOLINE)S: A VERSATILE POLYMER CLASS 
III.1. TAKING ADVANTAGE OF THE LIVING POLYMERIZATION: COPOLYMERS 
SYNTHESIS 
By taking advantage of the “controlled/living” character of the polymerization, statistic and block 
copolymers or even more complex architectures can be readily synthesized. The easiest and widely 
used method to obtain block copolymers is via the “one pot two stages” method where the second 
monomer is added once the first one is consumed.69,70 This method is also refered to as the 
sequential polymerization method. When two different monomers are added simultaneously, the 
composition of the copolymer can be predicted thanks to the reaction rate of each monomer: if the 
reactivities of both monomers are comparable, statistical copolymers are expected64 whereas if one 
monomer is less reactive than the other, gradient copolymers are obtained.61,71 In some cases, block 
copolymers can also be obtained by this method, as it was demonstrated for the synthesis of 
PMeOx-b-(2-heptafluoropropyl-2-oxazolines), on the basis of highly different reactivity between the 
two parent monomers.53 Some examples of statistical, block and gradient copolymers are given in 
Table 1. 
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Table 1 Example of copolymers synthesized in the literature 
Statistical 
rM1 ≈ rM2 
 
 Gradient 
rM1 > rM2 
 
M1 M2 Ref.  M1 M2 Ref. 
  
72 
 
 
 
71 
 
 
73 
 
  
71 
    
  
71 
Diblock 
rM1 >>> rM2 
 
 
M1 M2 Ref. 
 
  
74 
  
53 
 
  
61 
III.2. INTRODUCTION OF FUNCTIONALITIES 
By varying the initiator and termination agents, both α- and ω-chain ends of POx can be 
functionalized. The synthesis of POx with functional handles can also be achieved by resorting to 
specific functional 2-oxazoline monomers (Figure 3). 
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Figure 3 Possible ways to functionalize poly(2-oxazoline)s 
For the scope of this PhD thesis, recent examples of such functionalized POx will be presented. This 
list may not be exhaustive, but synthetic strategies to functionalized POx have been recently 
reviewed.1,43,75 In addition, a patent about chain-end POx functionalization has been filed,76 whereas 
the synthesis of monomers with various substituents was reported in papers.77,78 
III.2.1. IN-CHAIN FUNCTIONALIZATION THROUGH THE USE OF FUNCTIONAL MONOMERS 
The first option to functionalize POx is to directly polymerize a monomer bearing a reactive handle 
(R). Whatever the R group is, the side chain of the monomer may not interfere during the CROP 
process. Consequently, a protecting group has often to be used to avoid any side-reaction of the R 
group with the propagating species. For example, monomers with an unprotected hydroxyl79 or 
amino group80 gave rise to chain transfer leading to the synthesis of branched polymers of high 
dispersity. As illustrated in Table 2, monomers containing alcohol,79 carboxylic acid,79,81,82 amine,83,84 
aldehyde73 or thiol85 functionalities thus require protection in the form of ester groups, tert-
butyloxycarbonyl groups (BOC), ketal rings or methoxybenzyl groups, respectively. The resulting 
polymers were deprotected, most of the time in the presence of trifluoroacetic acid (TFA), before 
any post-polymerization modification.86–88 For example, POx with the aldehyde functionality (obtained 
from monomer 1, Table 2) further reacted in a quantitative way with amino-oxy compounds forming 
the corresponding oxime. POx with amino functionalities (from monomers 2 and 3) were able to 
react with different isocyanate compounds such as a fluorescence dye (tetramethylrhodamine 
isothiocyanate), or bifunctional isothiocyanates in order to form hydrogels.83 Hydrogels were also 
formed from POx with pendant amino functionalities (monomer 2) in reaction with 
epichlorohydrin.84,89 
On the other hand, alkene and alkyne functionalities are increasingly being used because they are 
compatible with the living cationic polymerization, consequently no protecting group is needed, and 
because of the possible coupling reactions by further “click chemistry”.90,91 For example, 2-(pent-4-
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ynyl)-2-oxazoline (monomer 13) could be copolymerized with MeOx and EtOx92 and pendant alkyne 
moieties could quantitatively yield triazoles by copper-catalyzed coupling. A monomer bearing an 
azide functionality has also been reported (monomer 14). 93 
The synthesis of a 2-oxazoline monomer bearing an alkyl chain with alkene functions from renewable 
raw materials, such as unsaturated fatty acids present in vegetable oils, was reported (monomer 
11).94,95 Thiol-ene chemistry could be performed on related POx using different mercaptans (RSH), 
resulting in the binding of protected glucose, fluorinated compounds,96 dodecane chain95 or 2-
mercaptoethanol (monomer 10 and 11).94 Diehl et al. synthesized thermoresponsive poly(2-
oxazoline)s with a wide range of tunable low critical solution temperature (LCST, i.e. the critical 
temperature below which the components of a mixture are  miscible for all compositions97) by 
“clicking” different α-functionalized thiols to a statistical poly[2-(isopropyl/3-butenyl)-2-oxazoline] 
copolymer.98 POx with aryl, ester, amine, and carboxylic acid side chains were synthesized using the 
thiol-ene coupling between a thiol and the pendant alkene of 2-isopropenyl-2-oxazoline before the 
polymerization (monomers 6 and 7).81 Apart from the classic azide-alkyne and thiol-ene coupling 
reactions, a reaction between a POx with an alkene side group with different functional acrylates, by 
cross-metathesis, was also reported.99 
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Table 2 R side groups of 2-R-2-oxazolines allowing for functionalization of POx pendant chains 
  Monomer side functionality Post-polymerization reaction Ref. 
Monomer 
with 
protected 
functionalities 
 
 
P = protective 
group 
R = reactive 
functionality 
1 
 
With amino-oxy 
compound 
73 
2 
 
With epichlorhydrin  84,89 
3 
 
With (di)isocyanates 83 
4 
 
With acrylamide or 
maleimide 
85 
5 
 
n.i. 79 
6 
 
n.i. 81 
7 
 
n.i. 81 
8 
 
n.i. 79 
With a secondary 
amine 
82 
9 
 
With a secondary 
amine 
82 
n.i.: not investigated 
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  Monomer side functionality Post-polymerization 
reaction 
Ref. 
Monomer 
with 
unprotected 
functionalities 
 
 
10  Thiol-ene 
16,96,98,
100–104 
11  
Epoxidation with 
3-
chloroperoxybenzoic 
acid  
105,106 
Thiol-ene  
38,39,94,
95,107,10
8  
Cross-metathesis 
with functional 
acrylates 
99 
12 
 
Cross-linking under 
UV-radiation 
2,106,109
–111 
13  Azide-alkyne  
92 
14  Azide-alkyne  93 
 
In comparison to PEG, the ability to introduce various functionalities along the polymer backbone 
that could be involved in post-polymerization reactions to covalently attach, for instance a drug, 
represents a major advantage of POx.30 
III.2.2.  FUNCTIONALIZATION OF THE α-CHAIN END  
As illustrated in section II.1, a wide variety of initiators can be used to polymerize 2-oxazolines via 
either a cationic or a covalent mechanism. More recently, an array of initiators with reactive 
functionalities has been reported. Major examples are given in Table 3. As with functionalized 
monomers, if the initiator functionality is suspected to interfere with the polymerization process, it 
has to be protected (e.g. alcohol, amine or aldehyde functionalities). In addition, most of the designed 
initiators are oxygenated bases, with p-toluene sulfonate (OTs) or trifluoromethanesulfonate (OTf) 
functionalities operating in a true CROP process. 
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Table 3 Initiators with reactive functionalities for the CROP of 2-oxazolines 
  Initiator Deprotected 
function 
Post-
polymerization 
reaction 
Ref. 
Initiator with 
protected 
functionalities 
 
 
P = protective group 
X = OTs, OTf, Br, Cl 
or I. 
1 
 
Diol Acylation 112 
2 
 
Amine 
Reductive 
amination 
113 
3 
 
Diol 
Reaction with 
isocyanate and 
carbonate 
compounds 
114 
4 
 
Diol Acylation 112 
5 
 
Aldehyde - 115 
6 
 
Alcohol - 116 
Initiator with 
unprotected 
functionalities 
 
 
 
7 
 
- 
Polymerization 
of the vinyl 
unit 
117 
8 
 
- Azide-alkyne reaction 
118 
9 
 
- Azide-alkyne reaction 
118–
124 
10 
 
- - 125 
11 
 
- Diels-Alder 
reaction 
107 
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Most of the initiators presented in Table 3 were involved in post-polymerization reactions leading to 
more complex polymer structures. For instance, the azide-alkyne click chemistry reaction involving 
POx initiated by propargyl tosylate (initiator 9, Table 3) was extensively used. Propargyl tosylate 
initiated the CROP of MeOx and the polymer chain was further coupled to polydimethylsiloxane 
(PDMS) to produce an amphiphilic copolymer.121 Initiator 9 was also used to polymerize iPrOx, and 
subsequent coupling on fluorenylmethoxycarbonyl-tyrosine phosphate (Fmoc-pY) allowed forming a 
phosphatase/temperature responsive diblock copolymer.122 Last, Fijten et al. polymerized different 2-
oxazolines (MeOx, EtOx, PhOx, NonOx) with propargyl tosylate and clicked the acetylene-
functionalized PEtOx to heptakis-azido-β-dextrin giving rise to the formation of a star polymer.126  
Some initiators were not designed purposely for post-polymerization modification, but still illustrate 
the versatility of POx, as shown in Figure 4.  
 
Figure 4 (Macro-)initiators for the polymerization of 2-oxazolines 
Macro-initiators like fully brominated 1,2-polybutadiene,127 polyethylene glycol-tosylate,64 lipo-
triflates,128,129 lipo-tosylates,129,130 lipo-iodine131,132 or tris(triflate)benzene133 were used to initiate the 
polymerization of 2-oxazolines, resulting in graft, diblock and star copolymers, respectively. The 
capability of a range of protected glucose-, galactose-, and fructose-based tosylates and triflates to 
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initiate the CROP of EtOx was also investigated, leading to sugar-containing polymers.134,135 Last, 
EtOx polymerization was initiated by a fluorescent tosylate derivative.13 
Besides triflate and tosylate derivatives, EtOx was polymerized using acetyl bromide, acetyl chloride 
and acetyl iodide as initiator.136 This study broadened the range of possible acid halide initiators, 
which can be easily obtained from different commercially available carboxylic acid compounds. 
III.2.3. FUNCTIONALIZATION OF THE ω-CHAIN END  
Termination at the completion of CROP of 2-oxazolines proceeds via the addition of a compound 
with a higher nucleophilic power than the monomer. The most commonly used nucleophile is simply 
water, leading to a polymer with an alcohol terminal functionality. As a consequence, variation of the 
polymer chain end can either be achieved by post-polymerization modification of the terminal –OH 
group, or by direct attack of nucleophiles bearing a functionality, on the cationic polyoxazolinium 
species. In Table 4, an overview of the termination agents with protected or unprotected 
functionalities is provided.  
Table 4 Termination agents with reactive functionalities for the polymerization of 2-oxazolines 
  Termination agent 
Possible available 
function after 
deprotection 
Post-
polymerization 
reaction 
Ref. 
Termination agent 
with protected 
functionality 
 
P = protective 
group 
T = termination 
group 
1 
 
Amine 
- 116 
With carboxylic 
acid 
18 
With 
methacrylamide 
choroformiate 
137 
With carboxylic 
acid compound 
18 
2 
 
Silanol Intermolecular condensation 
138 
3 
 
Carboxylic acid 
With amine 
compounds 
139 
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  Termination agent 
Possible available 
function 
Post-
polymerization 
reaction 
Ref. 
Termination agent 
with unprotected 
functionalities 
 
 
4 
H2O/ 
KOH aqueous solution/ 
Na2CO3 aqueous solution 
Alcohol 
- 116 
With phtalimide 
compound 
115 
5 
 
Amine With anhydride 
compound 
140 
6 
 
Amine 
Cross-linking 
with dibromo, 
dialdehyde or 
diisocyanate 
compound 
141 
7 
 
Alkene Polymerization of the vinyl unit 
117 
8 
 
Acrylate/ 
methacrylate - 
142 
9 
 
Acrylate - 143 
 
10 
 
Methacrylate 
- 143 
Polymerization 
of the 
methacrylate 
units by ATRP 
21,38,134,
144 
11 
 
Methacrylate 
Hydrogel 
formation with 
a 
trimethacrylate 
cross-linker 
145 
12 
 
Alkyne Azide-alkyne 146 
13 
 
Carboxylic acid - 143 
14 
 
Carboxylic acid - 143 
15 
 
Carboxylic acid - 147 
16  Azide Azide-alkyne 107,148 
17 
 
Cyclopentadienyl 
Diels-Alder 
reaction with N-
substituted 
maleimides 
149 
18 
 
Alkoxyamine 
Radical 
polymerization 
of styrene 
150 
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Another common termination agent is N-tert-butyloxycarbonylpiperazine (N-BOC-piperazine) 
(termination agent 1, Table 4), that leads to an amine functionality after treatment with TFA.18 The 
as-formed amine end-function was coupled with a common chelator (N,N’,N’’,N’’’–
tetraazacylododecane-1,4,7,10-tetra-acetic acid (DOTA)), leading to a radio-labelled polymer after 
chelation of 111In, and used for in vivo imaging studies.18 Alternatively, methacrylamide chloroformate 
was employed for post chemical modification and the methacrylamide function was further 
polymerized by free-radical polymerization, leading to brush-like polymers.137 Clickable functions 
were also introduced by quenching the polymerization with sodium azide (termination agent 16),148 
sodium cylcopentadienide (termination agent 17)149 or hexynoic acid (termination agent 12).146  
Some of these termination agents directly imparted a specific property to the POx. A dye, such as 
fluorescein, could for instance terminate the polymerization, leading to a fluorescent polymer. 
Quaternary ammonium groups, like N, N-dimethyldodecylamine (DDA), known as a biocide 
functional group, led to polymer with antimicrobial properties (Figure 5).151–153 
 
Figure 5 Termination agents used to quench the polymerization of 2-oxazolines 
In summary, a plethora of chemical functionalities can be introduced into the POx structure, either 
within the polymer backbone or at both chain ends, giving rise to a versatile POx toolbox, which may 
be used to achieve polymers with various architectures and properties. 
III.3. POLY(2-OXAZOLINE)S HYDROGELS 
A hydrogel is one specific architecture that could be obtained thanks to the introduction of specific 
functionalities into the POx chemical structure. A hydrogel is defined as a cross-linked network of 
hydrophilic polymer chains.154 To be able to form this network, the polymer chains need to bear 
reactive functionalities. Different routes can be used to produce POx hydrogels, depending on the 
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way functionalities are introduced on the POx chains. All these strategies have been recently 
reviewed.155 Hydrogels could be produced by one-, two- or three-step reactions. The most 
straightforward way to synthesize a hydrogel is to directly copolymerize a 2-alkyl-2-oxazoline 
monomer with a bis-oxazoline comonomer serving as a cross-linking coupling agent. The hydrogel 
will be synthesized in situ as the polymerization proceeds. As presented in the last section, 
functionalities can also be introduced on the monomer or polymer chain end, in which case 
hydrogels will be obtained by post-polymerization reaction with a specific cross-linker. Last, 
functionalities can be introduced on the polymer chain by post polymerization functionalization, 
followed by a cross-linking reaction. These different strategies are illustrated in Table 5. 
Table 5 Different strategies to synthesize POx hydrogels 
One-step hydrogel formation Two-step hydrogel formation Three-step hydrogel 
formation 
 
 
 
 
 
In this PhD work, we will provide a novel synthetic strategy to POx hydrogels and nanogels (chapter 
2). 
III.3.1. HYDROGELS PREPARED BY POLYMERIZATION WITH A BIS-OXAZOLINE MONOMER 
The first hydrogel prepared by copolymerization with a bis-oxazoline monomer was reported by 
Chujo et al. in 1989. They performed the ter-polymerization of MeOx with 2-alkyl-2-oxazoline (alkyl 
= n-butyl, n-octyl or n-dodecyl) and 2,2’-tetramethylenebis(2-oxazoline) (Figure 6),156,157 where they 
combined, respectively, hydrophilic, lipophilic and bifunctional monomers. By varying the monomer 
ratio, they thus tuned the hydrophilicity and the swelling properties of the resulting hydrogels.  
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Figure 6 Hydrogel preparation by copolymerization of 2-alkyl-2-oxazoline and bis-oxazoline156 
The respective monomer reactivities were determined and it appeared that the bis-oxazoline 
monomer had a higher reactivity than MeOx and than the other 2-alkyl-2-oxazolines. As a 
consequence, the bis-oxazoline was incorporated more rapidly into the gel and the chain length 
between two cross-linking points could be varied.144 
More recently, this technique was used to synthesize a library of hydrogels from EtOx, PhOx and 
phenylene-1,3-bis-2-oxazoline monomers.158 Again, the ratio of hydrophilic, lipophilic and bifunctional 
monomers was varied allowing for the comparison of the swelling degree of the gels. The authors 
showed that swelling in water was enhanced for lower degrees of cross-linking, and when a lower 
amount of PhOx was used. Moreover, dye molecules could be trapped into the hydrogels and 
released in a controlled way by solvent exchange (diffusion-mediated release), or by pH change, 
leading to slow degradation-mediated release. As the solvent exchange did not degrade the 
hydrogels, they were well-suited for repeated release/loading cycles. 
III.3.2. HYDROGELS PREPARED BY DIRECT POST-POLYMERIZATION REACTION 
Another way to prepare hydrogels is by a post-polymerization reaction between a POx bearing 
functionalities and a cross-linker. Functionalities could be introduced on the polymer backbone or at 
both chain ends, as presented in Section III.2.  
If a polymer with side chains functionalities is used, a reaction with a difunctional cross-linker leads to 
hydrogel formation. For example, a hydrogel was prepared from a statistical copolymer with MeOx 
and 2-(dec-9-enyl)-2-oxazoline (monomer 11, Table 2) followed by thiol-ene coupling with different 
dithiol molecules.39,108 2-3’-Butenyl-2-oxazoline (monomer 10) was also used as one of the building 
block of a copolymer, and post-polymerization by thio-ene coupling was conducted with a tetrathiol 
under UV irradiation.104 Copolymers with amine side chain functionalities (monomer 2) also formed 
hydrogels when reacting with epichlorohydrin.84,89 Such hydrogels had the ability to absorb and 
release DNA thanks to electrostatic interactions. Hoogenboom also polymerized an unsaturated 
soybean fatty acid-based 2-oxazoline monomer (SoyOx) (monomer 12) using microwave irradiation.2 
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The unsaturated fatty acid side chains of the resulting polymer were then cross-linked under UV 
irradiation, without the need of any cross-linker, leading to hydrogel formation. 
Functionalities can also be introduced at the polymer chain-ends by using functionalized initiators and 
termination agents already presented (respectively in Table 3 and 4). Most of the time, a difunctional 
initiator is used and functionalities are only introduced at the termination step. By this way, hydrogels 
were prepared from telechelic PMeOx bearing trimethoxy-silyl end-functionalities (termination agent 
2, Table 4), followed by deprotection of silanol groups and further intermolecular condensation 
reaction.138 The swelling degree was found directly dependent on the [M]/[I] ratio. Telechelic PMeOx 
was also functionalized at both chain ends with hydroxy groups (termination agent 4). Reaction with 
pluri-isocyanates led to hydrogels.159  
The synthesis of block copolymers made from MeOx and BuOx was terminated by the addition of 
N,N-bis(2-aminoethyl)ethylendiamine (termination agent 6), and hydrogel formation occurred by 
reaction with 1,4-dibromo-2-butene.141 Last, dimethacrylate-functionalized PEtOx (termination agent 
11) was reacted with a 3-arm poly(D,L-lactide) trimethacrylate under UV irradiation.145 The hydrogel 
swelling/deswelling behavior was tuned by varying both the temperature and pH. When the 
temperature was increased, the PEtOx chains became dehydrated, as the hydrogen-bonds previously 
formed with water were disrupted, hence the gel shrunk. The pH effect was linked to the presence 
of amide groups on the polymer backbone. The amide groups were ionized at low pH leading to 
swelling of the gel. As PEtOx is hydrophilic, whereas poly(D,L-lactide) is hydrophobic, the 
hydrophilicity of the gel could be manipulated, by varying the ratio of each macro-monomer. 
Hydrogels were also prepared from a star-shaped PMeOx.133 A trifunctional initiator was used (i.e. 
1,3,5-tris(iodomethyl)benzene or 1,3,5-tris(p-toluenesulfonyloxymethyl)benzene, Figure 4) leading to 
a 3-arm POx with amine end functionalities. The hydrogel was then formed in the presence of a 
difunctional isocyanate.  
Vinyl-functionalized PMeOx was also synthesized, but the functionalities were introduced thanks to 
both the initiator and termination agent to produce a bis-macromonomer (initiator 7, Table 3 and 
termination agent 7, Table 4).117 The hydrogel was formed either by free radical polymerization of 
the bis-macromonomer or by copolymerization with N-vinyl-2-pyrrolidone (NVP). The density of the 
network and swelling characteristics were controlled by the degree of polymerization of the PMeOx 
and by the molar ratio between the bis-macromonomer and NVP as well.  
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III.3.3. HYDROGELS PREPARED BY 2 STEP POST-POLYMERIZATION REACTION 
The third synthetic method used to prepare POx hydrogels involves a three-step reaction. First, 
MeOx or EtOx is polymerized, and second, the polymer is partially hydrolyzed to introduce amine 
functionalities on the polymer backbone leading to a statistical copolymer. Last, the hydrogels is 
obtained by reaction of a cross-linker with amine functionalities.  
In biomedical applications, POx were first used as a source for linear PEI obtained after hydrolysis 
and which was further used to form polyplexes with DNA and used as gene-vector (see further and 
see also Scheme 10).24,160 The hydrolysis rate of POx could be easily controlled, leading to randomly 
distributed amine functions along the POx chain. As mentioned in section 1, when the polymer 
backbone is hydrolyzed up to 10%, no cytotoxicity is observed.25 The hydrolysis reaction was studied 
for different monomers (mainly MeOx and EtOx), under different conditions (base, acid or in a 
water-ethanol mixture); more information can be found in the literature.70,161–168  
Hydrogels were prepared by reaction of the amine functions of partially hydrolyzed POx with 
different cross-linkers. Most of this work was carried out in the 1990s, by the group of Saegusa, on 
the basis of a partially hydrolyzed PMeOx, as illustrated in Scheme 10.  
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Scheme 10 Strategies adopted by Saegusa’s research group to form hydrogels with partially-hydrolyzed 
poly(2-methyl-2-oxazoline) 
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A hydrogel was produced under mild conditions, at room temperature, using hexamethylene 
diisocyanate in the presence of 1,8-diazabicycloundec-7-ene (DBU) as an organic catalyst in DMF 
(Scheme 10).169 With a diisocyanate cross-linker bearing a disulfide bridge, a hydrogel that was 
cleavable in a reductive environment was synthesized (Scheme 10).170 Photo-responsive hydrogels 
were also prepared when the amine functionalities were reacted with coumarin moieties ((7-
coumaryloxy)acetic acid). The hydrogel was formed by photo-dimerization of the coumarin moieties, 
by exposing the polymer to mercury lamp irradiation at a wavelength greater than 300 nm (Scheme 
10).171 The photosensitive gel obtained could be cleaved by exposing it again to irradiation at a 
wavelength lower than 300 nm; the cyclobutane ring was thus cleaved and the coumarin moieties 
were regenerated, thereby reversing the process. 
Partially hydrolyzed PMeOx were also modified with (9-anthracenyl)methyl hydrogen 3,3'-dithio- 
dipropanoate, in the presence of dicyclohexylcarbodiimide as a condensing agent (Scheme 10),172 
leading to a modified PMeOx bearing disulfide and anthracene functions. As in the previous example 
with coumarin moieties, a hydrogel was formed by the dimerization of anthracene moieties, when 
the modified PMeOx was irradiated with a mercury lamp at a wavelength greater than 300 nm. This 
system proved to be photo- and redox-sensitive by means of reversible conversion between 
disulfides and thiols and the photo-dimerization of anthracene moieties. 
Temperature sensitive-hydrogels were also prepared using a maleimide modified PMeOx that reacted 
with an antagonistic furan-modified PMeOx, via a Diels-Alder reaction (Scheme 11).173  
 
Scheme 11 Schematic of the thermosensitive hydrogel formed by Diels-Alder reaction173 
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The gelification process was reversible: if the hydrogel was heated at 80 °C for 2h, the retro Diels-
alder reaction occurred thereby regenerating the starting compounds. Without heating, the hydrogel 
only swelled in water. 
Some of the hydrogels presented in this section are potential candidates for drug delivery 
applications, but only one paper reported on the evaluation of a POx hydrogel for such an 
application.174 An ABA triblock copolymer, prepared from PEtOx-b-PCL-b-PEtOx, was used to 
encapsulate Bevazumab, an antibody used to cure intra-ocular diseases, known to be efficient but 
with a short half-life. The triblock copolymer was subjected to a sol-gel transition when the 
temperature was increased. At room temperature and in a balanced salt solution (standard saline for 
intraocular use), it existed as a “sol”, but when temperature was increased to the physiological 
temperature, it turned into a “gel”. When the temperature was further increased, PEtOx segments 
became dehydrated and formed micellar aggregates. The Bevazumab release in vitro was slow, with no 
burst release, and lasted for up to 20 days. The release was achieved first by diffusion and when the 
equilibrium concentration was reached, the release was controlled by gel degradation. In vitro 
cytotoxicity studies were conducted by co-culturing hydrogels with cells at 37 °C. After 24h, more 
than 90 % of cell viability was observed. The in vivo cytotoxicity study performed on rabbit eyes 
showed that the hydrogel and its degradation products were not toxic to neuroretinal tissues for at 
least two months. This hydrogel thus exhibited a good in vitro and in vivo biocompatibility for 
neuronal tissues with extended drug release. 
To summarize, numerous synthetic strategies leading to POx hydrogels have been described in the 
literature. In situ cross-linking can be conducted by the addition of bisfunctional 2-oxazolines to the 
polymerization mixture, but hydrogels can also be synthesized by post-polymerization reactions. 
Cross-linking reaction can alternatively involve functionalization of ethylene imine repeating units 
obtained by partial hydrolysis, or by the direct introduction of reactive handles to the POx backbone. 
III.4. STRUCTURE-PROPERTY RELATIONSHIPS 
By taking advantage of the POx versatility, i.e. the living ROP combined with the potential for 
functionalization at both chain ends and/or in the polymer side chains, not only POx chemistry allows 
designing polymers with different architectures, but also tuning their physico-chemical properties 
such as thermal transitions, mechanical properties, solubility and surface energy. All these properties 
are obviously linked together. For example, mechanical and thermal properties depend directly on 
the presence of crystalline phases. Herein, only thermal transitions correlated to the polymer 
behavior in solution will be discussed. This is because this aspect has been investigated in the context 
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of this PhD work, from specific POx-based copolymers (see Chapter 3). Additional information on 
the mechanical properties and surface energy of POx can be found elsewhere. 2,175,176 
The nature of the substituent (R) on the polymer side chain determines its hydrophilicity: PMeOx is 
water-soluble in the entire temperature range of liquid water under atmospheric pressure, PEtOx 
and poly(2-n-propyl-2-oxazoline) (PnPOx) exhibit a LCST behavior in aqueous solution, whereas 
longer substituents result in hydrophobic polymers (Figure 7).177 PMeOx and PEtOx are also known 
to be hygroscopic and the effect of the water uptake has an influence on their mechanical 
properties.178,179 Due to the current trend in the use of renewable resources, many of the 
hydrophobic POx reported in the literature are based on fatty acids as mentioned in section III.2.1.106 
The polymer behavior in solution is greatly affected by the solvent used, and in water-ethanol solvent 
mixtures, some POx also present an upper critical solution temperature (UCST).180–182 
 
Figure 7 Structure-properties relationship for poly(2-oxazoline)s 
The LCST values given in Figure 7 varied with the polymer molecular weight,183 polymer 
concentration and the presence of salt (salting-in or salting-out effect)184 or surfactant in the 
solution.177 The polymer chain-end functionality also influences the LCST: the LCST increases with 
the hydrophilicity of the chain-end.185  
By post-polymerization modification, a poly(benzyl ether) dendrimer with carboxylic acid functions at 
the periphery was coupled to PiPrOx by one of its chain-end, leading to a hybrid copolymer with a 
pH-tunable LCST.123  
Last, when the polymer contains branching in its side chains, the branching position has an important 
influence on the glass transition temperature (Tg)186 and on the LCST as well.  
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Numerous studies on the modulation of POx LCST and Tg by synthesizing block,67,175,187 gradient,61 
random175 or brush/graft188–190 copolymers have been also reported. Tuning the LCST by post-
polymerization modification is also an option.98,191  
The state of the polymer in bulk will also change drastically, from amorphous to semi-crystalline, 
depending on the length of the alkyl side chain. Polymers with short side chains such as PMeOx, 
PEtOx, and PnPOx are amorphous, whereas POx with 4 and more carbons on the side chains show 
a semi-crystalline behavior.176,192,193 Some POx have the ability to crystallize also when annealed in 
dilute solution. For example poly(2-isobutyl-2-oxazoline) and PNonOx form crystalline self-
assembled  structures,  in a water-ethanol mixture, below their UCST.194 PEtOx forms crystalline 
fiber visible with the naked eyes within a few weeks, when kept above its LCST in water.195 The 
crystallization of comb-like POx copolymers144 or chiral POx196  have also been reported.  
A closer look should be given to PnPrOx and its two different isomers, PiPrOx and poly(2-
cyclopropyl-2-oxazoline) (PcPrOx) (Figure 8).197 It is interesting to highlight the key role played by 
the side chain architecture on the polymer properties: the three polymers have a LCST, but PnPrOx 
and PcpPrOx are amorphous, with a Tg of 40 and 80 °C, respectively, whereas PiPrOx is semi-
crystalline. 
 
Figure 8 Structure-properties relationship for poly(2-propyl-2-oxazoline)s isomers 
PiPrOx has been more extensively studied than its other two isomers because of its remarkable 
properties. On one hand, it is a structural isomer of poly(N-isopropylacrylamide) (PNIPAAm) and 
poly(L-leucine)198 and like PNIPAAm, it has an LCST close to body temperature making it a 
particularly interesting candidate for biomedical applications.199,200 The phase transition for PiPrOx is 
reported to be sharper, with almost no hysteresis compared to PNIPAAm, due to the weaker H-
bonding capacity of PiPrOx.201 
But on the other hand, when PiPrOx is annealed above its LCST (at 65 °C) for 3 hours or more,  it 
forms crystalline structures in an irreversible manner.1,177,202,203 The crystal structure evolves with the 
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annealing time, from a network-like structure to a micron-size assembly composed of fibers mesh. 
The crystal structure has been identified by X-Ray Diffraction (XRD),203 and crystallization  is driven 
by hydrophobic and dipolar interactions. Thanks to vibrational spectroscopy analysis and molecular 
orbital calculation, Winnik et al. were able to associate the crystallization of PiPrOx to a change in 
the conformation of the polymer chains, from trans and gauche to all trans (Figure 9).204  
 
Figure 9 Schematic representation of the changes in the conformation of PiPrOx in water as a function of 
temperature. Reprinted from ref. 204 
At a specific temperature, the PiPrOx solution undergoes first liquid/liquid phase separation and 
PiPrOx then crystallizes in the polymer-rich phase by changing its conformation.204 In contrast to 
POx with long alkyl side chains, PiPrOx crystallinity appears in the main chain and not in the side 
chains. Last, solvation appears to be especially important in lowering the kinetic barriers in the 
crystallization process, similarly to the self-organization of polypeptides and proteins.203 
PiPrOx crystallization was further exploited in copolymer systems. A statistical copolymer made of 
iPrOx and 2-(3-butenyl)-2-oxazoline units was also synthesized and found to self-assemble and 
crystallize above its LCST into spherical micron-size structures, which was further used for 
carbohydrate protein recognition.205 The self-assembly and crystallization of a PiPrOx-grafted pullulan 
copolymer were also reported.206 Micron-sized ring-like structures with short fibrils emanating from 
the ring circumference or “sea urchin”–like morphology were obtained, but other morphologies 
were also observed depending on the experimental conditions (addition of salts, with/without 
stirring).  
In chapter 4, we will describe how to take advantage of this specific property of PiPrOx to crystallize 
in water, by arranging the polymer into a block copolymer architecture. 
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These systematic studies on libraries of POx (co)polymers revealed several structure–property 
relationships for the thermal properties as well as solubility and crystallization. This allows moving 
forward toward POx engineering in order to meet defined properties.  
IV. POLY(2-OXAZOLINE)S AS POLYMER THERAPEUTICS 
POx is an interesting platform for biomaterials development and especially for polymer therapeutics 
because it meets some specific needs, such as biocompatibility, stealth behavior, but also in terms of 
tunable thermo-responsiveness and variation of architecture and functionalities. The use of POx as 
polymer therapeutics has been recently reviewed.207,208  
Except for one paper reporting on the use of a PEtOx matrix as an excipient in the formulation of 
oral tablets,209 POx are most often involved in the design of drug nanocarriers. POx could be 
conjugated to biological molecules, such as proteins or drugs, or be part of self-assembled structures, 
such as micelles, polymer vesicles or polyplexes. Serina Therapeutics, a pharmaceutical company 
based in Huntsville, Alabama, is currently advancing novel therapeutics for Parkinson's disease, 
cancer, inflammation, pain and metabolic disorders based on POx nanocarriers.210 
IV.1. OVERVIEW OF THE DRUG DELIVERY PROBLEMATIC 
One of the major challenges that needs to be addressed in current nanomedicine research is to 
deliver drugs at a controlled place and time in order to improve the drug efficacy, while decreasing 
the side effects. In oncology for example, current chemotherapeutic treatments are administered 
intravenously and their biodistribution and pharmacokinetics are not well-controlled.211 The majority 
of anti-cancer drugs being hydrophobic, their circulation in body fluids is challenging and requires a 
large volume for distribution. In addition, when drugs are hydrophilic, it is difficult for them to cross 
membrane barriers and to reach their final target site. Because the size of drug molecules is small (< 
10 nm), they are rapidly cleared from the bloodstream by renal filtration before being able to reach 
the tumor site. As a consequence, drug accumulation at the tumor site is difficult to achieve. 
Moreover, due to their small size and molecular weight, drug molecules penetrate not only to the 
diseased tissues but also to healthy ones, thereby damaging these tissues and resulting in a significant 
number of side effects.  
By using polymeric nanostructures as drug carriers, a balance between efficacy and toxicity can be 
achieved, opening a wide range of new opportunities for cancer treatment. The use of polymer 
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nanotechnologies holds enormous promise for various reasons: they can improve the solubility of 
hydrophobic drugs, and drug cell penetration. Because of their larger size, nanocarriers would not be 
cleared as rapidly as free drugs from the blood stream. The drug delivery can also be targeted to 
specific tissues or even cells, improving drug efficacy. It can allow the delivery of drug cocktails and 
also of therapeutic and diagnostic agents, leading to a “theranostic” platform.212–214 For example, 
imaging agents can be delivered at the same time as a drug, making possible the visualization of the 
drug delivery site. Lastly, the release can be triggered in a controlled manner.215,216 
Nanocarriers can be made from inorganic or organic compounds. Inorganic nanocarriers are out of 
the scope of this literature review, but some additional information can be found elsewhere.217 
Organic structures made from polymeric systems218 can be prepared by self-assembly, leading to the 
formation of polymer vesicles (polymersomes) or micelles.219 They can alternatively be highly 
branched and shape-persistent as in the case of dendrimers220 or chemically cross-linked as in the 
case of nanogels.221 For all these structures, the polymers used should fulfill some specific 
requirements: they should be biocompatible and approved by FDA for use in biomedical applications. 
They may also be biodegradable and readily cleared by the body.  
All these nanocarriers end up being made from the main polymers presented in Table 6, depending 
on the properties needed.218,222 
Table 6 List of polymers commonly used in biomedical applications. Adapted from ref. 222 
Polymers Acronyms Properties 
Poly(ethylene glycol) PEG Biocompatible, hydrophilic, stealth, FDA approved 
Poly(D,L-lactide-co-glycolide) PLGA Biodegradable, hydrophobic, FDA approved 
Poly(acrylic acid) PAA Hydrophilic, pH-responsive  
Poly(lactic acid) PLA Biodegradable, hydrophobic 
Poly(caprolactone) PCL Biodegradable, hydrophobic, FDA approved 
Poly(N-isopropylacrylamide) PNIPAAm Thermo-responsive 
Poly(ethyleneimine) PEI Cationic, pH-responsive 
Poly(amino acids) - Biodegradable, anionic 
Polysaccharides  
cellulose, chitin, pullulan 
- Hydrophilic, natural polymers 
   
Research is not only conducted on the cargo itself, but also on improving the targeting of the drug 
delivery system (DDS) which could be passive or active. All currently approved nanotechnology 
platforms in cancer treatment deliver cancer drugs to the tumor site via passive targeting that relies 
on the properties of the delivery system and the disease pathology, in order to selectively 
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accumulate the drug at the site of interest, thereby avoiding non-specific distribution.223 In the case of 
cancer, tumor cells are growing faster than healthy tissues resulting in the development of a 
“permeable” vasculature that allows nanomaterials of up to several hundred nanometers to 
penetrate in the tumor site. In addition, tumor tissues are also characterized by poor lymphatic 
drainage, thus once nanocarriers reach the tumor site, they will not be rapidly cleared. For a 
treatment to be efficient, drug delivery carriers should be able to circulate in the body for an 
extended duration, hence they should possess stealth behavior to exploit the enhanced permeability 
and retention effect (EPR) that enables the accumulation of drug carriers at the tumor site.  One has 
to be aware that this EPR effect is not specific to cancer. It is also present for other diseases, such as 
chronic inflammation and infections.223  
So far, improvement of the circulation time was made possible by coating PEG on the surface of 
liposomes that prevents non-specific binding and avoids recognition by the phagocytic system, 
resulting in clearance from the body. As presented in section I, PEtOx and PMeOx are presented as 
alternatives to PEG for such applications. However, the accumulation level at the tumor site also 
depends on the inherent characteristics of the DDS, such as its size, hydrophilicity, charge, etc.222,224 
Nanotechnology platforms can also target specific tissues or cells by bearing ligands on their surface, 
such as antibodies, peptides or proteins, where the ligands can bind to receptors on the targeted 
site. However, the DDS must first reach the tumor cells, before being able to bind to them. Active 
targeting would not improve the accumulation at the tumor site due to the EPR effect. However, the 
drug carrier will definitely be more efficiently internalized by tumor cells as cell recognition and 
uptake by targeted cells will be improved.224,225 In addition, one should also take into account that the 
introduction of targeting moieties on the surface of nanocarriers will reduce their stealth behavior by 
increasing their immunogenicity and protein adsorption.211 Up to recently, only a few active targeting 
systems were at the clinical trial stage, and none has been approved for clinical use yet.211 
In order to produce a successful nanoparticle-based DDS, once the nanoparticles have reached the 
targeted site, the drug should be released. The stability of the nanocarriers is a key factor, i.e. they 
have to be stable under physiological conditions while the drug must be released at the targeted site. 
The release can be achieved by diffusion through the nanoparticles wall or by erosion of nanoparticle 
matrices. Physiologically relevant stimuli can be used to trigger the release of the drug, and the 
factors chosen should vary between normal tissues and some pathological sites.226–228 Temperature is 
one of the most commonly used triggers since the temperature increases by 1-2 degrees at the 
inflammatory tissue site.229 As a consequence, polymers that exhibit temperature-dependent phase 
transitions around the physiological temperature, such as in the range 10–42 °C, are the ones used 
to construct drug carriers.  
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pH variations are also widely used as a trigger, especially in the case of cancer, because tumor tissues 
are known to possess a lower pH than healthy tissues.230,231 The release could be mediated by ligand 
exchange, by an enzymatic reaction, or even by a chemical reduction reaction,232–235 as certain 
biological molecules are produced in excess at a target site in comparison to healthy tissues. For 
example, glutathione (GSH) is the most abundant reducing agent in the body. In the cell, its 
concentration can reach 10 mM, whereas in the extracellular environment it only approaches 0.002 
mM. This significant variation in concentration has been used to trigger intracellular delivery.236 
Moreover, tumor tissues are known to be highly reductive compared to healthy tissues, with at least 
four-fold higher concentration of GSH in tumor tissues than in normal tissues, which makes a trigger 
release based on redox conditions even more relevant in the case of cancer treatments.235 The most 
popular method to obtain this reductive sensitivity is to introduce disulfide linkages in the 
nanocarrier. This can be achieved in the polymer main chain, side chain, or in the cross-linker. This 
disulfide bond is known to be stable under normal physiological conditions, but is cleaved under 
reductive conditions through thiol–disulfide exchange reactions.  
Other “smart chemistries” can be used to control the drug release.237,238 External stimuli, such as 
light or application of heat for instance, can also be used to trigger the release. 
Nowadays, significant activity is being focused on the development of “smarter” and multifunctional 
DDS, to achieve higher efficacy with less toxicity and better targeting. By manipulating the surface 
chemistry of the nanocarriers, or by attaching specific ligands to their surface, nanocarriers could 
become responsive to environmental conditions and could also be actively targeted.215,239,240 One has 
to be aware that despite the increasing number of papers published on DDS, less than 10 
nanocarriers have been so far approved by the FDA, to deliver drugs to solid tumors, proving how 
challenging the development of a DDS is.241 
IV.2. POLY(2-OXAZOLINE) CONJUGATION TO BIOLOGICAL MOLECULES 
Polymers can be conjugated to drugs, peptides or proteins. Because the biological molecule is 
covalently attached to the polymer, it undergoes some modifications. The main challenge is to 
preserve the biological activity of the active (bio)molecule while its stability, pharmacokinetics and 
solubility are improved. 
Drug-polymer conjugates are the oldest drug delivery nano-systems and have been developed in the 
1950’s.222 The first study on the conjugation of POx to biological molecules was conducted in 1992, 
with PMeOx and PEtOx that were conjugated to a synthetic peptide.242 The peptide used, called 
HCPC[6-17] corresponded to residues 6-17 of the heavy chain of human protein C. Both PMeOx- 
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and PEtOx-peptide adducts retained avidity for the antibody directed against human protein C 
(HPC4-MAb) relatively to the underivatized parent peptide or the human protein C. Furthermore, 
the avidity of the adducts was not appreciably affected by the size of the polymer employed over the 
1 to 10 KDa molecular weight range. This study served as a proof that POx-peptide conjugates could 
be a suitable polymer-drug conjugate, and numerous studies followed on the conjugation of POx to 
different proteins.  
In 2011, Viegas et al. conjugated PEtOx to different enzymes including catalase, urinase and 
ribonuclease, but also to insulin and BSA proteins.14 From the POx-enzyme conjugates, they showed 
that the in vivo enzyme activity was dependent on the extent of their modifications: the less the 
enzyme was modified, the higher was its activity. The glucose-lowering activity of the PEtOx-insulin 
adduct was studied in vivo, by injection into rats (Figure 10-A). The polymer-insulin conjugate was 
more efficient than insulin alone, or even than one of the actual commercial products (Glargine-
insulin conjugate), as it lowered the glucose activity for a longer time period after injection. PEtOx 
was also conjugated to bovine serum albumin (BSA, a serum albumin protein often used as protein 
standard) and injected into rabbits to test their immune response. The results showed that the 
conjugation to PEtOx decreased the immunogenic properties of BSA, which meant that it was no 
longer detected by the body as a “foreign guest”, representing another way to take advantage of the 
POx stealth behavior (Figure 10-B). 
  
Figure 10 A) Effect of the subcutaneous injection of insulin, insulin glargine, and poly(2-ethyl-2-oxazoline)-
insulin on the blood glucose levels in male rats. B) 11 Relative immunogenicity of BSA, PEG-BSA, Poly(2-
ethyl-2oxazoline)-BSA in rabbits treated as measured by anti-BSA antibody levels. Treated on days 1, 14, 28 
and 42. Adapted from ref. 14 
PEtOx was also conjugated to the granulocyte colony stimulating factor (G-CSF). Protein activity was 
retained in vitro and in vivo, while the conjugation improved its stability toward aggregation at 37 °C, 
as compared to the protein alone, and prevented its premature degradation.139 Almost the same 
conclusions were drawn for a POx conjugated to the protein superoxide dismutase 1 (SOD1), 
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involved in some antioxidant therapies: the conjugate was highly stable in serum, while retaining 30 to 
50% of its activity and enhancing the cellular uptake as compared to the native protein or even the 
PEG-SOD1 conjugate.243 
POx copolymers were also used for protein conjugation, and the influence of POx composition and 
architecture on the protein activity was reported. Several homo-, random and block POx 
(co)polymers (MeOx, EtOx or 2-butyl-2-oxazoline (BuOx)) were conjugated with the horseradish 
peroxidase enzyme (HRP).244 Conjugation with P(MeOx-b-BuOx) led to the highest cellular uptake, 
in comparison to other conjugates. The inability of the conjugates produced from PMeOx or the 
copolymers P(EtOx-co-BuOx) in increasing the cellular uptake was attributed to the lack of a 
structurally ordered hydrophobic block, which could assist the hydrophilic enzyme in entering the 
cells. This was in agreement with results reported by Luxenhofer et al.11 The data showed that 
modification by amphiphilic POx block copolymers was a promising strategy to enhance cellular 
delivery and protein drug transport. 
PEtOx was also conjugated to a drug molecule employed for the treatment of acute and chronic 
human leukaemia, namely, cytosine arabinose, 1-(B-D-arabinofuranosyl)cytosine (Ara-C).32 
Accelerated stability tests to hydrolysis of Ara-C conjugates showed stability towards the degrading 
enzyme (cytidine deaminase), while the drug was released under physiological conditions. Finally, 
conjugation induced a decrease in the in vitro drug cytotoxicity (30 times less toxic than the drug 
alone).  
So far, all the systems presented were coupled by one polymer chain end, but an example of 
conjugate formed between a POx polymer with alkene functionalities on the side chain and an 
aptamer (a synthetic single strand nucleotide sequence with molecular recognition properties) has 
been recently reported.102 The aptamer was used against an allergy biomarker and the conjugate did 
not show any loss in activity. 
All these systems established that conjugating POx to a (bio)molecule with biological interest 
represents a viable strategy: it improves the protein/drug stability, while both maintaining its 
biological activity and taking advantage of the POx properties such as biocompatibility and stealth 
behavior. 
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IV.3. SELF-ASSEMBLY OF POLY(2-OXAZOLINE)S AND THEIR USE IN BIOMEDICAL 
APPLICATIONS 
As emphasized in the previous section, polymer-conjugates are one of the many possibilities for 
transporting a drug to a target site while using the stealth properties of POx. Most common DDS are 
self-assemblies issued from amphiphilic graft or block copolymers, and different structures can be 
obtained depending on the polymer characteristics: micelles, polymersomes (polymer vesicles) or 
aggregates. In these self-assembled structures, the drug is usually physically entrapped and not 
covalently linked to the polymer as in drug-polymer conjugates. 
In this section, a brief overview of some of the smart self-assembled systems derived from POx is 
presented; they are also all listed in Table 7 (see further). Some systems are derived from POx 
copolymers, while others are “mixed systems” containing POx as one block and another polymer as 
the other block. It has to be highlighted that these selected examples are at different stages in their 
evaluation as drug delivery systems. 
A statistical copolymer made of 2-decenyl-2-oxazoline (DecOx) (monomer 11, Table 2)  and EtOx 
monomer units formed nanoparticles with a size between 240 and 660 nm by nanoprecipitation in 
water.245  In vitro studies showed that, after 24 h of incubation with mice fibroblast cells, the cellular 
uptake was efficient, with a uniform distribution into the cytosol. No toxic effect was observed 
during incubation. DecOx not only introduces hydrophobicity, but it can also be used as functional 
sites. As a consequence, the next step with this system would be not only to examine the drug 
loading and release profiles but also to functionalize the particles. 
Milonzki et al. synthesized gradient copolymers from MeOx and PhOx and showed that different 
nanotructures (polymersomes, micelles and aggregates) were obtained depending on the monomer 
ratio, polymer chain length and solvent used.246 The encapsulation of a hydrophobic anti-
inflammatory drug, namely, indomethacin, led to an increase of the system size by almost 50% (from 
9 to 16 nm) compared to the unloaded structures. 
Hruby et al. designed thermoresponsive micelles from ABA triblock copolymers, PMeOx-b-(PiPrOx-
co-PButylOx)-b-PMeOx, with hydrophilic A blocks and a central thermoresponsive B block.247 Above 
the LCST of the copolymer, micelles were formed. The copolymer was radio-labelled with different 
iodine isotopes and these systems showed no cytotoxicity in vitro up to a concentration of 1 mg/mL. 
Depending on which isotope was attached, these micellar systems could be used for radio-diagnostic 
(123I or 124I, which are beta-emitting isotopes) or radiotherapy (131I, gamma-emitting isotope).  
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A complete study on another micellar system prepared from di- and triblock POx and used as drug 
delivery system was conducted by Luxenhofer et al. as depicted in Figure 11.248,249 
 
 
Figure 11 Structure of the triblock copolymers used to form micelles. Reprinted from ref. 249 
In vitro toxicity studies conducted on different cell lines showed that, after 2 hours of incubation, the 
polymer itself was not cytotoxic up to a concentration of 20 mg/mL.248 These micelles were tested 
for single- and multi-drug cancer therapy. First, Paclitaxel (PTX), an anti-cancer drug which has a low 
solubility in water of 1 µg/mL, was encapsulated within the micelles. With the single-drug loaded 
micelles, a high loading was achieved (8.2 mg/mL of PTX, corresponding to 45 wt.%) combined with 
promising in vitro and in vivo tests.248 When micelles were loaded with hydrophobic binary or ternary 
drug combinations, loading capacities were slightly improved as compared to the single-drug loaded 
micelles (up to 50 wt.%), but more importantly, the stability was enhanced.249 The in vivo antitumor 
effect of the PTX-loaded micelles was studied on mice with subcutaneous lung tumors. A reduction 
in tumor growth was visible even after only one injection. Between 11 days and 25 days after 
injection, tumors in animals treated with PTX-micelles became even smaller than in animals treated 
with a commercial product (Cremophor EL i.e. Taxol®). Interestingly, the drug loading of such self-
assembled structures could induce morphology changes. The drug loading of a micellar system made 
of a triblock polymer P(MeOx-b-BuOx-b-MeOx) changed, from worm-like micelles to spherical 
micelles, with also a raspberry-like micellar core when drug loading was increased.250 
Dual stimuli responsive self-assembled systems were prepared from PiPrOx coupled to 
fluorenylmethoxycarbonyl-tyrosine phosphate (Fmoc-pY).122 The polymer, Fmoc-pY-PiPrOx, is 
thermoresponsive and has an LCST around body temperature, whereas the Fmoc-pY function is 
enzyme-responsive. Dephosphorylation occurred in the presence of phosphatase, leading to the self-
assembly of FMoc-Y. By tuning the temperature and the phosphatase concentration, different 
nanostructures were obtained, such as micelles and mesoglobules (Figure 12). 
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Figure 12 Schematic representation of enzyme- and temperature-induced self-assembly behavior of the 
polymer bio-conjugate. Reprinted from ref. 122 
Knowing that phosphatase is present at the cell surface, one can expect to use such a system to 
release bioactive payloads, in response to cell surface phosphatase, but such tests have not yet been 
reported. 
Polymersomes produced from di- or triblock copolymers made of PMeOx and PDMS, and used as a 
DDS, have been extensively studied by Meier et al.251 Functionalities were introduced at the polymer 
chain-ends, which led to surface-functionalized polymersomes once self-assembled. Biotin-
functionalized polymersomes (Figure 13)252 were targeted against the scavenger receptor A1 from 
macrophages. Receptor-specific binding of these generic carriers was followed by vesicular uptake in 
human and transgenic cell lines, while low non-specific binding supported the stealth properties of 
the carrier with no toxicity being noted.252 
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Figure 13 A) Biotinylated poly(2-methyl-2-oxazoline)-b-PDMS-b-poly(2-methyl-2-oxazoline) B) 
Functionalized polymersomes by streptavidin bridging. Reprinted from ref. 252 
The same polymersomes were prepared from PDMS-b-PMeOx diblock copolymers functionalized 
with a secondary amine at the chain end.253 These amino-functional groups were then used to attach 
different antibodies to the surface of the polymersomes. Antibiotin IgG, which targets biotin surfaces, 
was first attached and specific attachment of these polymersomes to biotin patented surfaces was 
demonstrated. Functionalized polymersomes with Trastuzumab, an antibody known to target 
specifically HER2-positive breast cancer cells, were also prepared.253 Cellular uptake experiments 
with cells expressing the HER2 receptors on their surface were performed and, as expected, the 
uptake of polymersome-trastuzumab conjugates was significantly faster than for polymersomes 
without Trastuzumab. The in vitro cell proliferation inhibition activity was also studied and showed 
that after 24h, the conjugates were able to inhibit cell proliferation by a factor of 2. These studies 
showed how easy it could be to actively target a drug carrier by functionalizing the POx chain-ends 
to then functionalize the polymersome surface, providing a platform for targeting experiments. These 
polymersomes were also used as nanoreactors and as models to study the internalization of 
nanoparticles, thanks to polymersome properties that are similar to the one of phospholipids from 
cell membrane (fluidity and mechanical stability).254,255 
The self-assembly of PMeOx-grad-PPhOx in presence of  phospholipids, namely, dipalmitoylpho- 
sphatidylcholine (DPPC), led to the formation of chimeric vesicle-like nanostructures.256 
Indomethacin was successfully incorporated into these chimeric nanocarriers. 
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Micellar systems prepared from POx conjugated with other biocompatible polymers were also 
reported. Micelles formed from PEtOx coupled to a hydrophobic glycopolymer, namely, 
peracetylated maltoheptaose, were used to encapsulate Indomethacin.257 The micelles were 
thermoresponsive with an LCST around 45 °C. In vitro drug release studies showed that the higher 
the temperature, the faster the release. For temperatures close to the LCST or higher, burst release 
was observed because of a change in the morphology (micelle deformation due to the fact that 
PEtOx became hydrophobic). Micelles were also prepared by the self-assembly of the block 
copolymer PEtOx-b-poly(4-methyl-ε-caprolactone).258 They were loaded with a hydrophobic drug 
used in cancer chemotherapy, namely, Doxorubicin (DOX). Thanks to the DOX entrapment, the 
cellular uptake was faster as compared to the free drug and it could reach the intracellular 
compartment and enter the nucleus. 
Grafted copolymers can also serve to form micelle-like nanostructures. Star-shaped poly(ε-
caprolactone) (PCL) with PEtOx brush-like shell formed spherical nano-aggregates of 20 nm in 
diameter.21 No short term cytotoxicity was noted, nor adverse reaction with human blood in 
general. DOX was encapsulated successfully in these nano-aggregates.  
The self-assembly of a grafted copolymer consisting of a PCL backbone and PMeOx coupled via click-
chemistry was also reported.34 As both PCL and PMeOx moieties are non-cytotoxic and 
biocompatible, one can assume that the resulting copolymers may show a similar behavior, but no in 
vitro nor in vivo studies have been reported. 
Polyplexes are another kind of drug delivery carriers reported in the literature which can be 
prepared by the self-assembly of POx. As POx are neutral polymers, they have to be coupled to 
another charged polymer, to be able to form polyplexes. For example, block copolymers made from 
PEtOx attached to hyaluronan, a natural anionic polysaccharide, formed polyplexes with cationic drug 
like diminazene, an anti-infective drug for animals.113 Stable colloidal particles with a hydrodynamic 
radius (RH) around 130 nm were obtained.  
Most commonly, polyplexes are made from branched or linear PEI as a transfection vector for gene 
delivery. It turns out that linear PEI is obtained from hydrolysis of PMeOx or PEtOx as discussed 
earlier (section III.3.3). Diblock copolymers prepared from partially hydrolyzed PEtOx coupled to 
non-hydrolyzed PEtOx were also self-assembled in presence of DNA.24,259 A core-shell structure was 
obtained where the core was formed by the PEI-plasmid DNA complex. The core was sparingly 
soluble due to charge neutralization, but the shell containing the hydrophilic PEtOx improved the 
overall solubility of the complex. In vitro trials showed that the block copolymer was less toxic than 
linear PEI because PEtOx decreased the charge density, while the transfection was as high as for the 
linear PEI.  
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Table 7 Self-assembled nanostructures made from poly(2-oxazoline)s 
POx/Polymer NP 
morphology 
Size – d       
(nm) 
Drug 
loaded 
Biological 
test 
Ref. 
P(DecOx-stat-EtOx) Aggregates 240 to 660 -  In vitro  245 
P(MeOx-grad-PhOx) Micelles, 
polymersomes 
aggregates 
18 to 32            
82                       
- 
Indomethacin - 246 
 
PMeOx-b-(PiPrOx-co-
PButylOx)-b-PMeOx 
Micelles 200 - In vitro 247 
P(MeOx-b-BuOx-b-
MeOx) 
Micelles 24 to 44 Paclitaxel In vitro;     
In vivo 
248–
250 
P(MeOx-b-BuOx-b-
MeOx) 
Micelles 28 to 43 Drugs 
combinations 
In vitro 5 
Fmoc-pY-PiPrOx Micelles, 
mesoglobules 
Varies with pH - - 122 
PMeOx-PDMS-PMeOx Polymersomes 50 to 500 - In vitro 251–
255 
P(MeOx-grad-PhOx)      
+ DPPC 
Vesicle-like 
structures 
Varies with the 
ratio 
Indomethacin - 256 
PEtOx-b-peracetylated 
maltoheptaose 
Micelles 120 to 180 Indomethacin - 257 
PEtOx-b-poly(4-methyl-ε-
caprolactone) 
Micelles 127 to 318 Doxorubicin In vitro 258 
PCL-b-(PEtOx brush) Micelles 20 Doxorubicin In vitro 21 
PCL-b-PMeOx Micelles 70 to 80 - - 34 
PEtOx-hyaluronan Polyplexes 260 Diminazene - 113 
PEtOx-b-PEI Polyplexes 380 DNA In vitro 24 
P(EtOx-stat-EI)-b-PEtOx Polyplexes 100 to 200 DNA In vitro 259 
 
All these self-assembled DDS have major advantages, such as the possibility to functionalize the 
surface or to design multi-compartment systems, e.g. polymersomes. However, they have one major 
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drawback which is their low stability toward dilution or changes in the environmental conditions. To 
prevent the drug delivery vehicle from disintegrating in the blood stream, there is a great need to 
produce structures with enhanced stability or robustness against environmental stimuli.  
Chemically cross-linked structures, like nanogels (nanosize hydrogels154), could be appropriate 
candidates for this purpose. The aim of the last section of this literature review is to present the few 
POx-based nanogel structures reported in the literature. This is also one important direction that we 
took in this PhD work (see chapter 2 and 5). 
IV.4. POLY(2-OXAZOLINE)S CROSS-LINKED NANOSTRUCTURES 
As discussed in section III.3, different processes can be used to form POx hydrogels. Nanogels are 
defined as soluble polymer networks with a dimension lower than 100 nm.154 Hydrophilic nanogels 
possess the ability to swell in water or aqueous solution as they are soluble.260 The polymer network 
could be hydrophilic or amphiphilic, and the resulting nanogels may be composed entirely of a 
polymeric network or a core-shell structure with a hydrogel core or shell.261 A general overview on 
nanogels will be given below, but several reviews have been published on the use of microgels and 
nanogels as DDS and the reader is invited to refer to them for more details.221,262–265 
IV.4.1. BRIEF OVERVIEW OF NANOGELS  
As compared to other DDS, nanogels present some unique advantages. First, they are highly stable 
due to the fact that they are internally cross-linked. They can be highly hydrophilic and in biological 
environment, they will swell and contain a high level of water/body fluids making them generally 
biocompatible.260 In principle, higher drug-loading capacities can be expected for nanogels as 
compared to other drug nanocarriers, because in their swollen state, a larger inner space is available 
for the incorporation of drugs or macromolecules.266 
The soft structure of nanogels is another distinctive quality. Hendrickson et al. showed that if a 
pressure close to the renal filtration pressure is applied to nanogels, they can pass through pores 
more than ten times smaller than their size.267 Nanogels softness has a direct influence on their 
biodistribution and circulation time in the body: nanogels can bypass some organs more easily and by 
decreasing the modulus of nanogels by eight times, the circulation time in the body was increased by 
30 times.268 
Nanogels are thus versatile systems: by manipulating the polymer or cross-linker structure, nanogels 
with radically different properties can be produced.269 They can be responsive to environmental 
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factors, like changes in pH, temperature or redox conditions depending on their chemical 
composition. For example, by introducing disulfide bridges in their structure (most often using a 
disulfide-containing cross-linker), nanogels will break apart in reductive environment leading to the 
release of their payload. The release rates can also be controlled by manipulating the cross-linking 
density. The position of the cross-linking group in the nanogel structure (i.e. the homogeneity of the 
nanogels) also affects the degradation rate of the carrier: when the cross-linking groups are 
individually and evenly spaced in the nanogels structure, varying the percentage of cross-linking has 
negligible influence on the degradation rate.270 However, when cross-linker groups are placed in 
pairs, the degradation rate decreases as the percentage of cross-linker increases. Moreover, the 
release is up to eight times slower as compared to nanogels produced with individually spaced cross-
linking groups.  
Due to their high surface area, there is also the possibility to functionalize effectively their surface 
with ligands that could be particularly useful for targeting. 
IV.4.2. SYNTHETIC METHODS TO NANOGELS 
Nanogels can be synthesized by different methods that have already been reviewed in the 
literature.266,271–273 Some techniques like microfluidic, photolithography or even spray drying involved 
some special piece of equipment and, hence are not the focus of this section. The two main 
approaches to synthesize nanogels involve cross-linking of preformed polymers and polymerization in 
heterogeneous media.266,271–273 
IV.4.2.1. Nanogel synthesis by cross-linking preformed polymers 
This technique could either be used for natural or synthetic polymers that are water soluble. If there 
is no reactive group on the polymer backbone, the polymer has first to be functionalized (chemical of 
physical treatments). If the polymer is fully hydrophilic, the cross-linking reaction can be achieved 
either in dilute aqueous solution, or in an inverse emulsion. If the polymer exhibits amphiphilic 
character, it has to be self-assembled first in aqueous media, and the cross-linking reaction will then 
secure the self-assembled structure. 
IV.4.2.2. Nanogel synthesis by polymerization in heterogeneous media 
The advantage of this technique is that it is a one-pot process where the polymerization and the 
formulation of the nanogels are performed simultaneously. In this process, nanogels are commonly 
prepared by free-radical cross-linking copolymerization (RCC) directly in water. Recently, nanogels 
have also been prepared by atom-transfer radical-polymerization (ATRP)274 and reversible addition-
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fragmentation chain-transfer (RAFT)260,275, and in each case, a bifunctional monomer acting as the 
cross-linker and a controlling agent that delays macrogel formation were introduced.  
If both the monomer and the polymer are hydrophilic, the polymerization can take place in inverse 
emulsion. Monomer(s) and initiator are introduced in the aqueous dispersed phase and surfactant(s) 
are added to stabilize the emulsion. Polymerization occurs in the water droplets and the nanogels 
thus obtained have the size of the initial droplets. If the monomer and initiator are soluble in water 
but the polymer is not, it can be polymerized by so-called precipitation polymerization. To do so, the 
monomer and initiator are placed in an aqueous solution, and as the polymerization takes place, the 
polymer precipitates out of the water, forming nanogels. 
IV.4.3. POLY(2-OXAZOLINE)S CROSS-LINKED NANOSTRUCTURES/NANOGELS 
Cross-linked nanostructures prepared from POx were first reported by Nardin et al.251 
Polymersomes were produced from a PMeOx-b-PDMS-b-PMeOx triblock copolymer, with 
methacrylate groups at both chain ends. This copolymer formed vesicular structures in dilute 
aqueous solution with a size that could be tuned between 50 and 500 nm. Once the polymersomes 
were formed, the methacrylate end-groups could be polymerized by UV-induced RCC. The cross-
linking reaction did not lead to any morphological change, and the size and molecular weight were 
conserved.Thanks to this cross-linking reaction the vesicles maintained their integrity even after their 
isolation from the aqueous solution. 
The only fully POx cross-linked nanostructures that can be found in the literature are core cross-
linked micelles. First, a nanostructure was made from an amphiphilic P(EtOx-b-SoyOx) block 
copolymer (SoyOx corresponds to monomer 12 in Table 2).276 In aqueous solution, spherical 
micelles consisting of a PEtOx corona and a PSoyOx core were formed. The micellar core could 
then be stabilized by core-cross-linking under UV irradiation, as in the case of the hydrogel syntheses 
described above (see section III.3.2).2 The UV dose applied to the system had to be adjusted 
carefully, because if it was too low, the cross-linking density was insufficient, and if it was too high, 
inter-micellar cross-linking occurred. The morphology of such core-cross-linked micelles could be 
reversibly transformed, from spheres to small rods (rice grains), whenever the micelles were 
transferred from water into a non-selective solvent for the constituent blocks (e.g. acetone). This 
morphological transition was attributed to swelling of the slightly cross-linked core.  
The second example of core-cross-linked micelles made from POx was reported in 2011 by 
Brummelhuis et al.277 Amphiphilic poly(2-(3-butinyl)-2-oxazoline)-b-PEtOx formed micelles in water, 
which could be core-cross-linked by thiol-yne “click chemistry”. To do so, two different mercaptans 
were used: methyl 3-mercaptopropionate and 2-mercaptoethylaminehydrochloride.  Micelles cross-
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linked with methyl 3-mercaptopropionate bore carboxylate groups in their core, whereas micelles 
cross-linked with 2-mercaptoethylaminehydrochloride bore amino-group in their core. These 
micelles with core-confined ionic groups exhibited stimuli-responsive properties and were sensitive 
to changes in temperature, pH, ionic strength, and salt types.278 These systems are currently being 
evaluated as “smart drug carrier” and nanoreactors for catalysis.277 
Graft copolymers with thermo-sensitive PNIPAAm backbone and hydrophilic PEtOx graft chains 
demonstrated a typical amphiphilic behavior.279 Above the LCST of PNIPAAm chain, stable micelles 
with RH of 30-40 nm were obtained. They could be core cross-linked by electron-beam irradiation, 
and when the temperature was then lowered below the LCST of PNIPAAm, the core became 
hydrophilic and core/shell type nanogels were thus obtained. By substituting poly(2-carboxyethyl-2-
oxazoline) (monomer 8, Table 2) for PEtOx, the core/shell nanogels obtained were not only 
thermosensitive, but also pH sensitive, due to the carboxylic groups.280 As a consequence, the core 
size could be varied by manipulating the temperature, whereas the thickness of the poly(2-
carboxyethyl-2-oxazoline) corona could be tuned by changing the pH (Figure 14). 
 
Figure 14 Strategy for the production of bisensitive nanogels and their supposed reaction to changes in 
stimuli like pH value and temperature. Red: side chains of poly(2-carboxyethyl-2-oxazoline); Blue: main 
chains of poly(N –isopropylacrylamide). Adapted from ref. 280 
The other example of nanogels containing POx as one block was prepared from a triblock 
copolymer: PNIPAAm-b-POx-b-poly(2-hydroxyethyl methacrylate), where the POx segment 
corresponded to PMeOx or PEtOx.281 Telechelic POx was first synthesized, which was followed by 
nanogel preparation by precipitation free radical copolymerization of NIPAAm, 2-hydroxyethyl 
methacrylate (HEMA) with the POx multifunctional macromonomers. The swelling-deswelling 
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behavior was directly related to the chemical composition (hydrophilic/hydrophobic balance) and the 
length of the inserted POx sequence, which could be controlled by synthesis. To study the ability of 
these nanogels as drug delivery carrier, BSA was encapsulated as model protein. The release of BSA 
was investigated with respect to variation in the cross-linking density. The higher the cross-linking 
density, the lower the swelling ability and the slower the release.  
Even though these nanogels are promising candidates as DDS, none was studied for drug 
encapsulation or even for cytotoxicity studies. Such investigations, on specifically designed POx 
nanogels, were conducted in this PhD work and will be part of chapter 5. 
Furthermore, no shell cross-linked nanostructures or nanogels prepared in inverse emulsion have 
been reported. 
V. CONCLUSIONS 
POx represent a special class of synthetic polymers that are regarded as analogues of polypeptides. 
They can be obtained by “controlled/living” cationic ring opening polymerization of 2-alkyl-2-
oxazolines (CROP), under specific experimental conditions. CROP often requires long reaction times 
and can be complicated by the occurrence of some side reactions (transfer, coupling), when the 
polymerization is settled under conventional heating. Yet, these issues can be overcome when the 
reaction is performed in microwave reactors.  
POx engineering has been already intensively studied and researchers have now at their disposal a 
substantial POx chemical toolbox. Both chain termini can be modified independently with specific 
functional groups, including hydroxyls, amines or carboxylic acid, and so on. A number of 2-oxazoline 
monomers are also commercially available and functional side chains (-OH, -COOH, -ene or -yne 
functions, etc.) can be introduced in the monomer, in a straightforward manner. In this context, 
clickable functionalities have first been considered, but some other chemical handles (e.g. aldehyde) 
may be further exploited. 
By taking advantage of all these synthetic tools, it is now relatively easy to design POx with various 
architectures and compositions (copolymers, graft, star, hydrogels), and thus to tune their physico-
chemical properties, such as thermal transitions (LCST and Tg), solubility and physical state 
(amorphous or semi-crystalline). 
In many cases, POx show properties equivalent to or even outperform polymers that are commonly 
used in biomedical applications.282 For instance, POx, and especially PMeOx and PEtOx, proved non-
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toxic to cells, hemocompatible and were internalized by cells. They also exhibit the same stealth 
behavior in vivo as PEG, and can be used as protein repellent. POx possess several advantages over 
PEG: they are less prone to oxidative degradation and side products are less cytotoxic than PEG 
ones and they offers much more possibilities for functionalization.  
Consequently, there is a tremendous opportunity to develop engineered POx as key building blocks 
of drug delivery carriers. The background literature has shown that POx can be conjugated to 
proteins or drugs, can be grafted onto liposome surface and formulated as part of self-assembled 
systems. Numerous papers have also been published on the design of stimuli-responsive hydrogels 
that are mainly prepared from partially hydrolyzed POx. However, so far, not so many studies have 
been reported on POx nanogels and the use of such nanogels as drug delivery carriers.  
On the basis of this literature overview on engineered POx, different orientations to this PhD work 
have been taken, as discussed in the following chapters. In chapter 2, the design of dual-responsive 
hydrogels and nanogels is presented. Chapter 3 focuses on the crystallization-driven self-assembly of 
POx block copolymers. The POx chemical toolbox is expended in chapter 4 by the development of 
post-polymerization reactions with a 2-oxazoline monomer bearing a protected aldehyde handle. 
Finally, in chapter 5, some biological properties of POx nanogels are evaluated.  
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CHAPTER 2 
REDOX AND PH RESPONSIVE HYDROGELS 
AND NANOGELS MADE FROM  
POLY(2-ETHYL-2-OXAZOLINE) 
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Overview: This chapter describes the synthesis of hydrogels and nanogels made from partially hydrolyzed 
poly(2-ethyl-2-oxazoline) (PEtOx). Firstly, different cross-linkers (diglycidyl ethers, diacrylates, N-hydroxysuccinimide 
ester) were tested to achieve responsive and/or degradable PEtOx-based hydrogels. Secondly, nanogels were 
designed either in dilute aqueous media in the presence of 1,6-hexanediol diglycidyl ether (1) as the cross-linker 
or following an inverse w/o emulsion cross-linking process. In the latter case, in addition to cross-linker (1), a 
cleavable cross-linker homologue (2), namely 1,6-hydroxyethyl disulfide-bis-diglycidyl ether was used so as to 
produce cleavable nanogels. The pH-responsiveness of all the cross-linked PEtOx nanogels was demonstrated in 
acidic environment, owing to the protonation of residual ethylene imine groups and/or tertiary amines formed 
during the cross-linking reaction. As expected, nanogels derived from cross-linker (2) could readily be cleaved in a 
reducing environment, due to the presence of disulfide linkages at the cross-linking points. 
Part of the work presented in this chapter has been published in Polymer Chemistry in 2013.12 
 	  
 
1 Legros, C.; De Pauw-Gillet, M.-C.; Tam, K. C.; Lecommandoux, S.; Taton, D. Polym. Chem. 2013, 4, 4801-4808  
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INTRODUCTION 
Hydrogels are 3D-cross-linked polymeric networks capable of swelling in water while maintaining their 
overall structure. Cross-linking can be permanent (via chemical bonds) or temporary (via weak reversible 
interactions, such as hydrogen bonds, van der Waals or ionic interactions).1 By selecting the polymer 
building block and the type of cross-linker, hydrogels can be made biocompatible and/or responsive to 
specific environmental conditions, two key attributes for a smart delivery system with a potential use in 
biomedical applications.2–4 
As for nanogels, they are defined as soluble polymer networks with a dimension smaller than 100 nm.a5 
Hydrophilic nanogels display the same structural features as hydrogels, as a result of their intra- and 
inter-molecular cross-linking points. They have emerged as a new class of nanocarriers for drug delivery 
applications.6–10 Formulation of nanogels can be achieved by different methods.6,8,11,12 Specific processes 
like microfluidics, photolithography or spray drying require specific processing equipment; hence they are 
not widely employed. Some of the more common synthetic approaches are radical cross-linking 
copolymerization (RCC) in heterogeneous media, or cross-linking of pre-formed linear polymers, e.g. by 
chemical post-modification or radiation with a high energy source. In the former case, nanogels can be 
generated in a one-pot process, where both polymerization and formulation are performed 
simultaneously.13 Cross-linking of a pre-formed polymer requires a polymer backbone with pendent 
reactive groups, which is referred to as a post-polymerization modification method.14–17 With hydrophilic 
precursors, however, the cross-linking reaction can be achieved either in dilute aqueous solution, or in 
an inverse water-in-oil (w/o) emulsion.7,10,11 With amphiphilic copolymers, self-assembly in aqueous 
media can take place first, which is followed by the cross-linking reaction aimed at stabilizing the self-
assembled structure.7,10,11 
Poly(2-oxazoline)s are a particularly interesting class of hydrophilic polymers, as they can be regarded as 
amino-acid analogues.18 They are potential candidates for biomedical applications, in particular as drug 
carriers. More particularly, poly(2-ethyl-2-oxazoline) (PEtOx) is a biocompatible polymer that can be 
internalized by cells and that is characterized by stealth behavior, a feature that is commonly associated 
with poly(ethylene glycol) (PEG).19–22 As a consequence, PEtOx can act as protein repellent23–25 and 
enhance antimicrobial properties.26 Previous studies demonstrated that PEtOx can be conjugated to 
 
a Nanogels are defined by IUPAC as a particle of gel of any shape with an equivalent diameter of 
approximately 1 to 100 nm. There is indeed a misperception in the current literature between nanogels and 
microgels. As a consequence, in the following text, we will qualify some of our compounds as nanogels, although 
their size is greater than 100 nm. 
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proteins or drugs, or be grafted onto the surfaces of liposomes, and be formulated as part of self-
assembled systems, such as polmeric micelles or polymersomes, and used as drug delivery carriers.27  
Designing responsive hydrogels made from poly(2-oxazoline)s is relatively well documented,28 one of the 
major challenge being the introduction of a 2-oxazoline monomer bearing a reactive functionality.29 As 
presented in Chapter 1 (section 111.3.1), such materials can be prepared by copolymerization of 2-ethyl-
2-oxazoline (EtOx) with a bis-2-oxazoline comonomer.30,31 Another strategy consists in the introduction 
of a 2-oxazoline co-monomer bearing a reactive functionality followed by post-polymerization 
modification.32,33 Hydrogels were also prepared from poly(2-oxazoline)s functionalized at both chain 
ends; for example, methacrylate end-functionalized PEtOx can also be crosslinked to achieve hydrogels 
by reaction with a 3-arm polylactide analogue.26 Other examples of hydrogels formed with end-
functionalized poly(2-oxazoline)s were reported.34–36 More recently, hydrogels were prepared by the 
copolymerization of a 2-oxazoline monomer bearing a Boc-protected amino group on the side chain 
(BocOx) with EtOx and further treatment with epichlorohydrin.37 Hydrogels were also prepared by the 
copolymerization of 2-(dec-9-enyl)-2-oxazoline with either 2-methyl-2-oxazoline or EtOx and further 
cross-linking with dithiol molecules.38 Lastly, amine functionalities can be statistically introduced by partial 
hydrolysis of pre-formed poly(2-alkyl-2-oxazoline) (alkyl = methyl or ethyl). The latter method was 
developed by Saegusa and coworkers who prepared redox-, light-, or temperature-responsive hydrogels 
depending on the cross-linkers used (e.g. diisocyanate, dicarboxylic acid, etc.).39–43 (Chap 1, section 
111.3.3, scheme 10) 
In contrast, true soluble nanogels made of poly(2-oxazoline)s and their use as drug delivery carriers have 
rarely been investigated. For instance, core-cross-linked micelles based on an amphiphilic poly(EtOx-b-2-
“soy alkyl”-2-oxazoline) copolymer, where the 2-“soy alkyl”-2-oxazoline block was derived from a long 
fatty acid side chain bearing alkene functionalities, have been described by Huang et al.44 The cross-linking 
process was achieved by UV irradiation. Another recent example was reported by Brummelhuis et al.45 
who cross-linked micelle-like nanostructures formed by self-assembly of an amphiphilic poly(2-(3-
butinyl)-2-oxazoline)-b-PEtOx, using thiol-yne “click chemistry”. These core-cross-linked micelles 
exhibited stimuli-responsive properties and were sensitive to changes in temperature or pH or ionic 
strength. 
The aim of the present work is to propose different synthetic methodologies to hydrophilic hydrogels 
and nanogels based on PEtOx. Secondary amine functionalities were first introduced into the polymer 
backbone by partial hydrolysis. The as-obtained statistical copolymers were then reacted with different 
cross-linkers (diglycidyl ethers, diacrylates, N-hydroxysuccinimide ester) (Scheme 1). Copolymer 
pH and redox responsive hydrogels and nanogels made from PEtOx  
 69 
materials issued from the reaction with the bis-glycidyl ether cross-linker were studied more thoroughly. 
For instance, the redox-sensitive cross-linker containing a disulfide functionality was used to produce 
degradable poly(2-oxazoline) hydrogels and nanogels. Nanogel synthesis was achieved following two 
distinct processes: in dilute aqueous media and in an inverse w/o emulsion. The redox and/or pH-
responsive properties of nanogels obtained in this manner are demonstrated. 
I. SYNTHESIS AND PARTIAL HYDROLYSIS OF PETOX 
The cationic ring-opening polymerization (CROP) of 2-ethyl-2-oxazoline was performed in acetonitrile at 
85 °C, using methyl trifluoromethanesulfonate as the initiator, following a well-established procedure 
(see Scheme 1, further).46,47 A methanolic KOH solution was employed upon completion of CROP to 
quench the living polymer chain ends. The experimental degree of polymerization (DP) was 94 and a 
dispersity (Ð) of 1.28 was obtained (Figure 1). The absolute molecular weight of PEtOx was then 
determined by SEC equipped with a laser light scattering detector (Figure 2).  
 
Figure 1 1H NMR spectra (400 MHz, D2O) of poly(2-ethyl-2-oxazoline)94 
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Figure 2 SEC trace of poly(2-ethyl-2-oxazoline)94 in DMF obtained with a laser light scattering detector 
This PEtOx precursor was next partially hydrolyzed to introduce secondary amine functionalities along 
the polymer backbone (see Scheme 1). Such a hydrolysis procedure has previously been studied in both 
acidic and basic media,48–50 where the hydrolysis rate was found to depend both on the amount of acid 
or base added and on the reaction time. Upon performing the hydrolysis under basic conditions, a 
decrease in both the polymer solubility and the reaction rate was noted. The reduction in solubility can 
be explained by the crystallization of linear poly(ethylene imine) (PEI) domains. In contrast, the polymer 
solubility was retained by performing hydrolysis in acidic media, which resulted in better control over 
the hydrolysis rate. This can be explained by the fact that the pH of the reaction medium was lower than 
the pKa of PEI (pKa = 8.5), the ethylene imine functionalities being protonated. 
The hydrolysis kinetics were studied next with P(EtOx)94 at 50 g/L in a HCl solution at 18.5 %, under 
reflux. Aliquots were withdrawn periodically (0.5, 1, 2, 3, 4 and 6.5 h), and after 6.5 hours a significant 
tail at higher retention time was observed in the SEC trace (Supporting inforamtions - SI†, Figures S1 and 
S2). This could be due to polymer degradation or interactions of the polymer chains with the SEC 
columns, even in DMF, as previously described for similar polyamines.48 Hence, the PEtOx chains were 
hydrolyzed within a 4 hour time window. The degree of hydrolysis was evaluated both by 1H NMR 
spectroscopy and titration of the secondary amines (Figure 3 and Table 1).  
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Figure 3 1H NMR spectra (400 MHz, D2O) of poly((2-ethyl-2-oxazoline)88-stat-(ethylene imine)6) 
Table 1 Evolution of the degree of hydrolysis of poly(2-ethyl-2-oxazoline)94 with time  
Hydrolysis 
reaction time (h) 
Hydrolysis % 
(1H NMR) 
Hydrolysis % 
(Titration) 
0.5 3.4 - 
1 4.3 - 
2 6.7 5.3 
3 8.9 9.6 
4 11.3 12 
II. HYDROGEL FORMATION AND CLEAVAGE 
The critical concentration for gelation of P(EtOx)94 was determined by measuring the intrinsic viscosity 
(SI†, Figure S3) and the radius of gyration (Rg). A Rg value of 3.65 nm was obtained corresponding to a 
critical concentration of 56 mg/mL. 
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II.1. CROSS-LINKER SCREENING FOR THE HYDROGEL FORMATION 
Hydrogels were then prepared from a range of cross-linkers, as illustrated in Scheme 1 (see also Table 
2).  
 
Scheme 1 Synthesis of hydrogels made from poly(2-ethyl-2-oxazoline): (a) Cationic ring-opening polymerization 
(CROP) of 2-ethyl-2-oxazoline. (b) Partial hydrolysis of the poly(2-ethyl-2-oxazoline). (c)-(e) Formation of 
hydrogels by reaction with cross-linker (c) N-hydroxysuccinimide ester (d) diepoxide/diglycidyl ether (e) 
diacrylate. 
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Table 2 Cross-linkers used to form hydrogel with partially hydrolyzed poly(2-ethyl-2-oxazoline) and conditions 
used for the hydrogel formation 
 
 
 
Solvent 
T 
(°C) 
Reaction 
time 
EP
O
X
ID
E/
 
G
LY
C
ID
IL
 E
T
H
ER
 
1 
 
H2O 
80 
60 
Overnight 
3 days 
2 
 
H2O 
80 
60 
Overnight 
3 days 
3 
 
H2O 80 1 day 
4 
 
H2O 80 Overnight 
5 
 
H2O 
80 
60 
Overnight 
3 days 
6 
 
THF: H2O 
2:3 80 2 h 
A
C
R
Y
LA
T
E 
7 
 
H2O 
60  
40 
30 
2h30 
3 h 
3h30 
8 
 
Phosphate 
buffer 
0.04M 
pH = 8 
80 
30 
1h30 
Overnight 
9 
 
Phosphate 
buffer 
0.04M 
pH = 8 
30 Overnight 
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R = hexaglycerol core structure 
H2O RT 20 min 
Three main families of cross-linkers were tested to react with secondary amines of the polyoxazoline 
backbone. Bis-epoxides (cross-linkers 1 to 8, Table 2) reacted via ring-opening of the epoxides with 
secondary amines. Diacrylates (cross-linkers 7 to 9) and secondary amines reacted via a Michael-type 
addition reaction under slightly basic conditions.51 The reaction of amines with N-hydroxysuccinimide 
ester compound (NHS ester, cross-linker 10) is used to cross-link or label peptides and proteins under 
physiological or slightly alkaline conditions (pH 7.2 to 9), yielding stable amide bonds. The reaction 
releases N-hydroxysuccinimide (NHS) as a by-product.52 However, hydrolysis of the NHS ester can 
compete with the amine reaction. The rate of hydrolysis increases with the buffer pH and contributes to 
less-efficient cross-linking in less-concentrated solutions.  
All the reactions were conducted at a constant ratio of reactive functionalities in aqueous solution, 
except for tris(4-hydroxyphenyl)methane triglycidyl ether (cross-linker 6) that was not soluble in pure 
water. Hydrogels were obtained with all of the cross-linkers shown in Table 2, except 1,3-butadiene 
diepoxide (cross-linker 3). The flexibility of the cross-linker was found to be of great importance in 
order for the cross-linking reaction to proceed. A trial was carried out using cross-linker 3, but no 
hydrogel was obtained due to the tight/constrained structure of this cross-linker. On the other hand, 
increasing the alkyl chain length between the two epoxide rings decreases the water solubility of the 
cross-linker. Nevertheless, a gel was formed with 1,2,7,8-diepoxyoctane (cross-linker 4) despite the 
relatively poor water solubility of this cross-linker. This was confirmed by the formation of a white 
insoluble compound. In contrast, the use of diglycidyl ether cross-linker (cross-linkers 1, 2, 5 and 6) led 
to transparent gels exhibiting a greater affinity for water (di-epoxides are less soluble in water than the 
equivalent diglycidyl ether molecules). Diacrylate cross-linkers are more reactive than the diglycidyl ones, 
forming gels even at temperatures as low as 30 °C, which is a major advantage in the design of drug 
delivery devices. However, hydrogels formed with diacrylate cross-linkers in aqueous solution could be 
completely cleaved within two weeks by ester hydrolysis. As expected, the most efficient cross-linker 
tested in this series was the 8-arm NHS-containing PEG. This is due to the higher functionality of this 
commercially available cross-linker. NHS ester-amine coupling is one of the most popular coupling 
reactions for bio-systems as a result of the ease of the reaction and the mild conditions required.52 
Further hydrolysis was still possible with these hydrogels also, as a result of the ester functionalities 
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present in the structure. Through modifications of the cross-linker R-group, some of the resulting 
hydrogels could be responsive to specific stimuli. 
II.2. HYDROGEL FORMATION AND CLEAVAGE WITH DIGLYCIDYL ETHER CROSS-
LINKERS 
As the aim of the present study was to prepare hydrogels made of a polyoxazoline backbone that could 
be stimuli-responsive, only the compounds made from diglycidyl cross-linkers 1 and 2 (Table 2) were 
further studied. Hydrogels were formed using a non-cleavable cross-linker, namely 1,6-hexanediol 
diglycidyl ether (1) (Scheme 2). The cross-linking reaction was optimized via a kinetic study, withdrawing 
aliquots of various hydrolysis degrees (shown in Table 1) at a polymer concentration of 100 mg/mL. 
These precursors were first dissolved in deionized (DI) water and the cross-linker (1) was added to 
obtain a concentration of 40 mg/mL. The solutions were stirred at 80 °C overnight. The results suggest 
that a degree of hydrolysis of at least 6.7 % was required to observe gel formation. Thus, a new batch of 
P(EtOx)94 hydrolyzed to 6.7 % (P(EtOx88-stat- EI6)) was specifically synthesized and used for the rest of 
the study. Titrations were performed both before and after hydrolysis, as shown in Figure 4.  
 
Scheme 2 Synthesis of hydrogels made from poly(2-ethyl-2-oxazoline): (a) Formation of non-cleavable 
hydrogels by reaction with 1,6-hexanediol diglycidyl ether (1). (b) Formation of cleavable hydrogels by reaction 
with hydroxyethyl disulfide-bis-diglycidyl ether (2). (c) Hydrogel cleavage under reducing environment. 
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The dry gel was analyzed by FTIR and compared to the spectrum of the parent PEtOx. The appearance 
of a peak at 1109 cm-1 characteristic of an ether C-O stretch confirmed the incorporation of the cross-
linker (SI†, Figures S4 and S5).  
 
Figure 4 Titration of the secondary amine by pH-metry and conductivity measurements A) of parent poly(2-
ethyl-2-oxazoline)94 and B) of poly((2-ethyl-2-oxazoline)88-stat-(ethylene imine)6) copolymer 
Hydrogels that could be chemically cleaved in a reducing environment were also prepared, using the 
same partially hydrolyzed polymer precursor, P(EtOx88-stat-EI6), and hydroxyethyl disulfide-bis-diglycidyl 
ether (2) as the cross-linker. The latter compound was synthesized following a procedure reported in 
the literature (SI†, Figures S7 and S8).53 The appearance of a peak at 1104 cm-1 in the FTIR spectrum of 
the dry gel, again confirmed incorporation of the cross-linker (2) (SI†, Figure S6). Cross-linking points 
with a central disulfide bridge in related PEtOx hydrogels could be cleaved in reducing environment. The 
cleavage reaction was implemented using 1 mL of a dithiothreitol (DTT) solution under nitrogen 
atmosphere. Within approximately 5 minutes, the central disulfide bridges were indeed cleaved and the 
gel transformed into a clear solution, as illustrated in Figure 5. 
 
Figure 5 A) Hydrogel formed by the reaction of ethylene imine groups on the polymer backbone with 
hydroxyethyl disulfide-bis-diglycidyl ether (2). B) Clear solution obtained after addition of DTT to the hydrogel.  
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III. SYNTHESIS OF PETOX NANOGELS  
III.1. IN DILUTE MEDIA 
By drastically decreasing the concentration of both the partially hydrolyzed PEtOx precursor to 10 
mg/mL (instead of 100 mg/mL used in the previous section) and that of the cross-linker (1) to 2.2 mg/mL, 
nanogels could be formed in dilute media. The polymer and cross-linker were thus dissolved in a mixture 
of water (97 %) and ethanol (3 %) to improve the solubility of the cross-linker and the nanogel formation 
was monitored by dynamic light scattering (DLS). At the initial stage, all the species were soluble in the 
solvent mixture and the low scattered intensity attested to the presence of unimers in solution. Upon 
nanogel formation, the scattered intensity increased and both the size and size distribution of the as-
formed compounds were directly determined. 
Non-cleavable nanogels were formed within 3 hours, using cross-linker (1). The variation of decay rate 
versus the squared scattering vector is shown in Figure 6A. The slope of the linear fit corresponds to the 
translational coefficient and the hydrodynamic radius can be calculated using the Stokes-Einstein 
equation. A hydrodynamic radius of 205 nm was thus obtained. The formation of spherical 
nanostructures was also evidenced by transmission electron microscopy (TEM), a size in agreement with 
the DLS results was achieved (Figure 6C). 
Attempts to derive cleavable nanogels using cross-linker (2) under the same conditions were less 
successful. Indeed, reduced solubility of cross-linker (2) was observed in the solvent mixture at the initial 
stage as compared to its non-cleavable analogue (1). Hence, no nanogels were successfully formed using 
this protocol; instead, macroscopic hydrogels were obtained after approximately 3 hours. Tries to 
optimize the conditions, including changes in solvents ratio, solvent mixture (H2O/EtOH, H2O/DMSO), 
polymer concentration, cross-linker concentration and ratio of reactive functionalities, did not allow us 
to achieve nanogels from cross-linker (2) in dilute media. 
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Figure 6 DLS analysis and TEM of permanently cross-linked nanogels prepared in dilute media, using cross-
linker (1). A) Variations of decay rate versus squared scattering vector with a linear fit. B) Relaxation time plot 
obtained at 90°. C) TEM micrograph (scale bar = 500 nm) 
III.2. IN INVERSE EMULSION 
An inverse emulsion process was also implemented to access the targeted nanogels. The aqueous phase 
was composed of P(EtOx88-EI6) and the diglycidyl ether cross-linker (1) or (2) in 100 µL of DI water. The 
aqueous phase was added to 0.8 g of cyclohexane with 5% Span 80, a non-ionic surfactant. The 
emulsification was triggered by an ultrasonic probe and the reaction mixture was stirred at 80 °C 
overnight. The resulting compounds were then thoroughly washed, first with cyclohexane and THF, then 
by dialysis against water. The successful transfer of the materials into DI water confirmed the efficient 
removal of the surfactants. 
Non-cleavable nanogels were first prepared using cross-linker (1). The variation of nanogel size with pH 
was investigated, as summarized in Figure 7. At neutral pH, a hydrodynamic radius of 126 nm was 
obtained. Upon addition of diluted HCl, yielding a solution pH of 3-4, an increase in nanogel size to 156 
nm was noted, indicative of nanogel swelling. This can be explained by the protonation, in acidic 
environment, of residual ethylene imine groups and/or tertiary amines formed during the cross-linking 
reaction. This protonation increases the hydrophilicity of the compounds and charge repulsion within the 
nanogels. Average sizes determined by TEM were smaller than those obtained by DLS. This effect was 
attributed to the shrinking of the nanostructures on the TEM grid, during the preparation process. The 
main difference between the two techniques is the state of the nanogel compounds during analysis 
(hydrated state in DLS and dried state in TEM).   
Nanogels were then successfully prepared with the cleavable cross-linker (2) via the inverse emulsion 
w/o process, and the influence of pH on nanogel size was studied (Figure 7). An increase in size, from 
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154 to 179 nm, was noted upon addition of HCl solution (pH = 3-4), demonstrating the pH-sensitivity of 
the compounds. The morphology was confirmed by TEM, the sizes being smaller as compared to those 
obtained by DLS, which again may be explained by solvent evaporation (the large diffuse areas 
correspond to residue of surfactants or artefact due to solvent drying).  
 
Figure 7 DLS and TEM analysis of the cleavable and non-cleavable nanogels. Panel A: Variations of decay rate 
versus squared scattering vector with linear fits at different pHs. Panel B: Relaxation time plot obtained at 90° at 
different pHs. Panel C: TEM micrographs at neutral pH 
The influence of a second stimulus was then studied by the addition of a reducing agent. In the presence 
of DTT, indeed, the count rate decreased dramatically confirming the disruption of the nanogel structure 
(SI†, Figure S9). To confirm that this behavior was not linked to a dilution effect, the same volume of DI 
water (as DTT) was added to a second sample, also analyzed by DLS. In the latter case, the count rate 
decreased slightly but not as significant as in the case of DTT. Thus, the use of a cleavable cross-linker 
(2) enabled the synthesis of stimuli-responsive nanogels, responding to both a reducing environment and 
a pH change, as illustrated in Scheme 3.  
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CONCLUSIONS 
We have demonstrated that partially hydrolyzed poly(2-ethyl-2-oxazoline) (PEtOx) can react with 
different of cross-linkers including bis-epoxides, bis-acrylates and bis-N-hydroxysuccinimide ester, in 
water to form cross-linked derivatives. Dual stimuli-responsive hydrogels and nanogels can be readily 
prepared from partially hydrolyzed PEtOx and hydroxyethyl disulfide-bis-diglycidyl ether.  
Hoogenboom et al. recently reported that partially hydrolyzed PEtOx with up to 10 % of ethylene imine 
functions did not show any cytotoxicity in vitro.54 The extent of hydrolysis of the PEtOx used in our study 
(6.7 %) is below this in vitro cytotoxicity limit. Additional cell viability experiments are addressed in 
Chapter 5.  
Nanogel formation by cross-linking of the secondary amino groups can be triggered either in inverse w/o 
emulsion or in dilute aqueous media, using diglycidyl ethers as cross-linkers. The dilute medium process 
offers some noticeable advantages as nanogels were formed within a few hours in water, without the 
need of any surfactants or catalysts. However, this method is limited by the solubility of the reagents. For 
instance, no nanogels were obtained in the presence of the cleavable cross-linker, most likely due to its 
poor solubility in aqueous media. In contrast, non-cleavable and cleavable nanogels were synthesized 
using an inverse w/o emulsion process. Their sizes can potentially be tuned by adjusting the diameter of 
the emulsion droplet. The synthesized nanogels exhibited stimuli-responsive behavior, swelling in acidic 
environment was observed for all nanogels. This was a result of the protonation of residual ethylene 
imine groups and/or tertiary amines formed during the cross-linking reaction. In addition, nanogels made 
from the cleavable cross-linker could be readily disrupted in reducing environment due to the presence 
of disulfide bridges (Scheme 3).  
 
Scheme 3 Schematic illustration of the dual-responsiveness of PEtOx-based nanogels: swelling in acidic 
environment and chemical cleavage in reducing environment. 
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These nanogels may potentially be used to encapsulate hydrophilic bio-macromolecules such as proteins 
which can be released specifically in tissues of low pH (acidic environment, i.e. inflamed tissues) and/or 
where reducing agents are present such as glutathione, a reducing peptide mainly found in tumor tissues.  
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EXPERIMENTAL SECTION 
Materials and reagents 
2-Ethyl-2-oxazoline (99%), methyl trifluoromethanesulfonate (96%) (MeOTf), and acetonitrile (99%) were 
purchased from Sigma-Aldrich, stored over calcium hydride and purified by vacuum distillation prior to 
use. Methanol purchased from Sigma-Aldrich was refluxed with sodium and distilled prior to use. Diethyl 
ether, ethanol, potassium hydroxide (KOH), sodium hydroxide (NaOH), hydrochloric acid solution 
(37%) (HCl), dithiothreitol (DTT), cyclohexane (99%), 1,4-butanediol diacrylate (90%) PEG diacrylate (Mn 
= 700 g/mol), tris(4-hydroxyphenyl)methane triglycidyl ether and sorbitan monooleate (Span 80) were 
used as received from Sigma-Aldrich. 1,6-Hexanediol diglycidyl ether (98%) was purchased from BOC 
sciences. 1,2,7,8-Diepoxyoctane (97%), 4- butanediol diglycidyl ether (>90%) were purchased from TCI. 
4-arm PEG acrylate (pentaerythritol), Mw 10000 g/mol (99.8%) and 8-arm PEG succinimidyl adipate 
(hexaglycerol) Mw = 15000 g/mol (94.7%) were purchased from Jenkem technology. Hydroxyethyl 
disulfide-bis-diglycidyl ether was synthesized following a procedure reported in the literature (see 
Experimental procedure).53 
Instrumentation  
NMR spectroscopy. 1H NMR measurements were carried out at room temperature, on a Bruker 
Avance 1 spectrometer operating at 400 MHz. The D2O signal was used as the reference signal (δ = 4.79 
ppm), and the relaxation time was fixed to 7.5 sec for all measurements.  
Size-exclusion chromatography. Size-exclusion chromatography (SEC) using dimethylformamide 
(DMF) with LiBr (1 g/L) as the eluent was performed at 80 °C at a flow rate of 0.8 mL/min. The column 
set consisted of two 7.5 mm x 300 mm PLgel, 5 µm Mixed-D columns (Polymer laboratories) coupled to 
a guard column, 7.5 mm x 50 mm, PLgel, 5 µm model (Polymer laboratories). Injections were carried out 
in a 20 µL loop and calibrated using polystyrene standards. Differential refractive index (RI) and UV 
detectors were used. To determine the absolute polymer molecular weight, analytical SEC 
measurements were performed on a system with a Waters 510 HPLC pump, a 50 µL injection loop, and 
a Waters 410 differential refractometer (DRI) detector. A Wyatt MiniDAWN laser light scattering 
detector operating at a wavelength of 690 nm served to determine the absolute molecular weight of the 
polymers (measured at an angle of 90°). The column used was a 250 mm x 10 mm JORDI X-tream 
column Mixed bed model with a linear polystyrene molecular weight range of 102–107. This column is 
coupled with a guard column, a 50 mm x 10 mm JORDI X-tream Mixed Bed model. DMF with LiCl (1 
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g/L, added to minimize adsorption of the polymer on the column) at a flow rate of 1.0 mL/min served as 
the mobile phase, at room temperature. 
Titration. Titration was performed with a Metrohm 809 Titando autotitrator for simultaneous 
measurement of conductivity and pH. The titrator is equipped with Tiamo software, which doses µL 
quantities of titrants. All measurements were performed in a jacketed vessel at 25 °C while stirring at a 
medium speed. 50 mL of solutions of the samples at 0.8 g/L were prepared in DI water. The pH of the 
solutions was adjusted to ~3 by adding 0.5 M HCl. The solutions were titrated using 0.01 M NaOH 
under nitrogen blanket and stirring. Conductivity and pH of the solutions were measured simultaneously 
until the pH of the samples approached 11. Finally, the pH and conductivity values were plotted against 
the volume of NaOH (in mL). 
Intrinsic viscosity measurement. The intrinsic viscosities of partially hydrolyzed polymers were 
measured with an automated kinematic viscometer, MiniPV model, from the Cannon Instrument 
Company, at 25 °C. To do so, samples at different concentrations were prepared (1, 2, 4, 6, 8 mg/mL). 
For a known volume of a sample, the time taken for the level of the liquid to pass between two marks 
was measured twice. The relative, specific and reduced viscosities are directly calculated from these time 
values. The intrinsic viscosity corresponds to the value of the reduced viscosity when the concentration 
approaches zero.  
Polymers dn/dc measurements. The refractive index increment (dn/dc) measurements were 
conducted on a Brookhaven instrument, BI DNDC, at a wavelength of 620 nm. Polymer solutions were 
prepared in DMF with LiCl (1 g/L, the same solvent used for SEC measurements) at the following 
concentrations: 0.5, 1, 2, 3 and 4 mg/mL. Analyses were carried out with the preparatory software 
supplied with the instrument. 
Infrared spectroscopy. Infrared spectra were obtained on a Thermoscientific Nicolet IS10 
spectrometer using the attenuated total reflection (ATR) mode. The spectra were acquired using 16 
scans at a resolution of 4 wavenumbers. 
Dynamic light scattering. Dynamic light scattering (DLS) experiments of the nanogels prepared in 
dilute media were performed using an ALV CGS-3 Compact Goniometer System, equipped with a 35 
mW HeNe linear polarized laser with a wavelength of 632.8 nm and an ALV/LSE-5004 light scattering 
electronic and Multiple Tau Digital correlator. The accessible scattering angles ranged from 30° to 150°. 
Samples (2 mL in 2 cm diameter cylindrical glass cells) were immersed into a filtered toluene bath. Three 
independent 20 s measurements were carried out to obtain the dynamic data. Mean hydrodynamic 
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diameters and size distributions were determined using a cumulant analysis method. Samples were first 
filtered with 0.8 µm nitrocellulose membrane. DLS measurements of nanogels prepared in inverse 
emulsion were performed using a Brookhaven BI-200SM instrument equipped with a He-Ne laser 
operating at λ= 636 nm, at 20 °C. Measurements were performed at different angles and data analyses 
were carried out using the Gendist software. The samples were first filtered with 0.8 µm nitrocellulose 
membranes. 
Transmission electron microscopy. Transmission Electron Microscopy (TEM) images were 
recorded at Bordeaux Imaging center (BIC) on a Hitachi H7650 microscope working at 80 kV. Samples 
of nanogels synthesized in dilute media were prepared by drop depositing 0.7 µL of the nanogels solution 
in water onto a copper grid (200 mesh coated with carbon) and removing the excess after 5 min. 
Samples of the nanogels synthesized in inverse emulsion were prepared by drop depositing 0.7 µL of the 
solution of nanogels in THF onto a copper grid and left to dry. The grids were prepared in THF as it is 
miscible with both cyclohexane and water (the two emulsion phases), and if there is any surfactant left, it 
is also soluble in THF. As a matter of fact, only nanogels were observed. In both cases, they were 
subsequently stained with osmium tetraoxide vapour for 45 min. 
Experimental procedures 
Synthesis of hydroxyethyl disulfide-bis-diglycidyl ether (2). Cross-linker (2) was synthesized 
following an established synthetic protocol.53 In short, in a round bottom flask, 4.93 g of 2-hydroxyethyl 
disulfide (32 mmol), 3.98 g of sodium hydroxide (100 mmol) and 72 mg of tetrabutylammonium bromide 
(TBAB) (223 mmol) were mixed and heated to 40 °C. 8.3 mL of epichlorohydrin (105.9 mmol) was 
added dropwise and the reaction was stirred for 3 h. The final product was purified by column 
chromatography (alumina column, cyclohexane/ethyl acetate 1:4) to obtain a yellow liquid (973 mg, 11%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 3.77 (m, 6H, CHCH2OCH2CH2S), 3.35 (m, 2H, 
CHCH2OCH2CH2S), 3.08 (m, 2H, CHCH2OCH2CH2S), 2.86 (t, 4H, CHCH2OCH2CH2S), 2.74 (m, 2H, 
CH2OCHCH2OCH2CH2S), 2.54 (m, 2H, CH2OCHCH2OCH2CH2S). 13C NMR (400 MHz, CDCl3): δ 
(ppm) 71.8, 69.7, 50.8, 44.1, 38.6 
 
Scheme 4 Synthesis of cross-linker (2), hydroxyethyl disulfide-bis-diglycidyl ether 
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Synthesis of poly(2-ethyl-2-oxazoline) (PEtOx). A typical procedure is as follows. In a flame dried 
Schlenk flask, 13 mL of acetonitrile was introduced under vacuum. 56 µL of MeOTf (0.5 mmol) was 
added. The flask was then placed in an ice bath at 0 °C and 5.7 mL of 2-ethyl-2-oxazoline (56.6 mmol) 
was added. The flask was then heated to 85 °C where it remained for 3 days. The reaction as quenched 
via the addition of 2.7 equivalents of a 0.3 N KOH solution in methanol. The solution was left to stir at 
room temperature overnight and the polymer was precipitated twice into diethyl ether and dried under 
vacuum. Yield = 4.95 g (89%). 1H NMR (400 MHz, D2O): δ (ppm) 3.6-3.3 (d, NCH2CH2), 2.8 (d, CH3-
NCH2CH2), 2.4-2.1 (m, NCOCH2CH3), 1.0-0.8 (q, NCOCH2CH3). dn/dc = 0.0789 (in DMF + 0.1% LiCl). 
Mn (SEC) = 9259 g/mol, Ð = 1.28. DP = 94. 
Partial hydrolysis of PEtOx in acidic media. 1.14 g of P(EtOx)94 (1.22 × 10-4 mol) was dissolved in 
10 mL of DI water and heated under reflux (at 100 °C). Subsequently, 10 mL of 37% HCl solution was 
added to the polymer solution yielding a final polymer concentration of 50 g/L. After 2 h, the solution 
was left to equilibrate to room temperature. A solution of 2.5 M NaOH was added to achieve a solution 
pH of 8. The polymer was purified by dialysis against DI water for 3 days and collected by lyophilization. 
Yield = 0.59 g (52%). 1H NMR (400 MHz, D2O): δ (ppm) 3.6-3.3 (d, NCOCH2CH2), 2.8 (d, CH3-
NCH2CH2), 2.9-2.7 (s, NHCH2CH2), 2.4-2.1 (m, NCOCH2CH3), 1.0-0.8 (q, NCOCH2CH3). Ð = 1.20. IR: 
3484 (m), 2977 (s), 2939 (s), 2880 (m), 1621 (s), 1470 (m), 1420 (s), 1374 (s), 1320 (w), 1236 (m), 1194 
(s), 1078 (w), 1061 (m), 969 (w), 915 (w), 877 (w), 813 (m), 761 (w). %Hydrolysis: 1H NMR spectroscopy 
= 6.7%, titration = 5.3%. 
Hydrogel formation. To prepare the hydrogel, 10 mg of partially hydrolyzed poly(2-ethyl-2-oxazoline), 
denoted as P(EtOx88-EI6) where EI stands for ethylene imine, was dissolved in 100 µL of DI water and 4 
mg of 1,6-hexanediol diglycidyl ether (cross-linker 1) was added. The solution was stirred and heated at 
80 °C overnight. The mixture was then left to equilibrate to room temperature and a hydrogel was 
obtained. The gel was purified by dialysis against DI water for 2 days and collected by lyophilization. IR 
(hydrogel 1, Scheme 2): 3431 (m), 2976 (m), 2938 (s), 2875 (m), 1621 (s), 1470(w), 1420 (s), 1374 (m), 
1321 (w), 1238 (w), 1194 (s), 1109 (w), 1079 (w), 1061 (m), 914 (w), 814 (m), 761 (w). IR (hydrogel 2, 
Scheme 2): 3447 (m), 2976 (m), 2938 (s), 2875 (m), 1625 (s), 1470 (w), 1420 (s), 1375 (m), 1321 (w), 
1237 (w), 1194 (s), 1105 (w), 1079 (w), 1061 (m), 912 (w), 814 (m), 759 (w). 
Hydrogels made from the additional cross-linkers were prepared following the same procedure, keeping 
the molar ratio of reactive functionalities constant. Only the temperature and solvent were varied 
according to Table 2. 
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Chemical cleavage of hydrogels. Gels made with hydroxyethyl disulfide-bis-diglycidyl ether (cross-
linker 2) may be cleaved in a reducing environment. To do so, the hydrogel was purged with nitrogen for 
30 min and a solution of 30 mg (1.95 × 10-4 mol) of dithiothreitol (DTT) in 1 mL of degassed DI water 
was then added. The gel was stirred under nitrogen until complete dissolution of the gel was observed 
(within 5 minutes). 
Nanogel synthesis in dilute media. 10 mg of the partially hydrolyzed polymer P(EtOx88-EI6) was 
dissolved in 1000 µL of DI water. In another flask, a solution of 1,6-hexanediol diglycidyl ether (cross-
linker 1) at 80 mg/mL was prepared in ethanol. Both solutions were filtered through a 0.2 µm 
polypropylene filter and subsequently 28 µL of the cross-linker solution in ethanol was added to the 
polymer solution. The mixture was stirred at 800 rpm at 80 °C for 3 hours. The cross-linking reaction 
and nanogels formation was followed by DLS at an angle of 90° on a Malvern ZetaSizer NanoZS 
instrument. Once the nanogels were formed, they were purified by dialysis for 2 days against DI water. 
Nanogel synthesis in w/o emulsion. Nanogels were prepared in an inverse emulsion (W/O) process 
using ultrasonication. An aqueous solution containing 100 µL DI water, 10 mg of the partially hydrolyzed 
polymer P(EtOx88-EI6), and 4 mg of cross-linker was prepared. In another flask, 0.25 g of Span 80 in 5 g 
of cyclohexane were mixed together to form the organic phase. 0.8 g of the organic phase was 
transferred into an Eppendorf tube and the aqueous phase was added. The mixture was utrasonicated 
with an ultrasonic probe Q sonica, LLC from Misonix sonicators (XL-2000 series), for 2 min, at 6 W 
output. The emulsion was then transferred to a glass tube and placed in an oil bath to stir, at 80 °C, 
overnight. The product was then centrifuged and the supernatant (cyclohexane and surfactant) removed. 
The residue was then mixed with new cyclohexane, and the solution vortexed. This process was 
repeated 3 times. Subsequently, THF was added and the same process was repeated twice. Finally water 
was added and the resulting nanogel solution purified by dialysis for 3 days prior to any DLS 
measurements. The size of the nanogels was measured in DI water (0.5 mL). To study the influence of 
pH on the size of the nanogels, 24 µL of a 0.5 N HCl solution was added to 0.5 mL of the initial 
nanogels. When nanogels were prepared with the cleavable cross-linker (2), the nanogel sizes were 
measured after addition of DTT (16 µL of a DTT solution at 10 mg/mL was added to 0.5 mL of nanogel 
solution). 
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SUPPORTING INFORMATION  
The 1H NMR spectrum of PEtOx94 shows protons of the α-end of the polymer chain (CH3-) appearing 
as a double peak (peak a in Figure 1). The splitting of this peak was attributed to its attachment to the 
amide backbone, which has two resonance states.55 The rotation around the C-N bond of the amide is 
not completely free which leads to delocalization of the nitrogen to give a partial “double-bond 
character” to the C-N bond.  
 
 
Figure S1 SEC traces of poly(2-ethyl-2-oxazoline)94 and poly((2-ethyl-2-oxazoline)-stat-(ethylene imine)) 
copolymer obtained after 6.5 h of hydrolysis in DMF 
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Figure S2 SEC traces of poly(2-ethyl-2-oxazoline)94 and poly((2-ethyl-2-oxazoline)88-stat-(ethylene imine)6) 
statistic copolymer after 2 h of hydrolysis in DMF 
 
Figure S3 Determination of the intrinsic viscosity of poly(2-ethyl-2-oxazoline)94 by plotting the reduced viscosity 
as a function of the concentration. 
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Figure S4 FT-IR spectrum of poly((2-ethyl-2-oxazoline)88-stat-(ethylene imine)6) 
 
Figure S5 FT-IR spectrum of the dry hydrogel made with poly((2-ethyl-2-oxazoline)88-stat-(ethylene imine)6) 
and 1,6-hexanediol-diglycidyl ether 
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Figure S6 FT-IR spectrum of the dry hydrogel made up of poly((2-ethyl-2-oxazoline)88-stat-(ethylene imine)6) 
and hydroxyethyl disulfide-bis-diglycidyl ether (2) 
 
Figure S7 1H NMR spectrum (400 MHz, CDCl3) of hydroxyethyl disulfide-bis-diglycidyl ether (cross-linker 2) 
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Figure S8 HSQC NMR spectrum (400 MHz, CDCl3) of hydroxyethyl disulfide-bis-diglycidyl ether (cross-linker 2) 
 
Figure S9 Decrease in relative count rate (%) measured by DLS at 90°, after addition of DTT or DI water.  
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Appendix S1 – Determination of the critical concentration for gelation 
Once the intrinsic viscosity is known, the radius of gyration (Rg) of the polymer can be calculated using 
the Fox-Flory equation (1)56: 𝑅!!   = !   !!!       (1) 
where M is the polymer molecular weight, [η] its intrinsic viscosity and φ’ = 3.1 1024 (with [η] in cm3/g).  
The critical concentration corresponds to the concentration where the polymer chains start to entangle. 
Assuming polymer as hard spheres, the critical concentration can be written as follow: 
 
c* = 
!∗  !!!!  !!!!"# where ϕ*=  𝑉𝑐ℎ𝑎𝑖𝑛  𝑉𝑡𝑜𝑡𝑎𝑙  = 0.74 and  
Vchain = 
!!𝜋𝑅𝑔! 
 
 
Table S1 Determination of the critical concentration c* of poly(2-ethyl-2-oxazoline)94 
Polymer Mn (g/mol) 
PDI Mw 
(g/mol) 
[η] 
(dL/g) 
Rg 
(nm) 
V 
(m3) 
c* 
(g/L) 
P(Etox)94 9259 1.28 11851 0.1272 3.65 2.04 10-25 55.9 
 
Appendix S2 – DLS measurements/equations 
In DLS, a sample of particles in solution is placed in a laser beam. When the laser beam hits small 
particles, the light is scattered in all directions. DLS measurements rely on the fact that particles in 
solution undergo Brownian motions which lead to time-dependent fluctuations in the scattering intensity. 
The fluctuation rate is directly correlated to the size of the particles: the smaller the particle, the quicker 
they will move. 
The dynamic information on the particles is derived from an autocorrelation of the intensity trace 
recorded during the experiment (i.e. the cross-correlation of the intensity signal with itself, where the x 
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axis corresponds to the delay time, τ). From the inverse Laplace transformation of the intensity 
correlation function, a distribution plot of the relaxation times can be obtained. 
Then from equation (1), where n0 corresponds to the refractive index of the solvent, λ the wavelength 
of the laser and θ the angle at which the measurement is done, one can plot the decay rate (Γ) as a 
function of q², small spherical particles show no angular dependence, hence no anisotropy, 
resulting in a horizontal line. The translational diffusion coefficient DT corresponds to the slope 
of this line. 
𝑞 =    !!!!!"#  (!!)!      (1) 𝐷! =    Γ!! where Γ   =    !! 
The hydrodynamic radius can be calculated thanks to the Stokes-Einstein equation (2): 𝑅! = !!!!!η!!        (2) 
Where T is the temperature, kB the Boltzmann constant (1.38 10-23 J/K), η is the viscosity of the 
solvent.  
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Overview: A poly(2-isopropyl-2-oxazoline)-block-poly(2-methyl-2-oxazoline) copolymer, denoted as P(iPrOx-b-
MeOx), was synthesized by sequential cationic ring opening polymerization of the corresponding 2-alkyl oxazoline 
monomers. This copolymer exhibited a lower critical solution temperature (LCST) around 56 °C, due to the 
presence of the PiPrOx block. The ability of this polymer to crystallize in water above its LCST was further 
exploited to induce the self-assembly of the P(iPrOx-b-MeOx) block copolymer in aqueous solution. The influence 
of the hydrophilic stabilizing PMeOx block on the crystallization process and on the crystalline structures was then 
investigated in detail. Thus, spherical micelles of 32 nm diameter were observed by transmission electron 
microscopy (TEM) from an aqueous solution of the block copolymer solution above the LCST of PiPrOx. These 
micelles could be disassembled in a reversible manner when kept for a short period of time (i.e. t < 1h30) above 
the LCST and cooled down to room temperature. Annealing the copolymer solution for more than 1h30 at 65 °C 
induced the crystallization of PiPrOx, as evidenced by wide angle X-ray scattering (WAXS) experiments. This 
crystallization-driven self-assembly phenomenon resulted in a number of different morphologies, including core-
crystallized spherical micelles, non-spherical micelle-like nanostructures (nano-aggregates) and micron-size fibers, 
depending on annealing time, as observed both by dynamic light scattering (DLS) experiments and TEM imaging. 
The three morphologies were found to coexist, their relative proportion varying with the annealing time. Formation 
of micron-size range fiber-like structures might be explained by a re-organization of both core-crystallized micelles 
and nano-aggregates. The crystal structure, as determined by WAXS, indeed appeared to be identical to that of 
the PiPrOx homopolymer. Lastly, the influence of both the polymer concentration and the heating rate on the 
morphological behavior was also studied: while concentration was varied, the same crystalline structures were 
obtained but they were not predominant at the same annealing time, whereas when the heating rate was slower, 
the crystalline objects seemed to evolve towards better defined micron-size structures. 
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INTRODUCTION 
Block copolymers (BCPs) are formed by two or more homogeneous polymer fragments joined together 
by a covalent bond.1 Recent advances in precision macromolecular synthesis have allowed designing 
BCPs with engineered properties that can meet specific needs.2 As a result of the incompatibility 
between the two blocks, BCPs can self-assemble in solution3,4 into well defined nanostructures, including 
micelles of different shapes (spheres, cylinders or toroids)5,6 or polymeric vesicles (also referred to as 
polymersomes).7–9 In many cases, the self-assembly is driven by hydrophobic interactions. Some 
examples can also be found in the literature where the self-assembly is driven by electrostatic 
interactions between a pair of oppositely-charged BCPs,10 or BCPs with complementary chirality.11 
However, when multiple forces are involved, more complex nanostructures can be achieved.  
Interestingly, Manners and coworkers have reported that crystallization of one block can induce the self-
assembly of specific BCPs based on polyferrocenylsilane (PFS) that was used as the hydrophobic and 
crystallizable block. When PFS was arranged with a synthetic polypeptide block, namely, poly(γ-benzyl-
L-glutamate), self-assembly occurred in dimethylformamide (DMF). However, annealing the same 
solution induced crystal growth of PFS, which resulted into well-defined truncated elliptical micelles from 
the less ordered original structures.12 When PFS was associated to poly(2-vinylpyridine), the morphology 
of the self-assembled structures (spheres, cylinders, platelets) could be tuned, depending on the solvent 
selectivity, which was correlated to the different levels of crystallinity (amorphous, single core-crystal 
and polycrystalline, respectively).13 Cylindrical micelles of controlled length14 and fiber-like micelles15 
were also obtained with other copolymer systems. O’Reilly and coworkers also described some 
crystallization-driven self-assembly systems made from diblock poly(L-lactide)-block-poly(acrylic acid) 
(PLA-b-PAA), where the morphology was tuned from spherical to controlled-length rod-like micelles 
upon annealing. Interestingly, no core-crystallization occurred when amorphous atactic poly(lactide) was 
used.16–19  
In the present chapter, we report on the self-assembly and further crystallization of a particular 
polyoxazoline-based block copolymer, towards the formation of physically cross-linked structures at the 
nano- or the microsize range.  
As highlighted in the literature overview (chapter 1), the cationic ring-opening polymerization (CROP) of 
2-alkyl-2-oxazolines has been adapted for the synthesis of well-defined copolymers, which allows the 
tuning of their physico-chemical properties.20–22 For example, the hydrophobicity of the polymer is 
controlled by the length of the alkyl substituent, 2-methyl-, 2-ethyl-, and 2-isopropyl-2-oxazolines 
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resulting in water-soluble polymers at room temperature.23 Thermal properties of poly(2-oxazoline)s 
(POx) are also tunable over a broad range of temperature and are dependent on both their molar 
masses and their polymer architecture.24 The versatility of POx, associated with their interesting 
biological properties (structural similarities with polypeptides,25 biocompatible character and stealth 
behavior of some POx26–28) has led to their recent revival.  
Among the different 2-alkyl oxazoline monomers, the commercially available 2-isopropyl-2-oxazoline 
(iPrOx) is of particular interest. Its corresponding polymer, PiPrOx, is indeed a structural isomer of 
poly(N-isopropylacrylamide) (PNIPAAm). Like PNIPAAm, PiPrOx thus possesses a lower critical solution 
temperature (LCST) around 36 °C, 29–31 which makes it a good candidate for the design of thermo-
responsive polyoxazoline-based compounds.32 In addition, and in contrast to PNIPAAm, PiPrOx is 
capable of crystallizing above its LCST.33  
Advantage of such a behavior has been taken by Schlaad et al. who observed hierarchical structures, such 
as micron-size assemblies of fibrils from the homopolymer.34,35 The morphology was eventually found to 
evolve with time for a 1wt% PiPrOx aqueous solution that was heated to 65 °C; network-like structures 
developed into micron-size assemblies.36 A statistical copolymer made of iPrOx and 2-(3-butenyl)-2-
oxazoline units was also synthesized and found to self-assemble and crystallize above its LCST into 
spherical micron-size structures, which was further used for carbohydrate protein recognition.37 Self-
assembly and crystallization of a PiPrOx-graft-pullulan copolymer were also reported.38 Micron-sized 
ring-like structures with short fibrils emanating from the ring circumference, or a “sea urchin”–like 
morphology were obtained but other morphologies were observed, depending on the experimental 
conditions (addition of salts, with/without stirring). It is worth pointing out that PiPrOx is not the only 
POx that can undergo crystallization. Chiral POx,39 PEtOx40 and a series of homopolymers with linear 
side chains of different alkyl length41 were also demonstrated to crystallize upon annealing.  
In this chapter, we investigate the aqueous solution behavior of poly[(2-isopropyl-2-oxazoline)-block-
poly(2-methyl-2-oxazoline)] BCP, denoted as P(iPrOx-b-MeOx), above the LCST of PiPrOx. The 
synthesis, self-assembly and crystallization of P(iPrOx-b-MeOx) are investigated in details. To the best of 
our knowledge, this is the first study describing the self-assembly properties of POx-based BCPs induced 
by a crystallization phenomenon. The self-assembly into spherical micelles, above the LCST of PiPrOx, is 
evidenced by dynamic light scattering (DLS), whereas the change in morphology due to crystallization is 
monitored by DLS and transmission electron microscopy (TEM). The crystallization is analyzed by 
differential scanning calorimetry (DSC) and wide-angle x-ray scattering (WAXS). Lastly, the influence of 
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external parameters such as polymer concentration and heating rate on the morphologies formed is also 
discussed. 
I. SYNTHESIS OF P(IPROX50-b-MEOX50) COPOLYMERS BY CATIONIC RING 
OPENING POLYMERIZATION 
The P(iPrOx-b-MeOx) BCPs were obtained by sequential CROP of corresponding 2-oxazoline 
monomers, as depicted in  Scheme 1.42,43 In order to achieve a well-defined BCP, iPrOx has to be 
polymerized first as its corresponding macro-cation is more prone to initiate the polymerization of 
MeOx for the growth of the second bock, than if one starts by the polymerization of MeOx first.44,45 
Indeed, SEC traces showed some homopolymer PMeOx left over for the copolymer obtained by starting 
by the CROP of MeOx first (SI†, Figure S3). In contrast, a complete shift to the higher molecular weight 
region was noted when iPrOx was polymerized first, suggesting that all macro-PiPrOx chains could 
initiate the CROP of MeOx. Due to prolonged reaction times required for the synthesis of these BCPs 
(several days), some side reactions (chain transfer) also likely occurred to some extent, as a small tailing 
effect can be observed in the SEC traces (SI†, Figure S3). One possible way to obtain better defined 
copolymers would be to perform the sequential CROP in a microwave reactor, so as to dramatically 
shorten the reaction times.46 
The P(iPrOx-b-MeOx) block copolymer used in the rest of the study was obtained with a dispersity of 
1.19 and a degree of polymerization of 50 for each block (SI†, Figures S2 and S3). 
 
Scheme 1 Synthesis of P(iPrOx50-b-MeOx50) BCP by sequential cationic ring-opening polymerization  
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II. REVERSIBLE SELF-ASSEMBLY OF P(IPROX50-b-MEOX50) ABOVE THE 
LCST  
The cloud point, i.e. the temperature where turbidity first appeared,47 of a 10 mg/mL solution of 
P(iPrOx-b-MeOx) was evaluated by DLS measurements, and was determined to be approximately 57 °C 
(SI†, Figure S4). Due to the presence of the hydrophilic PMeOx block, the LCST was thus found to be 
higher than that reported for the PiPrOx homopolymer (around the body temperature).29,48–50 Below the 
LCST, the copolymer proved to be fully soluble in water. By increasing the temperature above the LCST, 
i.e. at 65 °C, the formation of well-defined micelles was noted, as shown in Figure 1. Sizes (d = 32 nm), as 
determined by DLS and TEM image statistical analysis, were in good agreement. 
 
Figure 1 P(iPrOx50-b-MeOx50) micelle characterization at 65 °C A) DLS analysis with correlogram and size 
distribution obtained at 90°, B) TEM micrograph C) distribution of micelle size by TEM, determined by Image J. 
Micelle formation above the LCST of the BCP was found to be a reversible process, but only if the 
corresponding aqueous solution was kept above the LCST for a short period of time (< 1h30). Thus, 
unimers were observed when the solution was cooled down to 25 °C, after heating at 65 °C, as 
summarized in Figure 2. 
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Figure 2 P(iPrOx50-b-MeOx50) micelles size evolution with temperature measured by DLS 
III. MORPHOLOGY EVOLUTION BY CRYSTALLIZATION OF P(IPROX50-b-
MEOX50) 
As mentioned above, PiPrOx has been reported to crystallize when kept for 2 hours or more above its 
LCST.34 In the present work, we studied the influence of the presence of the hydrophilic stabilizing 
PMeOx block on the crystallization process and on the as-formed crystalline structures.  
To monitor the morphology evolution with time, in situ DLS measurements were performed on a 10 
mg/mL copolymer sample of P(iPrOx50-b-MeOx50) in water, at 65 °C. We noted that the initially well-
defined and nearly monodisperse micelles progressively became unstable (Figure 3). Increase in 
polydispersity, count rate and size was indeed observed with time, indicating that micelles evolved into 
larger and increasingly less defined structures. Nevertheless, after about 4 hours, the system seemed to 
reach a steady state. 
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Figure 3 in situ DLS measurements of P(iPrOx50-b-MeOx50) in water at 10 mg/mL and 65 °C 
The change in morphology also resulted in a change of the solution turbidity. Crystal formation could 
also be macroscopically detected. This morphology evolution was found to be irreversible. In order to 
get a better understanding on the assembly behavior, aliquots were taken at different annealing times 
(1h30, 3h, 4h30, 7h and 24h) and were allowed to cool back to room temperature. No significant change 
in the scattered intensity was observed by DLS, compared to the sample measured in situ at 65 °C (SI†, 
Table S1), suggesting that the previously formed nano/micro-objects remained stable. Structures 
obtained at the different annealing times were further characterized by TEM (Figure 4). Withdrawn 
samples were deposited onto the TEM grid after cooling to room temperature, the nanostructures being 
supposedly ‘locked’, as suggested by DLS.  
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Figure 4 TEM micrographs of 10 mg/mL 
of P(iPrOx50-b-MeOx50) solution in water 
heated at 65 °C for 1h30, 3h, 4h30, 7h and 
24h 
At first glance, one can note that the 
P(iPrOx-b-MeOx) BCP did crystallize 
and that the morphologies obtained 
evolved with the annealing time. After 
1h30, indeed, some anisotropic fiber-
like structures were observed, with a 
polydispersity (PdI) of 0.28 as 
determined by DLS. After 3h, the 
proportion of fiber-like structures 
increased and appeared to arrange into 
denser “fiber-nods”. Nevertheless, 
some micellar nanostructures still 
remained present, suggesting that these 
micelles experienced a core-cross-
linking phenomenon due to the 
crystallization process. At longer 
annealing times, the proportion of 
fibers further increased until network-like structures were achieved. Yet, small non-spherical micelle-like 
nanostructures (nano-aggregates), around 30 nm in diameter, could still be detected. We assumed that 
the aforementioned structures could coexist at each annealing time, but differed only in their proportion. 
Due to the length scale difference, however, all of these structures could not be imaged. Our hypothesis 
is supported by the fact that small-sized nano-structures (core-cross-linked micelles or nano-aggregates) 
were still detected even after 24 h, as part of the fiber-like structures. It is thus highly likely that these 
primary crystalline nanostructures took part of the fiber formation.  
It is worth mentioning that crystallization only occurred above the LCST of P(iPrOx50-b-MeOx50) in 
aqueous solution. As the copolymer concentration was kept constant, progressive increase in the 
amount of crystalline materials, as determined by TEM, suggested that the extent of reversible micelles 
decreased proportionally. Thus, the self-assembled micelles might act as crystallization seeds and the 
spatial restriction caused by the crystallization of the PiPrOx block could result in the formation of the 
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observed nano-aggregates and fibers. A similar mechanism was described by O’Reilly et al. regarding the 
crystallization-driven self-assembly of PLA-b-PPA, where spherical micelles underwent crystallization that 
nucleated the growth of cylindrical structures.18 
The arrangement of the fibers seemed to evolve following specific steps. Firstly, individual growth was 
observed after which some fibers-nods were found. With increasing proportion of the fibers, inter-
connection between fibers occurred leading, ultimately, to a more uniform fiber-network.  
TEM observations were in agreement with results delivered by DLS (Figure 3). Initially (in the first hour), 
an increase in polydispersity was noted, as individual anisotropic fibers were formed, which coexisted 
with a large number of reversible micelles (not observable by TEM prepared at room temperature). 
Subsequently, a drop in polydispersity was noted, corresponding to the formation of larger and more 
isotropic fiber-nods shielding the smaller nanostructures. In a final step, upon formation of the fiber 
network, an increase in polydispersity was again observed  
Morphologies observed herein with the P(iPrOx50-b-MeOx50) BCP differed from those observed with 
the PiPrOx homopolymer, for which fibers initially formed and further assembled into micron-size 
spherical structures.36 This difference can obviously be explained by the presence of the PMeOx block, 
forming a hydrophilic stabilizing shell. Both core-cross-linked micelles and nano-aggregates were directly 
issued from the self-assembly of the BCP above its LCST, and the formation of a network -rather than a 
micro-spherical aggregated structure as observed by Schlaad et al.34,36- can be ascribed to the likely core-
shell structure of the block copolymer fibers.   
Crystal formation was also evidenced by DSC experiments. Thermograms of the P(iPrOx50-b-MeOx50) 
BCP obtained without any further post-treatment (dry polymer, at room temperature) and after 24 h of 
annealing at 65 °C are compared in Figure 5.  
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Figure 5 DSC thermograms of P(iPrOx50-b-MeOx50) without any further post-treatment and after 24 h heating 
in aqueous solution at 65 °C 
The glass transition temperature (Tg) was clearly detected at 74 °C for the non-treated BCP, highlighting 
its amorphous character. After 24 h of annealing at 65 °C (10 mg/mL), however, no Tg could be detected 
(DSC trace is flat in this region). In addition, three endothermic and exothermic peaks appeared, 
respectively, upon heating and cooling the latter sample. These peaks could be attributed to the melting 
and crystallization of the PiPrOx block, respectively (peaks areas matching very well each other). Multiple 
melting peaks during the heating scan is a known phenomenon for semi-crystalline polymers, such as 
poly(ethylene),51 poly(ether ether ketone)52,53 or poly(ether terephtalate).54 More recently, crystal main-
chain of enantiopure and racemic poly(2-butyl-4-ethyl-2-oxazoline)s also showed a similar behavior.39 
Multiple melting transitions can be explained by the following major mechanisms: partial melting-re-
crystallization of original crystals and subsequent re-melting during heating scan, namely, melt-
recrystallization, or melting of coexistent lamellar stack populations with different lamellar thicknesses 
and/or different degree of ordering or perfection, namely, dual lamellae population or finally melting 
and/or phase transformation between the different crystal structures.39,55  
It is interesting to note that, on the first heating curve of each copolymer (SI†, Figure S6), a melting peak 
was also detected around 200 °C, but that was not reversible in the time scale of the DSC experiment. 
This temperature corresponds to the melting temperature of the PiPrOx homopolymer.35 As the 
polymer was kept for over 2 years before DSC analyses, this peak might correspond to slow 
Chapter 3 
 110 
crystallization occurring under storage conditions. PMeOx and PiPrOx are both known to be 
hygroscopic polymers;35,56,57 thus, even small amounts of water uptake under storage conditions can 
induce crystallization, by increasing the polymer chain mobility, and favoring chain alignment.35 
In addition, the melting temperatures observed for the block copolymers on the DSC thermograms are 
lower than the melting temperature of the PiPrOx homopolymer, indicating that the crystals formed 
with the block copolymer are less perfect.  
In order to monitor the crystal structure with time, the same aliquots were dried and analyzed by wide 
angle X-ray scattering (WAXS; Figure 6).  
 
Figure 6 A) WAXS patterns of P(iPrOx50-b-MeOx50) after 1h40, 3h, 4h30, 7h and 24h of annealing at 65 °C. 
Peaks assignment according to ref. 35 B) Crystal structure adapted from ref. 35 
As in the case of the crystallization of the PiPrOx homopolymer, an amorphous halo was observed, and 
both the intensity and the sharpness of the crystalline peaks increased with time,36 confirming that the 
BCP exhibited semi-crystalline character. The majority of X-ray peaks could be assigned, matching those 
reported in literature (SI†, Figure S5 and Table S2).35,58 Thus, the two main peaks were observed at the 
same scattering angle as that of the homopolymer (2θ = 8° and 18.25° corresponding to d = 11.25 and 
4.85 Å, respectively). The first crystalline structure was thus identical to PiPrOx, with the polymer 
backbone being aligned along the [001] direction while the isopropyl side groups were alternately aligned 
along the [100] direction to either side of the backbone, and the amide dipoles oriented along the [010] 
direction, also alternating in direction (Figure 6 B).35 
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To gain a better insight into the types of crystallites, the nature of the interactions into the crystal 
structure was evaluated. Hydrophobic interactions59 are expected to play a crucial role in the 
crystallization phenomenon of our POx-based BCP, the crystallization occurring above the LCST, when 
the copolymer becomes amphiphilic. However, and as reported earlier, dipolar interactions could also be 
involved in the crystallization process.20,33,35 Solubility tests were carried out to investigate that point. 
BCPs were first annealed for 24h at 65 °C, dried and dispersed in pure water or in a mixture of water 
and trifluoroacetic acid (TFA) (SI†, Figure S7). In the former case, a turbid suspension was obtained, 
confirming that nanostructures remained intact, while in the water/TFA mixture, a clear solution was 
observed, suggesting that crystalline structures were disrupted by TFA. TFA is often used as additive to 
minimize aggregation phenomena due to hydrogen bondings34 in naturally occurring or synthetic 
polypeptides. However, hydrogen bonding interactions are not expected to develop neither in PMeOx 
nor in PiPrOx, although Schlaad et al. have suggested the existence of such interactions in PiPrOx in his 
first report.34 In our case, it is highly likely that TFA could minimize strong dipolar Van der Waals 
interactions in water solution of our BCP, and prevent crystallization from developing. In absence of 
TFA, the crystallization mechanism might be similar to that proposed by Winnick et al.,33 where 
hydrophobic interactions initially enable to arrange PiPrOx blocks close to each other, while the polymer 
chain shifts from trans and gauche conformation to an all trans conformation, leading to the alignment of 
dipolar amide groups35 and the development of inter-chain dipolar interactions, which favors main chain 
crystallinity (Figure 7).56  
 
Figure 7 Schematic representation of the changes in the conformation of PiPrOx in water as a function of 
temperature. Reprinted from ref. 33 
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IV. INFLUENCE OF EXTERNAL PARAMETERS ON THE CRYSTALLIZATION 
PROCESS 
It was previously demonstrated that the annealing time significantly not only influenced the crystal 
structures (core-crystallized micelles, nano-aggregates or fibers), but also their relative proportion. 
Other parameters, such as the heating rate and the polymer concentration, were varied in order to 
elucidate their respective influence on the crystalline structures.  
IV.1. POLYMER CONCENTRATION 
Firstly, the influence of BCP concentration on the crystallization process was investigated. To do so, a 
solution of 1 mg/mL was annealed at 65 °C and compared to the results previously obtained at 10 
mg/mL. The crystallization and morphology evolution were monitored both by DLS (Figure 8) and TEM 
(Figure 9).  
 
Figure 8 In situ DLS measurements of P(iPrOx50-b-MeOx50) in water at 1 mg/mL and 65 °C 
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Figure 9 TEM micrographs of 10 mg/mL of P(iPrOx50-b-MeOx50) solution in water heated at 65 °C for 1h30, 3h, 
4h30, 7h and 24h 
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At this lower concentration, the three morphologies previously observed at 10 mg/mL, i.e. fibers, nano-
aggregates and core-cross-linked micelles, were again evidenced. In this case, as the concentration was 
lower, smaller morphologies (nano-aggregates and core-cross-linked micelles) could be more easily 
detected. The polymer concentration was also found to have an influence on the kinetic of 
crystallization: at 10 mg/mL, core-cross-linked micelles were mainly observed after 7h of annealing at 65 
°C, whereas at 1 mg/mL the same structures were predominant already after 4h30. In addition, an 
increase in the count rate and size was again noted after 7h, by in situ DLS measurements whereas a 
plateau was already reached after 3h30 at a concentration of 10 mg/mL. 
IV.2. HEATING RATE 
The influence of the temperature was then studied by monitoring the morphology evolution with 
temperature. The BCP concentration was maintained at 10 mg/mL, and the solution was gradually 
heated, from 25 to 65 °C, at a rate of 0.1 °C/min (Figure 10). 
 
Figure 10 In situ DLS measurements of a 10 mg/mL P(iPrOx50-b-MeOx50) solution in water heated at 0.1 °C/min 
from 25 °C up to 65 °C. 
As long as the temperature was maintained below the LCST of the BCP, the count rate was close to the 
detection limit of the DLS, indicating that the BCP was well dispersed in water. Above the LCST, 
however, an increase in the count rate and size was observed, along with a decrease in polydispersity. A 
final size of 1100 nm (polydispersity of 0.20) was determined at 65 °C. In addition, when the solution 
was allowed to cool to 25 °C, a particle size of 1500 nm (polydispersity of 0.12) was found, with a count 
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rate comparable to that obtained at 65 °C (4007 kcps). This was attributed to the crystallization of the 
micron-size aggregates. The increase in particle size upon cooling might be explained by re-swelling of 
the aggregates as the BCP chains became more hydrophilic: the PMeOx blocks became more hydrated 
when the temperature was decreased to room temperature, and if all the PiPrOx blocks were not 
involved yet in the crystallization, the non-crystallized ones could swell. 
The heating rate had also a major influence on the nature of nanostructures:60 from micelle-like 
structures (16 nm of radius) to micron-size particles. The slower the BCP solution was heated, the 
longer the time was needed to reach and pass the LCST for all copolymer chains (LCST is molecular 
weight dependent).29 As a consequence, there is a temperature range where copolymer chains are partly 
amphiphilic, with other chains being still hydrophilic. Their organization being slower, self-assembly 
competes with the crystallization process, leading to the formation of larger structures. However, when 
the copolymer solution is heated rapidly above its LCST, all the chains become amphiphilic more or less 
simultaneously, self-assembling into micelles. To get more insight into the micron-size structure formed, 
it would be worth trying to image them and study their crystalline morphologies (micelle-like structure 
or micron-size aggregates made of fibers, etc.).  
CONCLUSIONS 
In this chapter, the aqueous solution behavior of a particular block copolymer, P(iPrOx50-b-MeOx50), 
synthesized by sequential CROP, was investigated at temperatures above the cloud point (56°C) of the 
PiPrOx. When heated to 65 °C for a short period of time, well-defined and reversible micelle-like 
nanostructures were evidenced by DLS and TEM imaging, with a hydrodynamic diameter of 32 nm.  
Annealing this BCP above its LCST for a period of time higher than 1h30, induced the crystallization of 
PiPrOx, as attested by combined techniques, including WAXS, DSC, and TEM. The longer the annealing 
time, the higher the extent of crystallinity. Monitoring the crystallization process by DLS and TEM 
showed that three different morphologies, namely, core-crystallized micelles, nano-aggregates and fibers 
were achieved, as illustrates in Scheme 2. 
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Scheme 2 Schematic representation of the nano-structures formed depending on the annealing time 
These structures were eventually found to coexist at varying ratios as a function of the annealing time. 
TEM analysis suggested that the initially formed nano-aggregates and/or micelle-like structures were 
involved in fiber formation. Different morphologies were thus obtained, in comparison to those 
previously observed for the PiPrOx homopolymer, which was attributed to the stabilizing effect of the 
hydrophilic PMeOx block. Investigations by WAXS showed that the observed crystal structure was the 
same as that of the homopolymer (PiPrOx), at the short range, despite achieving different morphologies 
by TEM. Main chain crystallinity was evidenced and proved to be driven by both hydrophobic and dipole-
dipole interactions. These can be disrupted using a simple additive such as trifluoroacetic acid, that would 
minimize strong dipolar Van der Waals interactions in water solution of our BCP, and prevent 
crystallization from developing. Lastly, as the copolymer chains were in a non-equilibrium state, the final 
crystalline structures obtained were varying with external parameters: both the polymer concentration 
and heating rate were found to influence the final morphologies obtained. Further tuning of the annealing 
conditions and copolymer properties (block ratio, copolymer architecture) may be interesting to achieve 
control over the crystal evolution and the final morphology. It might also be possible to achieve other 
crystalline structures 
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EXPERIMENTAL SECTION 
Materials and reagents 
2-Methyl-2-oxazoline (99%) (EtOx), methyl trifluoromethanesulfonate (96%) (MeOTf), and acetonitrile 
(99%) were purchased from Sigma-Aldrich, stored over calcium hydride and purified by vacuum 
distillation prior to use. Methanol purchased from Aldrich was refluxed with sodium and distilled prior to 
use. Diethyl ether, potassium hydroxide (KOH), isobutyronitrile (99.6%) and cadmium acetate dehydrate 
(98%) were purchased from Sigma-Aldrich and used as received. 2-Aminoethanol was purchased from 
Fisher Scientific. 2-Isopropyl-2-oxazoline (iPrOx) was synthesized as described elsewhere (see 
Experimental procedures).61 
Instrumentation and measurements 
NMR spectroscopy. 1H NMR measurements were carried out at 298K on a Bruker Avance I 
spectrometer operating at 400 MHz. CDCl3 or D2O were used as an internal reference (δ = 7.26 and 
4.79 ppm respectively), and the relaxation time was fixed to 5 sec for all measurements.  
Size-exclusion chromatography. Size-exclusion chromatography (SEC) using dimethylformamide 
(DMF) with LiBr (1 g/L) as the eluent was performed at 80 °C at a flow rate of 0.8 mL/min. The column 
set consisted of two 7.5 mm × 300 mm PLgel, 5 µm Mixed-D columns (Polymer laboratories) coupled to 
a 7.5 mm × 50 mm, PLgel, 5 µm guard column (Polymer laboratories). A 20 µL injection loop was used 
and calibration was performed with polystyrene standard. Differential refractive index (RI) and UV 
detectors were used. 
Dynamic light scattering. Dynamic light scattering measurements (DLS) were run in triplicate on a 
Malvern Zetasizer apparatus (Nano-ZS90 model), at a back scattering angle of 90 °. 
Transmission electron microscopy. Transmission Electron Microscopy (TEM) images were 
recorded at Bordeaux Imaging center (BIC) on a Hitachi H7650 microscope working at 80 kV. Samples 
were prepared by drop depositing 0.7 µL of a 0.05 wt% of the desired copolymer solution onto a copper 
grid (200 mesh coated with carbon) and removing the excess after 5 minutes. In order to image the 
reversible micelles observed only above the LCST of the copolymer, the grid was left to dry at 65 °C (i.e. 
above the LCST). Statistical size analyses of particles observed by TEM were carried out using Image J. 
Differential scanning calorimetry. Differential scanning calorimetry (DSC) measurements were 
carried out on a Q1000 apparatus from TA Instruments. DSC experiments were performed in 
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aluminium sealed pans, at a constant heating/cooling rate of 10 °C/min and gas purging (N2) at a flow rate 
of 100 mL/min.   
Wide angle X-ray scattering. Wide angle X-ray scattering experiments (WAXS) were carried out at 
the Centre de Recherche Paul Pascal (CRPP, Pessac, France). Measurements were carried out on a 
Rigaku Nanoviewer (XRF microsource generator, MicroMax 007HF ) with a rotating copper anode 
coupled to a confocal Osmic Max-Flux mirror (Applied Rigaku Technologies, Austin, USA), producing a 
beam with a wavelength of 1.5418 Å with an energy of 8 keV. Data were collected with a Mar345 
detector (Marresearch, Norderstedt, Germany). Polymer solutions were freeze-dried and put into a 1.5 
mm diameter glass capillary, placed at a distance of 150 mm away from the detector (diameter of 345 
mm), providing access to 2θ angles in the range of 0.9° to 49°. 
Experimental procedures 
Synthesis of 2-isopropyl-2-oxazoline (iPrOx). 2-Isopropyl-2-oxazoline (iPrOx) was synthesized as 
described elsewhere: 61 
 
Scheme 3 Synthesis of 2-isopropyl-2-oxazoline 
2-Amino-ethanol (51 g, 0.83 mol) was added drop-wise to a suspension of isobutyronitrile (54.5 g, 0.79 
mol) and cadmium acetate dihydrate (10.65 g, 0.04 mol) at 130 °C. The solution was stirred for 24 h at 
130 °C and then fractionated by vacuum distillation. Yield: 64 g (0.57 mol, 72%). 1H NMR (400 MHz, 
D2O, δ): 1.1 (d, 6H, CCH(CH3)2 ), 2.35 (m, 1H, CCH(CH3)2), 3.7 (t, 2H, OCH2CH2N), 3.96 (t, 2H, 
OCH2CH2N). NMR Spectrum: Figure S1. 
Synthesis of poly[(2-isopropyl-2-oxazoline)50-block-poly(2-methyl-2-oxazoline)50] 
(P(iPrOx50-b-MeOx50)). A typical procedure was as follows: in a flame dried Schlenk flask, 6.6 mL of 
acetonitrile was introduced under vacuum. 28.3 µL (0.25 mmol) of MeOTf was added. The flask was then 
placed in an ice bath at 0 °C and 1.48 mL (12.5 mmol) of 2-isopropyl-2-oxazoline was added. The flask 
was then maintained at 85 °C for 3 days, until complete consumption of the monomer (monitored by 1H 
NMR spectroscopy). 1mL of 2-methyl-2-oxazoline (11.7 mmol) was added and the reaction was 
quenched by adding 2.7 equivalents of a 0.3N KOH solution in methanol at 95% conversion (determined 
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by 1H NMR spectroscopy). The solution was left to stir at room temperature overnight and the polymer 
was precipitated twice into diethyl ether and dried under vacuum. Yield = 2.08 g (89 %). 1H NMR 
(400 MHz, D2O, δ): 3.7-3.3 (s, NCH2CH2), 3.1 (s, CH3-NCH2CH2), 3.0-2.55 (d, COCH(CH3)2), 2.2-2.0 
(m, NCOCH3), 1.15-1 (s, NCOCH(CH3)2). Ð = 1.19. 
Synthesis of poly[(2-methyl-2-oxazoline)50-block-poly(2-sopropyl-2-oxazoline)50] (P(MeOx50-
b-IPrOx50)). The same procedure, as described above for P(iPrOx50-b-MeOx50) was also used to 
synthesize P(MeOx50-b-IPrOx50), except the monomers were added in the reverse order. Yield = 1.15 g 
(47 %). 1H NMR (400 MHz, D2O, δ): 3.7-3.3 (s, NCH2CH2), 3.1 (s, CH3-NCH2CH2), 3.0-2.55 (d, 
COCH(CH3)2), 2.2-2.0 (m, NCOCH3), 1.15-1 (s, NCOCH(CH3)2). Ð = 1.33. DP(MeOx) = 52, DP(iPrOx) 
= 50. 
SUPPORTING INFORMATION 
 
Figure S1 1H NMR spectrum (400 MHz, CDCl3) of 2-isopropyl-2-oxazoline (iPrOx) 
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Figure S2 1H NMR spectrum (400 MHz, CDCl3) of poly[(2-isopropyl-2-oxazoline)-b-(2-methyl-2-oxazoline)] 
(P(iPrOx-b-MeOx)) 
 
 
Figure S3 SEC trace of A) poly[(2-methyl-2-oxazoline)-b-(2-isopropyl-2-oxazoline)] and B) poly[(2-isopropyl-2-
oxazoline)-b-(2-methyl-2-oxazoline)] in DMF 
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Figure S4 DLS measurements determining the cloud point of P(iPrOx-b-MeOx) (cloud point =  57 °C) 
 
Table S1 DLS measurements determined at 65 and 25 °C of aliquots taken at a various annealing times after 
annealing at 65 °C 
 65 °C  25 °C 
Annealing 
time 
Size 
d (nm) 
PdI Count rate 
(kcps) 
 Size 
d (nm) 
PdI Count rate 
(kcps) 
1h30 423 0.69 1898  796 0.28 1947 
3 h 2666 0.71 4810  2712 0.62 9879 
4h30 2956 1 4580  3793 0.85 9546 
7 h 3140 1 4510  2725 1 4676 
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Figure S5 WAXS patterns of P(iPrOx50-b-MeOx50) after 1h40, 3 h, 4h30, 7 h and 24 h of annealing at 65°C. Peak 
assignment according to ref. 35 
 
Table S2 WAXS scattering angles and corresponding spacing between the crystallographic planes obtained 
from Bragg’s law 
Crystallographic 
planes 
2θ 
(°) 
d 
(Å) 
(100) 7.89 11.21 
? 15.05 5.89 
(101) 16.56 5.35 
(010) 18.28 4.86 
? 19.22 4.62 
(201) 21.72 4.09 
(011) 23.59 3.77 
(210) 24.38 3.65 
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Figure S6 DSC thermograms of the first heat ramp of P(iPrOx50-b-MeOx50), non-treated and kept under 
storage condition (blue) and after 24 h of heating in aqueous solution at 65 °C (red) 
 
 
Figure S7 Appearance of P(iPrOx50-b-MeOx50) in water/trifluoroacetic acid mixture (1/5 v/v) and in pure water 
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Appendix S1 - WAXS measurement principle and determination of the crystal structure 
Wide-angle X-ray scattering (WAXS) is a non-destructive characterization technique which probes 
matter ordering on the angstrom-scale. It is often used to determine the crystalline structure of 
polymers. It consists of the observation of the scattered intensity of an X-ray beam hitting a sample as a 
function of the incident and scattered angles. As the angles for coherent and incoherent scattering from 
a crystal lattice are obtained (Figure S8), by using Bragg's law (equation 1), the spacing between the 
crystal planes can be calculated, and a crystal structure can be proposed. 
 
Figure S8 Illustration of constructive and destructive interferences. Adapted from ref. 62 
Bragg’s law:     λ = 2dsin(θ)       (1) 
Where  λ is the wavelength of the incident wave 
d is the spacing between the crystalline planes 
θ is the angle between the incident ray and the scattering planes 
Demirel et al.40 reported the structural model of the homopolymer PiPrOx crystal, based on WAXS and 
scanning force microscopy (SFM) data of the nanofibers, collected using Cerius 2 software. A periodicity 
of d = 11.25 Å (corresponding to WAXS peak at 2θ = 7.85°) could only be achieved when the side 
chains of neighboring polymers formed a bilayer. Steric constraints prevent the orientation of the 
neighboring side chains in the same direction, thus alternation of side chains on either side of the 
backbone was determined. This starting structure was then refined by rotations of the isopropyl groups 
and the carbonyl groups separately such that the calculated WAXS peaks by Cerius 2 software 
reproduced the experimental WAXS data.  
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CHAPTER 4 
KETAL- AND ALDEHYDE-FUNCTIONAL 
COPOLYMERS BASED ON POLY(2-OXAZOLINE) 
FOR POST-POLYMERIZATION MODIFICATION 
 
 
 
Keywords: Aldehyde, hydrogel, poly(2-oxazoline), post-polymerization modification, aldolization, 
        transacetalization. 
 126 
  
 
 
 
 
 
  
 127 
Overview: Protected and non-protected homopolymers and related statistical copolymers based on poly(2-
oxazoline) were synthesized by cationic ring-opening (co)polymerization, using a protected aldehyde 2-oxazoline 
monomer, namely, 2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline (DPOx). The (co)polymer precursors were 
subsequently used as reactive platforms enabling the synthesis of miscellaneous derivatives, including graft and 
cross-linked copoly(2-oxazoline)s. Aldehyde-functional (co)polymers were first reacted with mono- or bi-functional 
amino- and hydrazido-containing reagents, forming grafted copolymers or chemically cross-linked networks, 
respectively. The latter compound consisting of hydrazone-type linkages formed hydrogels that could be slowly 
degraded at physiological pH over 3 days, but readily cleaved in a more acidic environment (pH = 3). Aldehyde-
containing (co)polymers were also found to be subject to an intermolecular self-aldolization reaction under acidic 
conditions, leading to branching and ultimately to the formation of dense 3D-networks. As for (co)polymer 
precursors possessing protected aldehyde functions in the form of ketal rings, they could be directly reacted with a 
large excess of poly(ethylene glycol) (PEG), via transacetalization, forming PEG-grafted poly(2-oxazoline)s.  
Part of this chapter has been published in European Polymer Journal in 2014.12 
  
 
1 Legros, C.; Pauw-Gillet, M.-C. De; Tam, K. C.; Lecommandoux, S.; Taton, D. Eur. Polym. J. 2014,  
DOI: 10.1016/j.eurpolymj.2014.08.026. 
 
 128 
 	  
 129 
 
CHAPTER 4 
KETAL- AND ALDEHYDE-FUNCTIONAL COPOLYMERS 
BASED ON POLY(2-OXAZOLINE) FOR POST-
POLYMERIZATION MODIFICATION 
	  
INTRODUCTION	  ..........................................................................................................................................	  131	  
I.	   SYNTHESIS	  OF	  PDPOX21	  BY	  CATIONIC	  RING-­‐OPENING	  POLYMERIZATION	  ............................................	  132	  
II.	   CONJUGATION	  OF	  POBOX	  WITH	  AMINO-­‐CONTAINING	  REAGENTS	  .....................................................	  133	  
III.	   COPOLYMER	  SYNTHESIS	  AND	  DEPROTECTION	  OF	  P(MEOX41-­‐STAT-­‐DPOX9)OH	  ....................................	  135	  
IV.	   HYDROGEL	  FORMATION	  BETWEEN	  P(MEOX93-­‐STAT-­‐OBOX11)PIP	  AND	  ADIPIC	  ACID	  DIHYDRAZIDE	  ..	  138	  
V.	   TRANSACETALIZATION	  REACTION	  FROM	  P(MEOX41-­‐STAT-­‐DPOX9)OH	  WITH	  AN	  EXCESS	  OF	  PEG300	  .......	  139	  
CONCLUSIONS	  ............................................................................................................................................	  142	  
EXPERIMENTAL	  SECTION	  ............................................................................................................................	  143	  
SUPPORTING	  INFORMATION	  ......................................................................................................................	  149	  
REFERENCES	  ...............................................................................................................................................	  161	  
 
  
 130 
 
 
 
 131 
INTRODUCTION 
Post-polymerization modification, also called polymer-analogous modification, is a powerful synthetic 
tool in polymer chemistry. It consists in accessing new polymers by modification of a preformed polymer 
carrying functional handles that are chemically or physically transformed. Interestingly enough, diverse 
polymer derivatives with different structures and properties can be achieved from one single reactive 
polymer precursor.1–3 For example, post-polymerization modification allows for chemical transformation 
of commodity polyolefins into value-added materials,4 or to tailor poly(carbonate)s for specific 
biomedical applications.5–7 A wide variety of chemoselective and/or orthogonal reactions, including thiol-
ene addition,8 thiol exchange, Diels-Alder cycloaddition,9 Michael addition or reactions with active 
esters,10 epoxides, anhydrides, isocyanates, ketones and aldehydes, have been applied to modify 
functional polymer precursors.11,12  
Aldehyde functional groups are of special interest owing to the diversity of reactions that can be 
implemented with antagonist functional groups, such as alcohols, amines and hydrazines, forming 
reversible acetal, imine, and hydrazone linkages, respectively. Moreover, aldehydes can also be reduced 
to hydrocarbons via the so-called Wolff-Kishner reaction.13 They are also involved in key reactions in 
molecular chemistry, such as Grignard, Wittig and aldolization reactions.14,15 Surprisingly, the number of 
reports describing polymers with pendant aldehydes is somewhat limited. The synthesis of polymers with 
aldehyde handles can be achieved by anionic16 and cationic polymerization,17 ring opening metathesis 
polymerization,18 reversible addition-fragmentation chain transfer19–22 or by the modification of 
biopolymers.23 Related (co)polymers have been further employed to engineer polymer materials for 
specific applications: injectable hydrogels,24–27 microgels via a microfluidic device,28 or shell cross-linked 
micelles29 obtained with dihydrazide cross-linkers. Nanoparticles were also formed using a copolymer 
based on vinylbenzaldehyde units; further cross-linking or conjugation with chemotherapy compounds via 
Schiff base or imine formation was achieved.30 Lastly, poly(4-vinyl benzaldehyde) has also been 
successfully functionalized with desired compounds using the Kabachnik-Fields post-polymerization 
reaction.31 
Here, we investigate the potential of poly(2-oxazoline)s (POx) possessing pendant aldehyde functions for 
polymer-analogous modification. POx represent a special class of polymers that have (re)gained an 
increasing interest in the last decade. This is due, in particular, to their structural similarities with 
polypeptides,32 the biocompatible character and the stealth behaviour of some POx.33–35 In addition, the 
relatively easy access to POx by cationic ring opening polymerization36,37 allows the tuning of their 
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physico-chemical properties, such as hydrophilicity and thermo-responsiveness.38–40 The synthesis of POx 
with functional handles can also be achieved by resorting to specific functional 2-oxazoline monomers, 
which most often requires protection of the functional group prior to its (co)polymerization, in order to 
avoid side reactions. Synthetic strategies to functionalize POx have been recently reviewed.41,42 Alkene- 
or alkyne-functionalized monomers can remain unprotected,43–45 but monomers containing an amine46 or 
alcohol47 require protection in the form of tert-butyloxycarbonyl (BOC) or ester groups, respectively. To 
the best of our knowledge, there is only one report about the synthesis and post-polymerization 
modification of aldehyde-functional POx, as described by Taubmann et al.,17 who employed a protected 
aldehyde oxazoline monomer in the form of a ketal ring. POx with pendant aldehyde functions was 
readily obtained after deprotection, and subsequent modification with amino-oxy-containing reagents 
yielding the oxime was reported. 
In this chapter, we wish to further exploit the reactivity of such POx-based (co)polymers bearing 
pendant protected and non-protected aldehyde functions. We demonstrate that aldehyde-containing 
POx can readily react with mono- and bi-functional amines and hydrazines, enabling the synthesis of both 
grafted POx and POx-based hydrogels that can be chemically cleaved off under acidic conditions. We 
also evidence that aldehyde-containing POx chains can undergo intermolecular aldolization under acidic 
condtions. Lastly, the functionalization of POx through transacetalization of ketal-containing POx 
(protected form) is also presented. 
I. SYNTHESIS OF PDPOX21 BY CATIONIC RING-OPENING POLYMERIZATION 
Following a similar protocol to the one employed for non-functional polymers, the aldehyde protected 
polyoxazoline, PDPOx, was obtained via cationic ring opening polymerization of 2-[3-(1,3)-dioxolan-2-
ylpropyl]-2-oxazoline (DPOx), in the presence of N-methyl-2-methyl-2-oxazolinium triflate (MeOxOTf) 
as initiator, and acetonitrile as solvent (see Scheme 1). Taubmann et al. showed that MeOxTf and methyl 
trifluoromethanesulfonate (MeOTf) were both efficient to initiate this polymerization,17 but an 
oxazolinium salt was used as initiator for the polymerization as a proof of concept for further synthesis 
of an end-functionalized PDPOx.36 PDPOx was obtained with a degree of polymerization (DP) close to 
the target based on the initial [DPOx]0/[MeOxOTf]0 molar ratio, with a narrow dispersity (Ð = 1.17) 
(SI†, Figure S3). Both 1H and 13C NMR spectra confirmed that the aldehyde functionality remained 
protected in the form of the ketal ring after polymerization (SI†, Figure S3). The deprotection step of 
PDPOx21 was next accomplished by hydrolysis, using a 5% TFA solution. As discussed by Taubmann et 
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al.,17 this ketal hydrolysis is equilibrated, hence the reaction was carried out in a dialysis setup to achieve 
full conversion (see Scheme 1). Analysis by 1H NMR spectroscopy of the resulting compound attested to 
complete deprotection, as the characteristic signals due to the protons of the cyclic ketal rings vanished 
after hydrolysis; instead, the signal of the aldehyde proton appeared at 9.7 ppm (SI†, Figure S4). In 
addition, two peaks appeared at 2731 cm-1 and 1715 cm-1 in the FTIR spectrum, which could be assigned 
to the C-H and C=O stretches of the aldehyde group, respectively (SI†, Figures S5 and S6).  
 
Scheme 1 Cationic ring opening polymerization of 2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline and subsequent 
deprotection (inspired from ref. 17) 
II. CONJUGATION OF POBOX WITH AMINO-CONTAINING REAGENTS 
Taubmann et al. have already reported the post-polymerization modification of POBOx through the 
reaction of aldehyde groups with amino-oxy compounds in methanol, at 50 °C.17 Our aim here was to 
further expand the reactivity of this polymer precursor with respect to a range of either mono- or bi-
functional commercial amines and dihydrazines, under mild conditions. Both modifications involve a first 
step that is reversible, forming an imine and a hydrazone, respectively.48,49 The second step consists in 
the irreversible reduction of the functional polymer intermediate into a secondary amino-functional 
polymer derivative. POBOx21 was thus treated with an excess of benzylamine in a sodium acetate 
solution at pH = 5.4,50 which was followed by a reduction using sodium cyanohydroborate (see Figure 1). 
Note that benzylamine is sparingly soluble in water, favoring precipitation of the imino-containing 
reaction product.48 The poor solubility of the polymer in aqueous solution and in common organic 
solvents, even after purification, suggested the formation of an amphiphilic compound due to efficient 
grafting of benzylamine onto POBOx21. This was verified by FTIR showing the disappearance of the two 
signals of the aldehyde (2731 cm-1 and 1715 cm-1), while signals characteristic of aromatic C-H and C=C 
bendings appeared at 736 cm-1 and 700 cm-1 and at 1570 cm-1, respectively (SI†, Figure S7).  
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Reductive amination was also carried out using Jeffamine D400 and adipic acid dihydrazide in sodium 
acetate solution. As both reagents are bi-functional, both could act as cross-linkers, giving rise to gels, as 
illustrated in Figure 1. FTIR of compounds purified by dialysis was again used to confirm the successful 
ligation, with complete disappearance of the aldehyde peaks along with the appearance of a characteristic 
ether C-O stretch at 1090 cm-1 for the polymer derived from Jeffamine D400, and of the amine N-H 
stretch at 3248 cm-1 from that issued from adipic acid dihydrazide (SI†, Figures S8 and S9). In contrast, 
the same reaction performed with POBOx-based statistical copolymers did not lead to gel formation in 
aqueous solution (see further). 
 
Figure 1 Post-polymerization modification of POBOx21 with benzylamine, Jeffamine D400 and adipic acid 
dihydrazide  
Thus, the successful reaction of POBOx21 with several amine or hydrazine compounds confirmed the 
accessibility of the aldehyde functionalities, enabling the access to grafted or cross-linked polymer 
derivatives. In all cases, post-polymerization modification was effective under mild conditions, i.e. at room 
temperature in aqueous solution.17 The ligation with adipic acid dihydrazide can be considered as 
chemoselective as the amino-oxi “click” ligation reaction.51 
Ketal- and aldehyde-functional POx copolymers for post-polymerization modification 
 135 
III. COPOLYMER SYNTHESIS AND DEPROTECTION OF P(MEOX41-STAT-
DPOX9)OH 
A statistical copolymer based on 2-methyl-2-oxazoline (MeOx) and DPOx was synthesized in order to 
tune the density of pendant reactive groups. In their report, Taubmann et al. established that both 
monomers are consumed at the same rate during copolymerization, providing statistical 
copolyoxazolines.17 A statistical copolymer with 20% of DPOx was thus prepared. The copolymer was 
obtained with a DP for each monomer unit close to targeted values, and a dispersity of 1.14 (SI†, Figures 
S10, S11 and S12). Deprotection of the copolymer led to a derivative that was hardly soluble in DMF, 
hence SEC was performed in Tris buffer as the elution solvent. Broadening of the SEC trace and 
appearance of a shoulder in the high molecular weight region was noted after deprotection (Figure 2). 
Analysis by SEC of another copolymer sample, 10 days after deprotection, showed an even more 
noticeable molecular weight shoulder. This suggested the occurrence of subsequent intermolecular 
reactions involving the deprotected aldehyde functions in the dry state. 
 
Figure 2 SEC traces in Tris buffer of P(MeOx41-stat-DPOx9)OH before and after deprotection 
In the case of the P(OBOx)21 homopolymer discussed above, such intermolecular reactions were not 
studied in details; this sample was readily dissolved in acetate buffer after deprotection and the work-up 
procedure was slightly different from the copolymeric samples. Nevertheless, P(OBOx)21 was less 
soluble in the acetate solution during the post-polymerization reaction, indicating that some 
intermolecular branching/cross-linking may have also occurred in this case.  
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To explain these observations, we hypothesized that pendant aldehyde functions could be subjected to 
an aldolization reaction in the presence of catalytic acid traces. In a second step, the as-generated aldol 
units could undergo a dehydration step (referred to as the crotonization reaction15), leading to α,β-
unsaturated groups (see Scheme 2). It should be noted that the alcohol terminal functionality of the 
copolymer chain could also be involved in aldol formation.  
 
 
Scheme 2 Aldol condensation and subsequent dehydration resulting in α,β-unsaturated aldehydes 
To test our hypothesis the deprotected polymer, P(MeOx41-stat-OBOx9)OH, was analyzed by solid state 
13C NMR at two rotation speeds (changing the rotation speed allows determining the presence of 
rotation peaks; SI†, Figure S15). Only one rotation peak was found (indicated by a star in Figure 3), and 
the observation of diagnostic peaks due to alkene groups clearly confirmed the occurrence of aldol 
formation, followed by dehydration.  
 
Figure 3 Solid state 13CNMR of the self-cross-linked P(MeOx41-stat-OBOx9)OH, rotation speed = 10000 Hz, ns = 
160000 
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A series of statistical copolymers based on DPOx were then synthesized (P(MeOx63-stat-DPOx14)pip, 
P(Me Ox124-stat-POx12)OH and P(MeOx93-stat-DPOx11)pip; see Table 1 in the experimental procedure 
section and SI†, Figures S13 and S14), in order to study the influence of aldehyde density on the 
occurrence of the aldol reaction. SEC traces show a bimodal distribution in some cases. For instance, a 
shoulder can be noted in the low molecular weight region of the SEC traces of both P(MeOx124-stat-
POx12)OH and P(MeOx93-stat-DPOx11)pip (SI†, Figures S16 and S17). This minor population can be 
ascribed to chains grown by chain transfer reaction to the monomer. As for SEC traces of P(MeOx63-
stat-DPOx14)pip (SI†, Figure S18), the side population appearing in the high molecular weight region is 
presumably due to the occurrence of irreversible coupling of a small proportion of growing chains at the 
completion of the polymerization. Both side reactions have indeed been described, and related 
mechanisms are well established. 52–54 The three different polymerization reactions were run in parallel 
and only stopped after three days, i.e., once all the monomer was consumed. Total consumption of the 
monomer was confirmed only in one case, for P(MeOx93-stat-DPOx11)pip, and all the polymerizations 
were quenched at the same time. One can thus assume that the synthesis of the P(MeOx63-stat-
DPOx14)pip sample, that is of a lower DP, was completed, in contrast to the two other polymers of 
higher DP. As a consequence, the occurrence of chain coupling was more likely for the former 
copolymer. Furthermore, the probability for chain transfer increases with the polymer molecular weight. 
Herein, the P(MeOx41-stat-DPOx9)OH sample had a lower molecular weight as compared to the three 
other copolymers, which can explain why no such side reaction was evidenced for the former 
copolymer. However, despite the existence of these side populations, it was decided to carry on the 
study with these samples, as they should not be detrimental to the reactivity of aldehyde functionalities.  
A P(MeOx90-stat-DPOx10)pip copolymer was also prepared in a stainless steel reactor following the 
procedure reported by Hoogenboom et al. (i.e. 140 °C at a monomer concentration of 4M).55,56 Under 
these condition, the polymerization was completed within 1h, as compared to 3 days when conducting 
the copolymerization at 85 °C in a Schlenk flask. However, the copolymer had a higher dispersity, Ð = 
1.61 at 140 °C, as compared to 1.34 at 85 °C, hence this sample was not used further in this study. This 
increase in polydispersity is likely due to the increased reaction temperature (140 °C), monomer 
concentration and viscosity (the reaction was carried out above the boiling point of the solvent but the 
pressure was not monitored), leading altogether to a loss of control.  
Characterization by SEC in Tris buffer of the deprotected copolymers did not indicate any 
intermolecular aldolization in the investigated time scale (1, 3, 7 and 10 days after deprotection; see SI†), 
in contrast to the P(MeOx41-stat-DPOx9)OH sample showing significant tailing at high molecular weight, 
seven days after deprotection (see Figure 2). Four and a half months later, the deprotected copolymers 
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were no longer soluble in Tris buffer, presumably owing to intermolecular self-cross-linking of the 
samples under storage conditions.  
The influence of the aldehyde functionality content on the aldolization is illustrated in Figure 4 when 
comparing vials A and C (20% and 10% aldehyde, respectively). The influence of the end group 
functionality can be observed for copolymers with the same aldehyde content (vials B and C 
corresponding to samples with OH and piperidine end groups, respectively; see Figure 4). It can be seen 
that the copolymer with the alcohol terminus is more prone to self-cross-linking as compared to the 
sample with the piperidine end group. The sample combining a high content in aldehyde functions and an 
alcohol terminal group, P(MeOx41-stat-DPOx9)OH, led to rapid intermolecular self-cross-linking (see 
Figure 4).  
 
Figure 4 Solubility in Tris buffer, after 4 ½ months, of A) P(MeOx63-stat-DPOx14) pip B) P(MeOx124-stat-
DPOx12)OH C) P(MeOx93-stat-DPOx11)pip 
In conclusion, deprotected PDPOx-based copolymers can undergo branching by aldolization, the rate of 
which reaction depends on both the aldehyde and alcohol content. Prolonged reactions can lead to 
cross-linked networks. However, aldehyde-functional copolymers can be manipulated in solution and be 
used for further post-polymerization reactions even ten days after the deprotection step, without the 
occurrence of aldolization, in particular using the P(MeOx93-stat-DPOx11)pip sample.  
IV. HYDROGEL FORMATION BETWEEN P(MEOX93-STAT-OBOX11)PIP AND 
ADIPIC ACID DIHYDRAZIDE 
The synthesis of hydrogels was also achieved from the P(MeOx93-stat-OBOx11)pip copolymer precursor 
that was reacted with adipic acid dihydrazide as cross-linker. The first attempt was carried out in a 2% 
acetate solution, under the same aforementioned conditions employed for the reaction between 
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POBOx21 and adipic acid dihydrazide. Hydrogel formation was instantaneous, though subsequent cleavage 
of the hydrazone linkages constituting the cross-linking points was also immediate under slightly acidic 
aqueous conditions (pH = 5.4).49 This rapid cleavage was not observed when the reaction was carried 
out with POBOx21, within a time scale of investigation of one hour, most likely because of the higher 
percentage of aldehyde functionalities. Keeping these observations in mind, hydrogel formation 
successfully occurred in dry DMSO, in the presence of sodium acetate and molecular sieves (3Å) at 
room temperature, such conditions favoring the formation of hydrazone linkages. The as-obtained gel 
was found to be stable over several weeks and was shown to swell when soaked in DMSO (Figure 5). 
This gel could be readily cleaved, however, by hydrolysis when immersed in an aqueous solution, and the 
reaction rate could be tuned by adjusting the pH. As shown in Figure 5, in 10 mM phosphate buffer (pH 
= 7.4), the hydrogel was completely cleaved after 3 days, whereas it was readily cleaved within 3 minutes 
in acidic conditions (0.01 M HCl, pH = 3).  
 
Figure 5 Gel formation and cleavage between P(MeOx93-stat-OBOx11)pip and adipic acid dihydrazide 
V. TRANSACETALIZATION REACTION FROM P(MEOX41-STAT-DPOX9)OH 
WITH AN EXCESS OF PEG300 
Lastly, we investigated the possibility to directly modify the protected ketal-functional P(MeOx41-stat-
DPOx9)OH by an acid-catalyzed transacetalization reaction, using a large excess of PEG300 (see Scheme 
3). It is important to note that, under such conditions, PEG300 plays both the role of reactant and solvent. 
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Scheme 3 Transacetalization reaction from P(MeOx41-stat-DPOx9)OH with an excess of PEG300 and its 
schematic representation 
In order to shift the equilibrium towards the PEG-functionalized derivative, ethylene glycol supposedly 
generated as by-product was removed by distillation (boiling point =197 °C). The P(MeOx41-stat-
DPOx9)OH sample was directly dissolved in an excess of PEG300, in presence of p-toluene sulfonic acid 
(PTSA) as catalyst. The polymer was subsequently purified by dialysis to remove the excess of PEG300.  
Analysis of the resulting compound by DOSY-NMR confirmed the successful grafting of PEG chains onto 
the poly(2-oxazoline) backbone (SI†, Figure S19). These data also suggested that transacetalization 
seemingly occurred by an intramolecular reaction rather than by intermolecular reaction pathway, as 
only one diffusion coefficient was observed.  
The 1H NMR spectrum (Figure 6) not only showed that characteristic peaks of ethylene glycol decreased 
significantly while the peak due to the protons of PEG appeared, but a small proportion of free 
(deprotected) aldehyde was also present. From the peak integration, the number of PEG grafted chains 
and of protected DPOx units left over was estimated to be 10 PEG chains per poly(2-oxazoline)s chain, 
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with 1.3 DPOx and 0.2 deprotected aldehyde. Since the initial P(MeOx41-stat-DPOx9)OH contained 9 
ethylene glycol protecting groups per chain, which could theoretically lead to 18 PEG grafted chains for a 
complete modification, these results suggested that cyclic PEG-type grafts were likely formed by 
transacetalization (see Scheme 3). This might be due to the fact that cyclic acetals are thermodynamically 
more stable than non-cyclic ones, mainly for entropic reasons.  
 
Figure 6 1H NMR spectrum after transacetalization between P(MeOx41-stat-DPOx9)OH and PEG300 
Unfortunately, attempts to access hydrogels by intermolecular transacetalization reaction using 
substoichiometric amounts of PEG300 relatively to DPOx units were not successful. In contrast to the 
previous case, indeed, a co-solvent with a high boiling point was required because of the high solid 
content, in order to remove ethylene glycol as by-product. Use of a low molecular weight PEG 
dimethylether as co-solvent was unsuccessful due to solubility issues. Designing alternative monomers 
from protecting groups with lower boiling temperatures (e.g. dimethylacetal) might enable to achieve 
polyoxazoline-based hydrogels with PEG cross-linkers.  
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CONCLUSIONS 
This study illustrates the versatility of protected and non-protected aldehyde-functional (co)poly(2-
oxazoline)s for post-polymerization modification under mild conditions. A library of statistical 
copolymers derived from 2-methyl and 2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline could be synthesized 
to this aim, with different contents of protected aldehyde and different polymer chain ends. Aldehyde 
handles along the polyoxazoline chains were shown to readily react with antagonistic groups, including 
amines and hydrazines, the functionality of which can be varied to generate grafted or 3D–cross-linked 
polymer derivatives. For instance, chemoselective ligation of adipic acid dihydrazide onto a statistical 
copolymer containing 10% of aldehyde enabled the synthesis of pH-responsive hydrogels. As the 
chemistry used for cross-linking is selective, it could allow for the simultaneous encapsulation or 
entrapment of molecules, such as drugs and proteins during the cross-linking process. Moreover, one 
could expect that the release of the encapsulated molecules could be controlled by the pH. 
The aldehyde functional copolyoxazolines were also found to undergo an acid-catalyzed intermolecular 
self-aldolization, leading to branched structures and ultimately to cross-linked networks under forced 
conditions. The cross-linking process could be time controlled by adjusting the copolymer composition 
(i.e. the aldehyde function density and polymer end group).  
Last but not least, copolymers with pendant aldehydes protected in the form of ketal rings could be 
directly modified by transacetalization using a large excess of a PEG precursor, generating preferentially 
cyclic pendant loops rather than PEG brushes. 
The versatility of post-polymerization modification of aldehyde-based reactive platforms developed in 
this work, combined with the known properties of poly(2-oxazoline)s, thus expand the range of 
possibilities of this special class of polymeric materials.   
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EXPERIMENTAL SECTION 
Materials and reagents 
2-Methyl-2-oxazoline (99%), methyl trifluoromethanesulfonate (96%) (MeOTf), and acetonitrile (99%) 
were purchased from Sigma-Aldrich, stored over calcium hydride and purified by vacuum distillation 
prior to use. Methanol (Sigma-Aldrich) was refluxed with sodium and distilled prior to use. 
Dimethylsulfoxide (DMSO, from Sigma-Aldrich), dichloromethane (CH2Cl2, from Sigma-Aldrich) and 
tetrahydrofuran (THF,) were cryo-distilled prior to use. 2-(2-Bromoethyl)-1,3-dioxolane (Sigma-Aldrich) 
and piperidine (99%, from Acros) were distilled prior to use. Trifluoroacetic acid (99%) (TFA), diethyl 
ether, ethanol, potassium hydroxide (KOH), sodium hydroxide (NaOH), hydrochloric acid solution 
(37%) (HCl), cyclohexane (99%), p-toluene sulfonic acid (PTSA), sodium acetate and Jeffamine D400 
were used as received from Sigma-Aldrich. Butyl lithium solutions in hexane (1.6 M), chloroform, 
magnesium sulfate (MgSO4), sodium hydrogenocarbonate (NaHCO3), ethyl acetate, cyclohexane and 
triethylamine were used as received. Tetramethylethylene diamine (TMEDA, from Sigma-Aldrich) was 
stirred with KOH pellets for 2 h before distillation. PEG300 was purchased from Fluka and used as 
received. Benzylamine (98%), adipic acid dihydrazide (98%), PEG350 monomethyl ether, molecular sieves 
3Å (0.4-0.8 mm) and sodium cyanohydroborate (NaBH3CN) were used as received from Alfa Aesar. 
Instrumentation and measurements 
NMR spectroscopy. 1H NMR, 13C NMR and HSQC measurements were carried out at 298K on a 
Bruker Avance spectrometer operating at 400 MHz. CDCl3 was used as an internal reference (δ = 7.26 
ppm), and the relaxation time was fixed to 2 sec for all measurements.  
DOSY (Diffusion Ordered Spectroscopy) measurements were performed at 298K on a Bruker 
Avance III HD 400 spectrometer operating at 400.33 MHz and equipped with a 5 mm Bruker 
multinuclear z-gradient direct cryoprobe-head capable of producing gradients in the z-direction with 
strength 53.5 G/cm. The DOSY spectra were acquired with the ledbpgp2s pulse program from Bruker 
topspin software. The duration of the pulse gradients and the diffusion time were adjusted in order to 
obtain full attenuation of the signals at 95% of maximum gradient strength. The values were 2.5 ms for 
the duration of the gradient pulses and 150 ms for the diffusion time. The gradients strength was 
linearly incremented in 32 steps from 5% to 95% of the maximum gradient strength. A delay of 3 s 
between echoes was used. The data were processed using 8192 points in the F2 dimension and 64 points 
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in the F1 dimension with the Bruker topspin software. Field gradient calibration was accomplished at 25 
°C using the self-diffusion coefficient of H2O+D2O at 19.0 × 10-10 m2/s. 
13C CPMAS (cross polarization magic angle spinning) NMR measurements were carried out on a 9,4T 
spectrometer operating at 100.6 MHz and equipped with a CPMAS probe (impulsion at 90 °: 3.4 µs at 
59.6 W, 2 ms contact time, 3 s relaxation time, 35 ms acquisition time). 
Size-exclusion chromatography. Size-exclusion chromatography (SEC) using dimethylformamide 
(DMF) with LiBr (1 g/L) as the eluent was performed at 80 °C at a flow rate of 0.8 mL/min. The column 
set consisted of two 7.5 mm × 300 mm PLgel, 5 µm Mixed-D columns (Polymer laboratories) coupled to 
a 7.5 mm × 50 mm, PLgel, 5 µm guard column (Polymer laboratories). Injections were realized in a 20µL 
loop and calibration was performed with polystyrene standard. Differential refractive index (RI) and UV 
detectors were used. 
SEC was performed at 40 °C at a flow rate of 0.6 mL/min, using Tris buffer as the eluent. The column set 
consisted of two 8.0 mm × 300 mm columns, OHpak, 10 µm and 6 µm respectively (Shodex) coupled to 
a guard column, 6.0 mm × 500 mm, OHpak (Shodex). Injections were realized in a 20µL loop and 
calibration was performed with PEG standards from Polymer Laboratories. Differential refractive index 
(RI) and UV detectors were used. Ethylene glycol was used as a flow marker. 
Infrared spectroscopy. Infrared spectra were obtained from a Thermoscientific Nicolet IS10 
spectrometer using the attenuated total reflection (ATR) mode. The spectra were acquired using 16 
scans at a resolution of 4 wavenumbers. 
Experimental procedures 
Synthesis of 2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline (DPOx) 
2-[3-(1,3)-Dioxolan-2-ylpropyl]-2-oxazoline (DPOx) was synthesized following a procedure reported in 
the literature (Scheme 4).17 
 
Scheme 4 Synthesis of 2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline 
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In a flame-dried round bottom flask, under inert atmosphere, 8.2 mmol of TMEDA were dissolved in 
37.5 mL of dry THF and cooled to -78 °C. 7.8 mmol of a 1.6 M butyl lithium solution in hexane were 
added dropwise during 30 minutes, under strong stirring, with a syringe purged with nitrogen. The 
mixture turned yellow. The solution was stirred for 1 hour at –78 °C. 8.2 mmol of MeOx in 3.75 mL of 
dry THF was then added dropwise to the reaction mixture. After 2 hours of stirring at –78 °C, 6.9 mmol 
of 2-(2-bromoethyl)-1,3-dioxolane in 3.75 mL of dry THF was added slowly. The solution was allowed to 
re-equilibrate to room temperature under stirring overnight. 5 mL of methanol was added to quench the 
reaction by deactivating the butyl lithium. A color change from brownish to light yellow was observed at 
this point. The solvent was then removed under reduced pressure, and the oily yellow residue dissolved 
in a mixture of 25 mL of chloroform and 25 mL of a saturated NaHCO3 solution. The aqueous phase was 
extracted twice with 12.5 mL of chloroform. The organic phases were combined, dried over MgSO4 and 
concentrated under reduced pressure. The crude product was subsequently purified by column 
chromatography (silica, mobile phase: ethyl acetate/cyclohexane/triethylamine, ratio 10/5/1), and 
distillation. A colorless liquid is obtained, yield = 262 mg (49%). 1H NMR (CDCl3): δ (ppm) 4.8 (t, 1H, 
CH2CH(OR2)), 4.2 (t, 2H, NCH2CH2O), 4-3.75 (m, 6H, NCH2CH2O/OCH2CH2O), 2.35 (t, 2H, 
NOCCH2CH2), 1.75 (m, 4H, CH2CH2CH2CH). 13C NMR (CDCl3): δ (ppm) 169 (NOCCH2), 105 
(CH2CH(OR2)), 67 (NCH2CH2O), 64 (OCH2CH2O), 54 (NCH2CH2O), 33 (NOCCH2CH2), 27 
(CH2CH2CH2CH), 19 (CH2CH2CH2CH). NMR Spectrum given in Figure S1 
Synthesis of N-methyl-2-methyl-2-oxazolinium triflate (MeOxOTf) 
N-methyl-2-methyl-2-oxazolinium triflate (MeOxOTf) was synthesized following the procedure 
described by Kobayashi et al (Scheme 5).57 
 
Scheme 5 Synthesis of N-methyl-2-methyl-2-oxazolinium triflate 
2 mmol of MeOx in 400 µL of CH2Cl2 was put into a flame dried Schlenk flask and cooled in ice. 4 mmol 
of MeOTf was added dropwise to the reaction mixture. The mixture was then stirred for 2 hours at 
room temperature and a color changed from clear to dark red was observed. The product was collected 
by precipitation into cold diethyl ether and dried under vacuum. Yield = 404 mg (81%). 1H NMR 
(CDCl3): δ (ppm) 5 (t, 2H, NCH2CH2O), 4.3 (t, 2H, NCH2CH2O), 3.45 (s, 3H, NCH3), 2.5 (s, 3H, 
CNOCH3). NMR Spectrum given in Figure S2 
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Synthesis of poly(2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline) (PDPOx21). A typical procedure 
is as follows. In a flame dried Schlenk flask, 4.4 mL of acetonitrile was introduced under vacuum. 10.8 mg 
(0.043 mmol) of MeOxOTf and 200 mg (1.07 mmol) of DPOx were added. The flask was maintained at 
85 °C for 3 days, and the reaction was quenched by adding 2.7 equivalents of a 0.3N KOH solution in 
methanol. The solution was left to stir at room temperature overnight and the polymer was precipitated 
twice into diethyl ether and dried under vacuum. Yield = 95 mg (48 %). Ɖ = 1.17. DP = 21. 1H NMR 
(CDCl3): δ (ppm) 4.86 (s, CH2CH(OR)2), 3.95-3.8 (m, OCH2CH2O), 3.6-3.3 (s, NCH2CH2), 2.8 (d, CH3-
NCH2CH2), 2.4-2.1 (m, NCOCH2CH2), 1.7-1.4 (s, NCOCH2CH2CH2). 13C NMR (CDCl3): δ (ppm) 174-
172 (NCOCH2), 104.4 (CH2CH(OR2)), 65 (OCH2CH2O), 48-41 (NCH2CH2N), 34-32 
(NCOCH2CH2CH2CH), 20 (NCOCH2CH2CH2CH). IR: 3459 (w), 2947 (w), 2882 (w), 2767 (s), 1630 (m), 
1566 (s), 1450 (w), 1366 (s) 1256 (s), 1224 (s), 1132 (m), 1029 (m), 939 (m) cm-1. 
Synthesis of poly[(2-methyl-2-oxazoline)-co-(2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline)]: 
P(MeOx40-stat-DPOx10)OH, P(MeOx40-stat-DPOx10)pip, P(MeOx90-stat-DPOx10)OH, 
P(MeOx90-stat-DPOx10)pip. Synthesis of P(MeOx40-stat-DPOx10)OH: In a flame dried Schlenk flask, 
22.5 mL of acetonitrile was introduced under vacuum. 55 mg (0.22 mmol) of MeOxOTf, 407 mg (2.2 
mmol) of DPOx and 750 mg (8.8 mmol) of MeOx were added. The flask was heated at 85 °C for 3 days, 
and the reaction was quenched by adding 2.7 equivalents of a 0.3 N KOH solution in methanol. The 
solution was left to stir at room temperature overnight and the polymer was precipitated twice in 
diethyl ether and dried under vacuum. 1H NMR (CDCl3): δ (ppm) 4.86 (s, CH2CH(OR)2), 3.95-3.8 (m, 
OCH2CH2O), 3.6-3.3 (s, NCH2CH2), 2.8 (d, CH3-NCH2CH2), 2.4-2.1 (m, NCOCH2CH2), 2.2-2 (m, 
NCOCH3), 1.7-1.4 (s, NCOCH2CH2CH2). 13C NMR (CDCl3): δ (ppm) 174-173 (NCOCH2), 172-170 
(NCOCH3) 104.4 (CH2CH(OR2)), 65 (OCH2CH2O), 48-41 (NCH2CH2N), 34-32 (NCOCH2CH2CH2CH), 
20 (NCOCH2CH2CH2CH). 
P(MeOx40-stat-DPOx10)pip, P(MeOx90-stat-DPOx10)OH and P(MeOx90-stat-DPOx10)pip were synthesized 
following a similar procedure to that described above, using the respective [MeOx]0/[DPOx]0 ratio and 
termination agent (SI†). 
P(MeOx90-stat-DPOx10)pip was synthesized as follows in a stainless steel reactor at 140 °C. 1.55 mL of 
acetonitrile, 0.766 mg (9 mmol) of MeOx, 185 mg (1 mmol) of DPOx and 25 mg (0.1 mmmol) of 
MeOxOTf were added into the reactor, in the glovebox. The global monomer concentration was 4M. 
The reactor was then heated at 140 °C for 1 hour and cooled in an ice bath. 2.7 eq. of piperidine was 
added to quench the reaction. The solution was left to stir at room temperature overnight and the 
polymer was precipitated twice into diethyl ether and dried under vacuum. 
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Table 1 Characteristics of DPOx-based copolymers 
a) Initial monomer to initiator molar ratio 
b) Experimental degree of polymerization as determined by 1H NMR spectroscopy 
c) Dispersity index as determined by SEC in Tris buffer  
 
Deprotection of the aldehyde functionality: synthesis of poly[2-(4-oxobutyl)-2-oxazoline] 
(POBOx). Deprotection of aldehyde functions of (co)polymers based on DPOx was carried out under 
acidic conditions, following a procedure described by Taubmann et al. 17. In a typical experiment, 150 mg 
of PDPOx21 was dissolved in 4 mL of 5% aqueous TFA solution (v/v). The solution was transferred into a 
dialysis membrane (Cut-off 1000 g/mol) and dialyzed for 2–3 h against 400 mL of the same aqueous TFA 
solution. The polymer solution was then dialyzed twice against 2 L deionized water (2 h) until the pH 
returned to neutrality and lyophilised, yielding the following (co)polymers.  
POBOx21: Yield = 128 mg (86%). 1H NMR (CDCl3): δ (ppm) 9.7 (s, CH2CHO), 3.6-3.3 (s, NCH2CH2), 
2.8 (d, CH3-NCH2CH2), 2.4-2.1 (m, NCOCH2CH2CH2CHO), 1.7-1.4 (s, NCOCH2CH2CH2). 13C NMR 
(CDCl3): δ (ppm) 202 (CH2CHO), 174-173 (NCOCH2), 48-41 (NCH2CH2N/ NCOCH2CH2CH2CHO), 
34-32 (NCOCH2CH2CH2CHO), 18-15 (NCOCH2CH2CH2CHO). IR: 3400 (w), 2938 (m), 2731 (s), 1714 
(m), 1617 (m), 1418 (m), 1245 (s), 1166 (s), 1123 (s), 1067 (s), 981 (s) cm-1. 
For P(MeOx41-stat-OBOx9)OH: 1H NMR (CDCl3): δ (ppm) 9.7 (s, CH2CHO), 3.6-3.3 (s, NCH2CH2), 2.8 
(d, CH3-NCH2CH2), 2.5-2.1 (m, NCOCH2CH2 CH2CHO), 2.2-2 (m, NCOCH3), 1.9-1.6 (s, 
NCOCH2CH2CH2). 13C NMR (CDCl3): δ (ppm) 202 (CH2CHO), 174-173 (NCOCH2), 172-170 
(NCOCH3), 48-41 (NCH2CH2N/ NCOCH2CH2CH2CHO), 34-32 (NCOCH2CH2CH2CHO), 20 
(NCOCH3), 18-15 (NCOCH2CH2CH2CHO).  
𝐌𝐞𝐎𝐱 𝟎𝐈 𝟎  a) DPMeOxb) 𝐃𝐏𝐎𝐱 𝟎𝐌𝐞𝐎𝐓𝐟 𝟎  a) DPDPOxb) Yield (%) Ð c) T (°C) Termination agent Polymer 
40 41 10 9 91 1.14 85 Methanol 
KOH (0.3 N) 
P(MeOx41-stat-
DPOx9)OH 
40 63 10 14  1.28 85 Piperidine P(MeOx63-stat-
DPOx14)pip 
90 124 10 12  1.13 85 
Methanol 
KOH (0.3N) 
P(MeOx124-
stat-
DPOx12)OH 
90 93 10 11 80 1.34 85 Piperidine P(MeOx93-stat-
DPOx11)pip 
90 101 10 10  1.61 140 Piperidine P(MeOx101-
stat-
DPOx10)pip 
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Conjugation of POBOx with amino-containing reagents. A typical procedure is as follows. 5 mg 
of POBOx21 was dissolved in 1 mL of a 2% sodium acetate solution (pH = 5.6) overnight. 3 µL of 
benzylamine was added into the polymer solution, and the mixture was stirred for 1h at room 
temperature. 43 µL of sodium cyanohydroborate (10 eq. of a 20 mg/mL solution) was added, and the 
solution was freeze-dried, re-dispersed in a mixture of chloroform and acetonitrile (1/1) and precipitated 
into diethyl ether. The polymer was dried under vacuum. IR: 3408 (w), 3000 (s), 2934 (s) 1580 (m), 1407 
(m), 1248 (s), 1183 (s), 1043 (m), 1012 (m), 923 (m), 736 (s), 700 (s), 646 (m), 609 (m) cm-1.  
The same procedure was used for conjugation of adipic acid dihydrazide and Jeffamine D400 instead of 
benzylamine. 
IR - Adipic acid dihydrazide: 3420 (w), 3248 (w), 2938 m), 2865 (s), 1621 (m), 1556 (s), 1454 (m), 1421 
(m), 1367 (s), 1246 (s), 1175 (m), 1123 (s), 1057 (s), 935 (s) cm-1. 
IR - Jeffamine D400: 3305 (w), 2968 (w), 2929 (w), 2666 (w), 2322 (s), 1636 (m), 1449 (m), 1421 (m), 
1372 (m), 1344 (s), 1298 (s), 1246 (s), 1090 (w), 1017 (s), 923 (s) cm-1. 
Hydrogel formation from POBOx-based copolymers with the bis-hydrazido-containing 
cross-linker. 10 mg of P(MeOx93-stat-OBOx11)pip was dissolved in 50 µL of dry DMSO in the presence 
of molecular sieves (3Å). In a separate Schlenk flask, 10 mg of adipic acid dihydrazide was dissolved in 
100 µL of dry DMSO. 5 µL of a 50 mg/mL sodium acetate solution in dry methanol was added to the 
polymer solution. Adipic acid dihydrazide solution was added to the polymer solution, and formation of a 
hydrogel was immediately observed.  
Transacetalization reaction from protected PDPOx with an excess of PEG300.  In a Schlenk 
flask, 20 mg of P(MeOx41-stat-DPOx9)OH, 300 mg of PEG300 and 3.5 mg of p-toluene sulfonic acid 
(PTSA) were added. Once the mixture was homogeneous, it was heated to 100 °C over 6 hours, in a 
distillation setup. The mixture was dialyzed against water (3500 MW cut-off) for 3 days and lyophilized. 
1H NMR (CDCl3): δ (ppm) 9.7 (s, CH2CHO), 4.86 (s, CH2CH(OR)2), 3.95-3.8 (m, OCH2CH2O), 3.8-3.6 
(m, PEG), 3.6-3.3 (s, NCH2CH2), 2.8 (d, CH3-NCH2CH2), 2.4-2.1 (m, NCOCH2CH2, CH2CHO), 2.2-2 (m, 
NCOCH3), 1.7-1.4 (s, NCOCH2CH2CH2, CH2CH(PEG)2). 
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SUPPORTING INFORMATION  
 
Figure S1 1H and 13C NMR spectra (400 MHz, CDCl3) of 2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline (DPOx) 
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Figure S2 1H NMR spectrum (400 MHz, CDCl3) of N-methyl-2-methyl-2-oxazolinium triflate 
 
Figure S3 1H NMR spectrum (400 MHz, CDCl3) of poly(2-[3-(1,3)-dioxolan-2-ylpropyl]-2-oxazoline)21 (PDPOx21) 
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Figure S4 1H NMR spectrum (400 MHz, CDCl3) of PDPOx21 after deprotection (POBOx21) 
 
Figure S5 FTIR spectrum of PDPOx21  
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Figure S6 FTIR spectrum of POBOx21 
 
 
Figure S7 FTIR spectrum of POBOx21 after reaction with benzylamine 
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Figure S8 FTIR spectrum of POBOx21 after reaction with Jeffamine D400 
 
 
Figure S9 FTIR spectrum of POBOx21 after reaction with adipic acid dihydrazide 
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Figure S10 1H and 13C NMR spectra (400 MHz, CDCl3) of P(MeOx41-stat-DPOx9)OH 
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Figure S11 SEC trace of P(MeOx41-stat-DPOx9)OH in DMF 
 
 
Figure S12 1H NMR spectrum (400 MHz, CDCl3) of P(MeOx41-stat-DPOx9)OH after deprotection (P(MeOx41-
stat-OBOx9)OH) 
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Figure S13 1H NMR spectrum (400 MHz, CDCl3) of P(MeOx101-stat-DPOx10)pip 
 
Figure S14 1H NMR spectrum (400 MHz, CDCl3) of P(MeOx101-stat-OBOx10)pip 
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Figure S15 Solid 13C NMR spectrum of the self cross-linked P(MeOx40-stat-OBOx10)OH, rotation speed = 8000 
Hz, ns = 7000 
 
 
Figure S16 Evolution with time of the SEC traces in Tris buffer of P(MeOx124-stat-OBOx12)OH 
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Figure S17 Evolution with time of the SEC traces in Tris buffer of P(MeOx93-stat-OBOx11)pip 
 
Figure S18 Evolution with time of the SEC traces in Tris buffer of P(MeOx63-stat-OBOx14)pip 
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Figure S19 DOSY spectrum after transacetalization between P(MeOx41-stat-DPOx9)OH and PEG300 
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CHAPTER 5 
POLY(2-OXAZOLINE) BASED NANOGELS AS 
BIOCOMPATIBLE PSEUDO-POLYPEPTIDE 
DRUG DELIVERY SYSTEM 
 
 
 
 
Keywords:  nanogels, poly(2-oxazoline), cytotoxicity, protein repellent 
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Overview: Hydrophilic nanogels based on partially hydrolyzed poly(2-ethyl-2-oxazoline) were synthesized in 
dilute aqueous media in the presence of 1,6-hexanediol di-glycidyl ether as a cross-linker. Nanogel formation was 
monitored by DLS and HSQC NMR spectroscopy, and the final nano-objects were characterized by DLS, TEM, 
AFM and NanoSight analyses. Nanogels with a hydrodynamic radius of 78 nm exhibiting a slight positive surface 
charge were obtained. MTS assays (cell metabolic activity test) evidenced that the nanogels were non-toxic in the 
investigated concentration range (i.e. 0.1 to 400 µg/mL), and that no specific interaction with bovine serum 
albumin was observed. Altogether, such nanogels showed a great potential as drug delivery systems, as they 
combined some of the major properties required for this application, namely appropriate size and morphology, 
robustness and flexibility, slightly positively charged surface, no cytotoxicity and potential stealth behavior. 
Part of this chapter has been published in Biomacromolecules in 2014.12  
 
1 Legros, C.; Wirotius, A.; De Pauw-Gillet, M.-C.; Tam, K. C.; Taton, D.; Lecommandoux, S. Biomacromolecules 
2014, DOI: 10.1021/bm501393q. 
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INTRODUCTION 
Drug delivery nanotechnologies have been studied for several decades1 and only a few therapeutic nano-
carriers have been approved for clinical use by the FDA.2 These systems are currently commercialized, 
mainly for cancer therapy, most of them being based on liposomes3 or polymer-drug conjugates.4 
Nevertheless, these systems are still far from ideal drug delivery systems (DDS) and one of the 
remaining challenges is to create DDS with increasing targeting efficiency while decreasing therapeutic 
side effects.2 As a consequence, an array of alternative nano-carriers is currently being developed. They 
can be produced from a wide variety of materials including inorganic materials,5 lipids6 or polymers,7,8 
and load different cargos such as drugs, proteins, DNA, siRNA, or magnetic nanoparticles, to address 
specific requirements. A rational design of a DDS requires taking into account specific parameters 
including morphology, size, stability, degradability, surface chemistry, charge, stealth properties and 
stimuli-responsive behavior.7,9 By controlling the aforementioned parameters, it may be possible to 
achieve less toxic DDS with improved pharmacokinetic and targeting properties.  
Polymeric nanoparticles have a great potential in this area due to their versatility. A wide range of 
polymer-based nano-systems have thus been designed, such as self-assembled polymeric micelles and 
polymersomes,8,10,11 dendrimers,12 microgels9 and nanogels,13 their properties being tuned by the nature, 
composition and architecture of the (co)polymer used. For all these nano-structures, the biocompatible 
character of the polymer is crucial to ensure the safety of patients which somewhat restricts the 
polymers that may be used in clinics. Poly(ethylene glycol) (PEG), poly(N-isopropylacrylamide), 
polysaccharides and poly(amino acid)s are the most commonly used polymer building blocks in this 
application. The group of S. Lecommandoux (LCPO, Bordeaux) has been, in particular, very interested 
over the last years in the development of polypeptide-based nanocarriers, taking advantage of the 
biocompatibility and responsiveness properties of poly(amino acid)s.14 In addition, poly(2-oxazoline)s 
(POx) represent a special class of polymers of particular interest for a use in biomedical applications, and 
especially as DDS. Indeed, POx are often viewed as pseudo-polypeptides,15 as the chemical composition 
of both families of polymers is very similar, and do not display any degradation issue. Moreover, 
biological studies carried out on poly(2-ethyl-2-oxazoline) (PEtOx) have established the biocompatibility 
of this polymer,16 and its non-toxicity for systems with molecular weights up to 15 000 g/mol.17 PEtOx 
can be internalized by cells18 and does not accumulate in the body.19 It also exhibits a stealth behavior 
similar to that of PEG.20–23 As part of a DDS, PEtOx has already been conjugated to proteins, drugs, or 
has been grafted onto the surface of liposomes and formulated as part of self-assembled systems, such as 
polymeric micelles and polymersomes.24  Because of the intensive use of PEG, especially in the food 
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industry, some anti-PEG antibodies have been recently detected in the serum of patients who did not 
even receive any medical treatment based on PEG.25 As a consequence, researchers are currently 
seeking PEG substitutes, and PEtOx is regarded as an interesting alternative candidate.20,21,26 
Self-assembled DDS can eventually show a low stability toward dilution or change in the environmental 
conditions, especially if they have a rather high critical micellar concentration. To prevent the drug 
delivery vehicle from disintegrating in the blood stream, there is a need to produce structures with 
enhanced stability or robustness against environmental stimuli. In this context, nanogels are particularly 
relevant, as they are expected to maintain their structural integrity in biological conditions. A nanogel is 
defined by IUPAC as a soluble polymer network with a dimension lower than 100 nm.27 Nanogels are 
also highly hydrophilic, and in a biological environment, they swell and contain a high level of water/body 
fluid making them biocompatible.28 The soft structure of nanogels is another distinctive quality. 
Hendrickson et al. showed that, if a pressure close to that of the renal filtration is applied to nanogels, 
they can pass through pores more than ten times smaller than their size.29 
In this contribution, we report on the synthesis of nanogels derived from reactive poly(2-ethyl-2-
oxazoline) chains. The same synthetic strategy reported in chapter 2 is used. Secondary amine 
functionalities were first introduced into the polymer backbone by partial hydrolysis, and used to form a 
cross-linked network using a bis-glycidyl ether cross-linker in aqueous dilute media. This cross-linking 
reaction was monitored by DLS and HSQC NMR spectroscopy. Nanogels were fully characterized by 
multi-angle laser light scattering (MALLS), transmission electron microscopy (TEM), atomic force 
microscopy (AFM) and NanoSight analyses. Their cytotoxicity towards fibroblast-like L929 cells and their 
potential interaction with proteins present in human serum were also investigated.  
I. PETOX SYNTHESIS AND PARTIAL HYDROLYSIS 
The PEtOx precursor was synthesized by cationic ring opening polymerization, following a well-
established procedure (Scheme 1).30,31  
 
Scheme 1 Cationic ring opening polymerization of 2-ethyl-2-oxazoline followed by partial hydrolysis 
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Polymerization went to completion, leading to a polymer with a degree of polymerization (DP) of 100 
and a dispersity of 1.23 (SI†, Figures S1, S2 and S3). In order to introduce secondary amine functionalities 
along the polymer backbone, partial hydrolysis was conducted in acidic media.32 A percentage of 
hydrolysis of 26 % was achieved, as confirmed by 1H NMR analysis (SI†, Figures S4 and S6). SEC trace of 
the as-hydrolyzed statistical copolymer, denoted as P(EtOx74-stat-EI26), displayed a larger retention time 
compared to the non-hydrolyzed PEtOx precursor, presumably due to polymer interactions with the 
SEC columns, as already reported (SI†, Figure S5).33 
II. NANOGEL FORMATION IN AQUEOUS DILUTE MEDIA 
Nanogels were next obtained in aqueous dilute media, by reacting the secondary amines of the polymer 
backbone with 1,6-hexanediol di-glycidyl ether as a cross-linker, following a slightly modified procedure 
developed in our group (see Chapter 2).32 The number of reactive secondary amine functionalities 
available for cross-linking was indeed increased to 26 % (as compared to 7 % in our previous study), 
allowing the formation of denser nanogels. The molar ratio of reactive functionalities was kept constant, 
i.e. the amount of cross-linker was increased. Note that 3% of ethanol was added to the aqueous 
solution so as to improve the solubility of the cross-linker. Nanogel formation could be monitored by 
DLS, upon heating at 80 °C for 6 h. Higher concentrations in cross-linker led to a non-homogeneous 
reaction mixture, even in the presence of up to 6% of ethanol. Under such conditions, nanogel formation 
could not be monitored only by DLS because of the formation of nano-aggregates at the early stage of 
the reaction.  
However, DLS measurements performed on the reaction mixture after heating and stirring it at 80 °C 
for 6 h followed by purification by dialysis against ethanol and water, evidenced the formation of nano-
objects. It is worth mentioning that nanogels of small size do not scatter much light (small size and low 
compactness inherent to the nanogel structure itself), making their analysis challenging. In order to 
differentiate the small aggregates observed after mixing the reactants and the final nanogels, control 
experiments were monitored by DLS, changing one parameter at a time: in the absence of polymer, in 
the absence of cross-linker, and without heating (Table 1).  
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Table 1 DLS measurements confirming nanogel formation 
Reactiona) 
Before reaction  After dialysis 
Count rate 
[Kcps] 
PDI 
 
Size, d 
[nm] 
 Count rate 
[Kcps] 
PDI 
 
Size, d 
[nm] 
Nanogels 963 0.08 288  43 0.31 172 
No polymer 1151 0.08 139  3.5 0.47 - 
No cross-linker 15.5 0.8 3  8.8 0.54 3 
No heating 2296 0.09 377  10 0.39 156 
a) Size given as the average of three measurements 
 
These experiments showed that nano-aggregates were only observed at the early stage of the reaction 
when the cross-linker was introduced in the reaction medium. This confirmed that initial nano-objects 
corresponded to nano-aggregates arising from the presence of the cross-linker, due to its low solubility. 
In the absence of polymer and without heating, nano-aggregates were observed at the initial stage but 
not at the final stage of the reaction. In fact the final count rate was low, in the same range as that of the 
solvent. This suggested that ‘cross-linker nano-aggregates’ observed at the initial stage had a higher 
solubility at 80 °C than at room temperature and are no longer observed at the final stage. In the 
absence of cross-linker, no nano-objects were detected at the initial or final stage of the reaction, 
meaning that the polymer alone is fully soluble in the reaction mixture. Lastly, no nano-objects were 
observed when the polymer and cross-linker were mixed and left at room temperature, confirming that 
the final nano-objects observed when heated at 80 °C correspond to real cross-linking between the 
polymer and cross-linker.  
The nanogel formation was also monitored by HSQC NMR experiments. These experiments were 
carried out in an NMR tube in the appropriate mixture of D2O and deuterated ethanol (EtOD), at 80 
°C. HSQC measurements were recorded every hour (Figure 1 and SI†, Figures S7 and S8).  
Figure 1 shows the progressive disappearance of both signals of the NHCH2CH2 of the polymer 
backbone (signal e) and of the diglycidyl ether (signal f and g), along with the appearance of new signals 
that are characteristic of linkages formed between the P(EtOx74-stat-EI26) and the cross-linker (signal g’). 
Moreover, broadening of peaks in the 1H NMR spectra was observed with time, indicating an increase in 
sample inhomogeneities, which is consistent with nanogel formation. 
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Figure 1 HSQC NMR spectra of the nanogel formation a) T0, b) T6h at 80 °C 
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III. NANOGEL CHARACTERIZATION 
Nanogels were first characterized by multi-angle laser light scattering (MALLS). The variation of decay 
rate versus the squared scattering vector is shown in Figure 2. From the Stokes-Einstein equation and the 
translational coefficient obtained from the slope of the linear fit, the hydrodynamic radius was directly 
calculated. A hydrodynamic radius (RH) of 78 nm with a polydispersity of 0.3 was obtained. The 
formation of spherical nanostructures was also confirmed by TEM and AFM (Figure 2 and SI†, Figures S9 
and S10).  
 
Figure 2 Nanogel characterization. Top: DLS analysis; left: variation of decay rate versus squared scattering 
vector with linear fits; right: relaxation time plot obtained at 90°. Bottom, left: TEM micrograph. Bottom, right: 
Taping mode AFM image and section profile of the AFM imaging 
Optimized POx nanogels: towards a biocompatible drug delivery system 
 173 
By statistical analyses of the images, radii of 99 ± 37 nm and 43 ± 13 nm were obtained, respectively, by 
TEM and AFM. The size obtained by AFM analysis was significantly smaller than that obtained by MALLS 
and TEM. This is expected because, compared to TEM statistical analyses where more than 100 nanogels 
were taken into account, the number of nanogels present on the AFM mica surface was lower, leading to 
less reliable statistics. In addition, surface interactions and spreading/contractions of the nanogels 
strongly depend on the surface properties. Indeed, one can expect that the slightly positively charged 
nanogels (see further) interact significantly with the negatively charged mica surface, then resulting to a 
nanogel contraction. 
Nanogels previously reported in the first chapter were made from P(EtOx-stat-EI) with a percentage of 
hydrolysis of 7% and exhibited a RH of 205 nm by MALLS. By comparing these two systems, a decrease in 
nanogel size was noted with increasing number of reactive functionalities involved in the cross-linking 
process. In this contribution, denser and smaller nano-systems were formed. 
In view of using these nanogels as DDS, an optimum size should be in the range from 20 to 200 nm. 
Below 20 nm, indeed, nano-systems would be cleared by renal filtration or extravasion, whereas above 
200 nm clearance by opsonisation would occur.2,7 With a RH of 78 nm, our nanogels are in the expected 
range, and would be able to circulate for longer in the blood stream. Pharmaceutical carriers with a long 
longevity in the blood, tend to accumulate in pathological sites with affected and leaky vasculature via the 
enhanced vascular permeability and retention effect (EPR), leading to passive targeting of the cargo.2,34 
Such a behavior is aimed for our nanogels.  
Conductivity titration also proved that not all the amine functionalities were involved in the cross-linking 
process, since 12.8 % remained in solution, 13.2 % being involved in the cross-linking reaction (SI†, Figure 
S11). The zeta potential of the nanogel solution was measured at different pH values, from 3 to 10.5, and 
was always positive, varying from +44 mV to +6 mV (SI†, Figure S12). This could be linked to the 
protonation of the tertiary amines present in the structure and/or the free ethylene imine functions. If 
these extra ethylene imine functionalities were accessible, they could potentially be used to covalently 
attach a fluorescent dye molecule for further biological studies, such as cell internalization, or to 
functionalize the surface with a targeting ligand for active targeting, leading to the formation of “smart 
DDS”.35,36 They could also be used as a gene carrier, for DNA or siRNA binding, as already mentioned in 
the literature for cationic nanogels37,38 and for P(Ox-stat-EI) hydrogels.39,40 
Additional nanogel analyses were carried out with the NanoSight LM10 apparatus. This technique is 
based on an optical microscope allowing monitoring the particles movement in a cell of a known volume 
illuminated by a laser light source. Particles can thus be observed individually as they diffuse due to 
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Brownian motion. By tracking them, the number of particles present in the cell can be evaluated. 
Measurements were carried out at different concentrations within the linear range of the device. Above 
1×109 particles/mL, the measured number of particles/mL no longer varied linearly with the mass 
concentration. If the concentration is too low, there are not enough particles for accurate statistical 
measurements. The final number of particles/mL obtained in a solution at 4.7 mg/mL was 4.3×1010 
particles/mL. From these measurements, the approximate mass of a single nanogel and the number of 
polymer chains per nanogel could be evaluated (see Table 2). 
Table 2 Nanogel characteristics calculated from NanoSight results 
Cma) 
[mg/mL] 
Cnb) 
[particles/mL] 
mc) 
[g/nanogel] 
Npolymer 
chains/nanogel c) 
4.7 4.3×1010 1.09×10-13 7.8×106 
a) Concentration measured by solvent evaporation 
b) Concentration measured by the NanoSight LM10 apparatus 
c) Calculated from Cm and Cn, considering M = 8420 g/mol for one polymer chain 
 
Finally, no aggregation or increased polydispersity of particles was observed by DLS monitoring over 6 
months, indicating that our nanogels were colloidally stable when stored at 4 °C. 
IV. CYTOTOXICITY TEST AND EVALUATION OF NANOGEL-PROTEIN 
INTERACTIONS 
Nanogels produced from P(EtOx-stat-EI) contained remaining ethylene imine functionalities even after 
cross-linking with 1,6-hexanediol di-glycidyl ether, as determined by titration. Cytotoxicity of both 
PEtOx and poly(ethylene imine) (PEI) have already been reported in the literature: PEtOx is an amino-
acid analogue (= pseudo-polypeptides),15 and is thus expected to be biocompatible. PEtOx is already 
approved by the FDA as an indirect food contact agent (which was also the case for polyethylene glycol 
(PEG) before being approved for biomedical applications), and can now rival with commonly hydrophilic 
polymers used for drug delivery applications,23 especially PEG.20,22,41 Cytotoxicity of a library of poly(2-
oxazoline)s with different pendant chains has been recently evaluated: no cytotoxicity has been observed 
even at high concentration.16 Another study has shown that PEtOx, even up to 15 000 g/mol, is non-
cytotoxic.17 The potential cytotoxicity of PEtOx-drugs, proteins42,43 or enzyme conjugates44 or of nano-
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assembled systems, such as micelles45–47 or nanoparticles48 with one block made of PEtOx, has also been 
assessed and no cytotoxicity has been evidenced. 
The cytotoxicity of partially hydrolyzed PEtOx has been reported to increase with increasing percentage 
of hydrolysis, and PEI is also known to be cytotoxic,49–51 mainly because of its high positive charges. 
However, up to the percentage of hydrolysis of 9%, at a concentration up to 5 mg/mL, no cytotoxicity 
has been found.52 However, due to the positive zeta potential values at physiological pH (ζ = 15 mV) 
(SI†, Figure S12), cellular toxicity and some interactions with the immune system can be suspected. 
The cell proliferation and viability were assessed with our nanogels, using the MTS cell metabolic activity 
test. The fibroblast-like L929 cells were incubated for 72 hours (a time long enough to reveal any 
eventual toxicity exerted by the nanoparticles) with increasing nanogel concentration. Metabolic activity, 
directly related to cell viability, was measured by spectrophotometry via the reduction of MTS into the 
colored formazan product by active mitochondrial dehydrogenases. As can be seen on Figure 3, nanogels 
do not show any cytotoxicity to the L929 cells in the concentration range tested (from 0.1 to 400 
µg/mL).  
 
Figure 3 MTS assay conducted on mouse fibroblast-like L929 cells. 
In addition, even after 72 hours of incubation, the cells were nicely spread in the wells, and some were 
still going through mitosis (SI†, Figure S13). Hence, our synthesized nanogels did not exhibit any 
cytotoxicity despite their positive surface charge. These characteristics are particularly interesting 
considering previous reports claiming that nanoparticles smaller than 200 nm and with slight positive 
charge are preferentially accumulated and remain within tumor sites compared to neutral or negatively 
charged nanoparticles. 53 
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When administered in the blood stream, nanogels could interact with plasma proteins. Nanogel-proteins 
interactions strongly depend on nanogel surface characteristics (e.g. functionalities,54 hydrophobicity55 or 
charges).56 Herein, nanogels might interact with negatively charged serum proteins (such as albumin, the 
main protein of human blood plasma) or red blood cells, forming big aggregates. The aggregation 
behavior of cationic nanogels in serum has already been demonstrated elsewhere.57 In our case, nanogel 
stability study in serum via DLS measurement was not feasible, as the count rate of the nanogels alone 
was already low. Bovine serum albumin (BSA) was chosen as a model protein to study the interactions 
between plasma proteins and nanogels. BSA was incubated with the nanogels overnight, at different 
incubation concentration (IC, corresponds to the mass ratio BSA over nanogels) (75%, 50%, 25%, 12.5%, 
6.25% and 3.5%), and the potential interactions were assessed by gel retardation assay. BSA is negatively 
charged at physiological pH (IP = 4.95 mV, SI†, Figure S14) and could potentially create electrostatic 
interactions with nanogels. The gel electrophoresis was run for each IC and the intensities of the bands 
obtained were compared to the ones of BSA alone, at the same concentration. Nanogels being more 
than 10 times larger than the protein, they should remain in the well and not migrate on the gel, or in 
the worst case situation migrate more slowly than the free BSA. As can be seen in Figure 4, for each IC, 
the intensity of the bands for BSA and for nanogels incubated with BSA overnight was similar, suggesting 
there was no retardation in BSA mobility and that BSA did not significantly bind to the nanogels.  
 
Figure 4 Native gels run for BSA and nanogels-BSA mixture at different incubation concentrations 
This can be attributed to their stealth behavior, as reported in the literature for PEtOx,58,59 one of the 
gold parameters to achieve for a DDS. These results were corroborated with other POx involved 
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polymer brushes,60 bottle-brush brushes,61 capsules,62 hydrogels,63,64 or simply amphiphilic POx block 
copolymers65 which were reported as protein repellent systems. 
V. COMPLEMENT SYSTEM ACTIVATION 
V.1. MEASUREMENT PRINCIPLES 
If administered intravenously, DDS could be rapidly cleared from the blood stream by different ways: 
renal and hepatic clearance, destabilization, aggregation, opsonization and clearance by the mononuclear 
phagocytic system (MPS).7,66 MPS is a part of the immune system that consists of phagocytic cells, such as 
blood monocytes and macrophages accumulated in lymph nodes, spleen and other tissues.67,68 The 
biochemical cascade that removes pathogens is known as the complement system: it consists of 
numerous plasma and membrane-bound proteins, numbered at more than 50 in 2010.69–71 A number of 
complement proteins are proteases that are themselves activated by proteolytic cleavage and such 
enzymes are called zymogens. In the case of the complement system, the precursor zymogens are widely 
distributed throughout body fluids and tissues without adverse effect. At sites of infection, however, they 
are activated locally and trigger a series of potent inflammatory events. The complement system activates 
through a triggered-enzyme cascade. In such a cascade, an active complement enzyme generated by 
cleavage of its zymogen precursor then cleaves its substrate, another complement zymogen, to its active 
enzymatic form. This in turn cleaves and activates the next zymogen in the complement pathway. In this 
way, the activation of a small number of complement proteins at the start of the pathway is hugely 
amplified by each successive enzymatic reaction, resulting in the rapid generation of a disproportionately 
large complement response.72 
There are three pathways of complement activation: the classical pathway, which is initiated by antigen-
antibody complexes or by direct binding of complement component C1q to the pathogen surface; the 
MB-lectin pathway, which is triggered by mannan-binding lectin, a normal serum constituent that binds 
some encapsulated bacteria; and the alternative pathway, which is triggered directly on pathogen 
surfaces. The three main consequences of complement activation are opsonization of pathogens, the 
recruitment of inflammatory cells, and direct killing of pathogens.70–72 
The opsonization corresponds to the interaction/adsorption of plasma proteins (opsonins) onto the 
pathogen which signals it as a foreign material and will subsequently lead to its ingestion by macrophages 
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by phagocytosis. It is considered as the main barriers to nanoparticles stability and delivery in vivo, 
especially opsonization by the most abundant plasma proteins such as albumin, apolipoprotein, 
immunoglobulins, complement and fibrinogen.  
It was previously demonstrated in this work that BSA did not adsorb to our nanogels, but protein 
binding to the surface of nanoparticles does not only depend on particle surface characteristics, such as 
hydrophilicity, charge and surface functional groups,54,55,73 but also on the protein properties. In order to 
evaluate in depth the potential stealth properties of the nanogels, complement activation assay, one of 
the standard hemo-compatibility assay,69 was investigated. To do so, different methods could be 
used69,74,75 such as CH50 and APH50 hemolytic assays,76,77 2D-immuno electrophoresis,78 enzyme 
immunoassay (EIA) or liposome immunoassay (LIA).76 A comparative study between CH50, EIA and LIA 
showed good correlation between the three, but better sensitivity for EIA and LIA.76  
V.2. EIA AND LIA RESULTS 
EIA and LIA assays were run at the same nanogel concentration as for the cytotoxicity assay, to ensure 
their biocompatibility. For both methods, negative and positive controls were used. Poly(methyl 
methacrylate) (PMMA) nanoparticles were suspended in sterile PBS and used as a positive control as 
previously reported in the literature.79,80 As poly(ethylene glycol) (PEG) is often used as the gold 
standard for stealth properties, poly(ethylene glycol)-b-poly(lactic acid) (PEG-PLA) micelles were used as 
a negative control.75,81 Lastly, hyaluronan-b-poly(γ-benzyl-L-glutamate) (Hya-PBLG) micelles and discs 
were also used as negative controls as hyaluronan is known to not activate the complement system.82–84 
The efficacy of nanogels treatment was established by comparison with control levels.  
Before evaluating the complement activation of our samples by the EIA method, a calibration was run 
using standards with known activity. The intensity measured evolved linearly with the activity up to 400 
U/mL. 
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Figure 5 Results for complement activation by A) the EIA method, B) the LIA method 
As shown in Figure 5, a nanoparticle concentration of 0.1 µg/mL is too little to lead to any complement 
activation as all the nano-particles tested (i.e. nanogels, positive and negative controls) presented really 
low complement activation. On the other hand, at 400 µg/mL, a clear difference in activity was noticed 
between the positive (PMMA nanoparticles) and negative controls. Surprisingly, the complement activity 
measured in the presence of nanogels appeared to be comparable to that of the positive control. A 
relatively low activity was measured at a concentration of 100 µg/mL for the nanogels, but unfortunately 
no control experiments were run at this concentration. 
Concerning the LIA assay, regardless of which nanoparticle were tested and their concentration, the 
activation levels measured were close to the one of the serum alone and at the limit of the linear range 
(see Figure 5). Some measurements were run with another serum presenting a higher activity, but again 
the activities measured were equal to the activity of the serum tested without nanoparticles, which 
means that no complement activation was detected. The LIA technique is used routinely in hospitals to 
analyze patients’ sera, but doesn’t seem appropriate for our nanoparticles. The fact that liposomes are in 
the same size range as some of the nanoparticles tested could be part of the problem.  
Finally, the experiments on complement activation are not conclusive and further analyses are needed to 
get clear information. 
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V.3. DISCUSSION 
One of the most successful strategies to avoid interaction of nanoparticles with components of biological 
fluids is coating with a neutral hydrophilic flexible polymer to prevent adsorption of plasma proteins and 
avoid recognition by the MPS and subsequent clearance, PEG being the most commonly used polymer. 
The current increasing interest for poly(oxazoline)s, and especially for poly(2-methyl-2-oxazoline) and 
poly(2-ethyl-2-oxazoline), is mainly due to their reported stealth properties, similar to PEG.20–23  
In the present work, BSA appeared not to interact with or adsorb on the nanogels. This is in good 
agreement with the literature where interactions between human serum albumin and micelles with the 
outside shell made of PEtOx was reported to be really low65 and where PEtOx is even presented as a 
good candidate to design non-fouling surface coatings.60 On the other hand, at a concentration of 400 
µg/mL, nanogels seemed to activate the complement system from EIA method, even though no activation 
could be seen by the LIA method, in our hands. The fact that BSA did not adsorb on the nanogel surface 
but that nanogels activated the complement system could be perceived as contradictory. It is actually 
reported in the literature that when biomaterials enter in contact with body fluids such as serum, the 
serum proteins immediately adsorb and cover the surface of the biomaterial. The complement upon 
activation, first associate to the already adsorbed proteins on the surface of the biomaterial and the 
extent of covalent complement protein adsorbing directly to the biomaterials is minor.85,86 There is also 
competitive protein exchange on surfaces, in which proteins already adsorbed on a surface could be 
displaced by subsequently arriving proteins (also called the Vroman effect).87 That is to say that the 
adsorption of the complement protein should takes place after that of serum albumin and biomaterials 
that adsorbed much larger amounts of serum proteins are being thus strong activators of the 
complement system.88 
Even though our nanogels had no specific affinity for BSA, other serum proteins such as globulin or 
fibrinogen for example could have been adsorbed, which could explain the complement activation. 
On the other hand, we are also well aware that particle characteristics such as the size, surface charge, 
surface polarity and morphology influence their in vitro and in vivo fate.89 Herein, we compared activation 
level of particles with different morphologies (nanogels, micelles, discs, plain nanoparticles) and different 
sizes (from 27 nm to 210 nm) which could definitely influence the complement activation. 
One has to take into consideration that these results are preliminary: the BSA-nanogels interactions 
were evaluated by gel electrophoresis, which cannot be fully considered as a quantitative method. In 
addition, EIA complement activation assays were only run in duplicate at two different concentrations. 
Optimized POx nanogels: towards a biocompatible drug delivery system 
 181 
Complementary assays will have to be carried out before reaching final conclusions (additional 
concentrations run in triplicate). Moreover, there is substantial inter-individual variation in complement 
response to an activator. This necessitates the testing of multiple sera in order to evaluate the frequency 
of reactions and the extent of activation in reactive sera.69  
CONCLUSIONS 
Hydrophilic nanogels based on partially hydrolyzed poly(2-ethyl-2-oxazoline) were synthesized in 
aqueous dilute media, in the presence of 1,6-hexanediol di-glycidyl ether as the cross-linker. The nanogel 
formation could be precisely monitored by DLS and HSQC NMR spectroscopy, where the 
disappearance of signals corresponding to the reactive functionalities of the polymer and cross-linker 
together with the appearance of new signals characteristic of the new linkages confirmed the successful 
nanogel formation. 
The nanogels thus obtained exhibited a spherical structure with a hydrodynamic radius of 78 nm. 
Overall, the influence of the extent of hydrolysis on the final nanogel size was clearly demonstrated: the 
size decreased when increasing the extent of hydrolysis, that was, by increasing the percentage of 
reactive amino-functionalities reacting with the bis-epoxide cross-linker. The nanogel size was found to 
be within the optimal range for drug delivery system (DDS), with a view at taking advantage of the EPR 
effect in order to reach the targeted site. By further characterizing the nanogels using the NanoSight 
LM10 apparatus, it was possible to obtain the approximate mass of a single nanogel and the number of 
polymer chains per nanogel, which were found to be 1.09×10-13 g/mol and 7.8×106, respectively. 
In addition, the nanogel surface was positively charged, but did not induce any cytotoxicity, as attested by 
the MTS assay carried out on fibroblast-like L929 cells. Furthermore, no specific interactions with bovine 
serum albumin were observed. This was attributed to the stealth behavior of PEtOx. Last, the 
synthesized nanogels remained stable over at least a 6 months period, as monitored by DLS: the 
robustness of such systems will enhance their in vitro and in vivo stability. 
These nanogels thus have great potential as DDS, as they combine some of the crucial properties 
required: appropriate size and morphology, robustness and flexibility, slight positive surfaces charge 
without any cytotoxicity and with potential stealth behavior. However, some additional assays should be 
conducted before drawing any conclusion on the complement activation ability of these nanogels. Last, 
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these nanogels were synthesized by a straightforward and surfactant free-method, which can be easily 
scalable and transferred to clinical trials. 
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EXPERIMENTAL SECTION 
Materials and reagents 
2-Ethyl-2-oxazoline (99%) (EtOx), methyl trifluoromethanesulfonate (96%) (MeOTf), and acetonitrile 
(99%) were purchased from Sigma-Aldrich, stored over calcium hydride and purified by vacuum 
distillation prior to use. Methanol (Sigma-Aldrich) was refluxed over sodium and distilled prior to use. 
Diethyl ether, ethanol, potassium hydroxide (KOH), sodium hydroxide (NaOH), hydrochloric acid 
solution (37%) (HCl), cyclohexane (99%), 1,4-butanediol di-acrylate, bovine serum albumin (fraction V, 
approximately 99 %) (BSA) were used as received from Sigma-Aldrich. 1,6-Hexanediol di-glycidyl ether 
(98%) was purchased from BOC sciences and used as received.  
Instrumentation  
NMR spectroscopy. 1H NMR measurements were carried out, at room temperature, on a Bruker 
Avance I spectrometer operating at 400 MHz. The D2O signal was used as reference (δ = 4.79 ppm), and 
the relaxation time was fixed to 7.5 sec for all measurements.  
Phase sensitive HSQC experiment was used to acquire the 2D spectra giving DEPT type information in 
addition to the 1H-13C connectivity. This experiment was performed at 353 K on a Bruker Avance III HD 
NMR spectrometer operating at 400 MHz. The spectral widths were 4800 and 16000 Hz for the 1H and 
13C dimensions, respectively. The number of collected complex points was 2048 for the 1H dimension 
with a recycle delay of 2s. The number of transients was 4, and 256 time increments were always 
recorded in the 13C dimension. The 1JCH used was 145 Hz. Prior to Fourier transformation, the data 
matrices were zero filled to 1024 points in the 13C dimension. The D2O signal was used as the reference 
signal (δ = 4.25 ppm). Data processing was performed using Mnova. 
Size-exclusion chromatography. Size-exclusion chromatography (SEC) using dimethylformamide 
(DMF) with LiBr (1 g/L) as the eluent was performed at 80 °C at a flow rate of 0.8 mL/min. The column 
set consisted of two 7.5 mm × 300 mm PLgel, 5 µm Mixed-D columns (Polymer laboratories) coupled to 
a guard column, 7.5 mm × 50 mm, PLgel, 5 µm model (Polymer laboratories). Injections were done in a 
20 µL loop and calibration was performed with polystyrene standard. Differential refractive index (RI) 
and UV detectors were used. 
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Infrared spectroscopy. Infrared spectra were obtained on a Thermoscientific Nicolet IS10 
spectrometer using the attenuated total reflection (ATR) mode. The spectra were acquired using 16 
scans at a resolution of 4 wavenumbers. 
Dynamic light scattering. Dynamic light scattering experiments were performed using an ALV CGS-3 
Compact Goniometer System, equipped with a 35 mW HeNe linear polarized laser with a wavelength of 
632.8 nm and an ALV/LSE-5004 light scattering electronic and Multiple Tau Digital correlator. The 
accessible scattering angles ranged from 30° to 150°. Samples (2 mL in 2 cm diameter cylindrical glass 
cells) were immersed in a filtered toluene bath. Three independent 20s measurements were carried out 
to obtain dynamic data. Mean hydrodynamic diameters and size distributions were determined using a 
cumulant analysis method. The samples were first filtered with 0.8 µm nitrocellulose membranes. 
NanoSight analyses. NanoSight analyses were conducted on a LM10 apparatus. This technique 
combines a conventional optical microscope with a laser light source to illuminate nano-scale particles 
within a 0.3 mL sample introduced to the viewing unit with a disposable syringe. Particles appear 
individually as point-scatters moving due to Brownian motion. Measurements were done in triplicate, at 
room temperature, over a period of 60s. The particles size and concentration were evaluated thanks to 
the Nanoparticle Tracking Analysis (NTA) software.  
Transmission electron microscopy. Transmission Electron Microscopy (TEM) images were 
recorded at the Bordeaux Imaging Center (BIC) on a Hitachi H7650 microscope working at 80kV. 
Samples were prepared by spraying a 4.7 mg/mL aqueous solution of the nanogels onto a copper grid 
(200 mesh coated with carbon) using a homemade spray tool. They were subsequently stained with 
osmium tetraoxide vapor for 45 minutes. 
Atomic force microscopy. Atomic force microscopy (AFM) images were recorded in air using a 
Veeco Dimension Icon System equipped with a Nanoscope V controller and operating in tapping mode. 
The probes were commercially available silicon tips with a spring constant of 42 N/m, a resonance 
frequency of 285 kHz and a typical radius of curvature in the 8-10 nm range. Freshly cleaved Mica was 
used as sample substrate materials. For the observation of isolated nanogels, sample solutions in water at 
a concentration of 4.7 mg/mL were deposited on the substrate (20 µL) and immediately spin-coated 
(duration: 60 s; rate: 2000 rpm). Measurements of diameter were done using the section Particle 
Analysis tool provided by the AFM software (Nanoscope Analysis V1.20 from Bruker). 
Titration. Titration was performed with a pH 730 pH-meter from inOLab (WTW series) and a 
conductivity meter K912 5.0 from Consort for simultaneous measurement of pH and conductivity. All 
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measurements were performed at 25 °C while stirring at a medium speed 30 mL of nanogels solutions at 
0.8 g/L in DI water. The pH of the solutions was adjusted to ~2 by adding 0.5M HCl. The solution was 
titrated using 0.01M NaOH under stirring. Conductivity and pH of the solutions were measured 
simultaneously until the pH of the samples approached 11. Finally, the pH and conductivity values were 
plotted against the volume of NaOH added (in mL). 
Electrophoretic mobility measurements. Zeta potential measurements were performed on a 
Malvern Nano ZS ZetaSizer at 25 °C. Laser Doppler electrophoresis in phase mode was conducted with 
sequential fast and slow field reversal applying a potential of ± 150 V. The so-measured electrophoretic 
mobility (µ) was then converted to zeta potential (ζ) using the Smoluchowski approximation. Samples 
were prepared at 4.7 mg/mL in DI water. 0.01M HCl or 0.01M KCl solutions were added respectively to 
adjust the pH. 
Experimental procedures 
Synthesis of poly(2-ethyl-2-oxazoline) (PEtOx). A typical procedure is as follows. In a flame dried 
Schlenk flask, 14 mL of acetonitrile was introduced under vacuum and 56 µL (0.5 mmol) of MeOTf was 
added. The flask was placed in an ice bath at 0 °C and 5.05 mL (50 mmol) of 2-ethyl-2-oxazoline was 
added. The flask was then heated at 85 °C for 3 days, and the reaction was quenched by adding 2.7 
equivalents of a 0.3N KOH solution in methanol. The solution was left to stir at room temperature 
overnight, and the polymer was precipitated twice into diethyl ether and dried under vacuum. Yield = 
4.51 g (89 %). 1H NMR (400 MHz, D2O, δ): 3.7-3.45 (d, NCH2CH2), 3.1 (d, CH3-NCH2CH2), 2.5-2.3 (m, 
NCOCH2CH3), 1.15-1 (q, NCOCH2CH3). Ɖ = 1.23. dn/dc = 0.0789 (in DMF + 0.1% LiCl). Degree of 
polymerization (DP) = 100. IR: ν = 3481 (m), 2977(s), 2939 (s), 2880 (m), 1621 (s), 1470 (m), 1420 (s), 
1374 (s), 1320 (w), 1238 (m), 1194 (s), 1078 (w), 1061 (m), 969 (w), 915 (w), 877 (w), 814 (m), 756 (w), 
637 (s), 571 (s). 
Partial hydrolysis of PEtOx in acidic media: synthesis of P(EtOx-stat-EI). The partial hydrolysis 
was adapted from our previously reported procedure.32 3.54 g (3.57 10-4 mol) of P(EtOx)100 was 
dissolved in 35 mL of DI water and heated under reflux (oil-bath set at 100 °C). Subsequently, 35 mL of 
37 % HCl solution was added to the polymer solution, yielding a polymer concentration of 50 g/L. Once 
the targeted percentage of hydrolysis was achieved, the solution was left to equilibrate to room 
temperature. A solution of 2.5M NaOH was added to reach pH = 8. Samples were then dialyzed against 
DI water for 3 days and freeze-dried. Yield = 1.84 g (52%). 1H NMR (400 MHz, D2O, δ): 3.6-3.3 (d, 
NCOCH2CH2), 3.1 (d, CH3-NCH2CH2), 3.0-2.7 (s, NHCH2CH2), 2.5-2.3 (m, NCOCH2CH3), 1.15-1 (q, 
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NCOCH2CH3). Ɖ = 1.201. IR: ν = 3484 (m), 2977(s), 2939 (s), 2880 (m), 1621 (s), 1470 (m), 1420 (s), 
1374 (s), 1320 (w), 1236 (m), 1194 (s), 1078 (w), 1061 (m), 969 (w), 915 (w), 877 (w), 813 (m), 761 (w). 
Percentage hydrolysis: 1H NMR = 26 %. 
Nanogel synthesis in dilute media under sterile conditions. 1.35 g of the partially hydrolyzed 
polymer P(EtOx74-stat-EI26) was dissolved in 135 mL of DI water. In another flask, a solution of 1,6-
hexanediol di-glycidyl ether at 80 mg/mL was prepared in ethanol. Both solutions were filtered through a 
0.2 µm polypropylene filter and 8.37 mL of the cross-linker in ethanol was subsequently added to the 
polymer solution. The mixture was stirred at 800 rpm at 80 °C for 6 hours. The cross-linking reaction 
and nanogel formation were monitored by DLS at an angle of 90° on a Malvern ZetaSizer NanoZS 
instrument. Once the nanogels were formed, they were dialyzed for 2 days first against ethanol to 
sterilize the nanogel solution and to remove excess cross-linker, secondly against DI water to remove 
any unreacted polymer chains. 229 mL of the nanogel aqueous solution was obtained at a concentration 
of 4.7 mg/mL. 
Cell culture and cell cytotoxicity assay against fibroblast-like L929 cells. The mouse fibroblast-
like L929 cells were routinely cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Lonza) 
supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, United States), 1% of 
antibiotics (penicillin/streptomycin 10 000 U/ 10 000 µg/ml, Lonza), 1% sodium pyruvate and 1% 
Glutamax (Gibco). Cells were maintained at 37 °C in a 5% CO2 humidified incubator. After rinsing with 
PBS (Ca2+/Mg2+ free, Lonza) buffer solution to remove the serum, the cells were detached with 0.5% 
Trypsin-EDTA solution 10 × (Gibco, Grand Island, NY, United States) diluted 10 fold in PBS (Ca2+/Mg2+ 
free) buffer solution. 
For cytotoxicity measurements, the cells were first seeded in 96-well plates at a density of 2000 
cells/well and grown in DMEM complete medium for 24 h prior to treatment. Cells were then exposed 
to the nanogels in a mixture of 10% PBS buffer solution (pH = 7.4, 154 mM NaCl, Ca2+/Mg2+ free) and 
90% DMEM complete medium with different concentrations (100, 10, 1, 0.1, 0.01 µg/mL) for 72 h. After 
72 h, the cells were rinsed with PBS (with Ca2+/Mg2+, Lonza) buffer solution (100 µL/well), and cell 
viability was evaluated via the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) solution (Promega) assay. Specifically, 20 µL of MTS and 100 µL of PBS 
(with Ca2+/Mg2+) buffer solution were added to each well, and then the plates were incubated at 37 °C 
for 30 min. The absorbance at 490 nm was measured using a Power wave X (Biotek instrument Inc.) 
micro-plate UV-vis spectrometer. For the positive control, cells were incubated with the media alone. 
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Results were expressed as the percentage of metabolic activity of treated cells relative to untreated cells. 
Independent experiments were carried out 3 times with 8 replicates per condition. 
Nanogel-protein interaction evaluation by gel retardation assay. The native polyacrylamide gel 
electrophoresis was performed according to the Laemmli procedure.90 BSA proteins were left to 
incubate with a 4 mg/mL nanogel solution in phosphate buffer, 10 mM, pH = 7.4, at different incubation 
concentrations (IC), overnight. The incubation concentration corresponding to the mass ratio of BSA 
over nanogels. The next morning, the nanogel-BSA solutions were mixed with 6 µL of loading buffer to 
achieve a final BSA content of 5 µg in each well (for the IC of 3.5%, only 2.8 µg were put in the well). 
The mixtures were loaded on a 7.5 % tris-acrylamide gel. Euromedex pre-stained protein ladder was 
used as reference. The gel run was performed in a Mini-Protean tetracell system from Bio-Rad. The run 
in the stacking gel was carried out with a constant voltage of 100 V. After the bromophenol blue band 
attained the resolving gel, the voltage was changed to 200 V. Staining was achieved by shaking the gel 
overnight in a solution of coomassie brilliant blue R-250. Destaining was performed in a solution of 40% 
ethanol and 10% glacial acetic acid.91 
Complement system activation - Samples preparation. To measure complement activation in 
vitro, we determined nanogel-induced rise of human serum complement activation products using 
respective ELISA kits or LIA immunoassay. First, sterile nanogels aqueous solution was diluted with PBS 
10× (purchased from Lonza) in order to obtain the desired concentrations (4000, 1000 and 1 µg/mL). 
The reaction was initiated by diluting the previous nanogel solutions with undiluted fresh human serum 
(Serum from human male AB plasma, USA origin, sterile-filtered purchased from Sigma-Aldrich), at a 
typical nanoparticles/serum volume ratio of 1/9, in Eppendorf tubes (in duplicate). Solutions were 
incubated at 37 °C for 1 h.  
Control nanoparticles were synthesized following procedures described in the literature, reported in 
Table 1. Control serum incubations contained PBS (the same volume as the nanogels) for assessing 
background levels of complement activation products. The efficacy of nanogels treatment was established 
by comparison with control levels.  
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Table 3 Characteristics of the control nanoparticles used for the complement system activation assay 
Control Particles Size (PDI) 
[nm] 
Ref 
+ PMMA 210 (0.12) 79 
- PEG-PLA micelles 27 92,93 
- Hya-PBLG micelles 40 (0.2) 94,95 
- Hya-PBLG discs 211 (0.13) 94,95 
 
Enzyme  immunoassay (EIA) principle. Measurements were carried out using the human total 50% 
complement hemolytic unit (CH50) ELISA kit from BlueGene. CH50 ELISA kit applies the quantitative 
sandwich enzyme immunoassay technique (see Figure 6). A microtiter plate had been pre-coated with a 
monoclonal antibody specific for complement activation (CA). Standards or samples were then added to 
the plate wells and complement if activated, would bind to the antibody pre-coated wells. In order to 
quantitatively determine the amount of CA present in the sample, a standardized preparation of 
horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for CA were added to each well 
to “sandwich” the complement immobilized on the plate. The microtiter plate was incubated, and then 
the wells were thoroughly washed to remove all unbound components. Next, substrate solutions were 
added to each well. The enzyme (HRP) and substrate were allowed to react over a short incubation 
period. Only the wells that contain complement activated and enzyme-conjugated antibody would exhibit 
a change in color. The enzyme-substrate reaction was terminated by addition of a sulphuric acid solution 
and the color change was measured spectrophotometrically at a wavelength of 450 nm. A standard curve 
was plotted relating the intensity of the color (O.D.) to the concentration of standards. The CA 
concentration in each sample was interpolated from this standard curve. The experimental data are the 
average of two independent experiments and measurement sensitivity is of 1 U/mL. 
 
Figure 6 Enzyme immunoassay (EIA) principle (adapted from ref. 96) 
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Liposome immunoassay (LIA) principle.97 Measurements were made at the Hospital CHR Citadelle 
in Liège, Belgium, in the medical analysis laboratory Labo Cita, using a Wako AutoKit CH50. 
Dinitrophenyl (DNP)-coated liposomes that contain the enzyme glucose-6-phosphate dehydrogenase 
was used (see Figure 7). When a sample is mixed with the reagent, the complement in the sample is 
activated by the antigen-antibody complex on the liposomes. The activated complement breaks the 
membrane of the liposome. The enzyme glucose-6-phosphate dehydrogenase (G6PDH) contained in the 
liposome reacts with nicotinamide adenine dinucleotide (NAD) and glucose-6-phosphate (G6P) in the 
reagent. During this enzyme reaction the NAD is reduced to NADH and an increase in absorbance at 
340 nm is observed. The absorbance increase is proportional to the total complement activity in the 
sample. The experimental data are the average of two independent experiments. The measurable range 
is from 10 to 60 U/mL and the sensitivity is 4 U/mL. 
 
Figure 7 Principle of the LIA assay (adapted from ref. 97) 
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SUPPORTING INFORMATION  
 
Figure S1 1H NMR spectrum (400 MHz, D2O) of PEtOx100 
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Figure S2 SEC trace of PEtOx100 in DMF 
 
 
Figure S3 FT-IR spectrum of PEtOx100 
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Figure S4 1H NMR spectrum (400 MHz, D2O) of P(EtOx74-stat-EI26) 
 
 
Figure S5 SEC trace of P(EtOx74-stat-EI26) in DMF 
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Figure S6 FT-IR spectrum of P(EtOx74-stat-EI26) 
 
Figure S7 HSQC NMR spectrum of nanogel formation after 2 h at 80 °C 
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Figure S8 HSQC NMR spectrum of nanogel formation after 5 h at 80 °C 
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Figure S9 TEM micrograph of nanogels with size measurements 
 
 
Figure S10 Statistical distributions of TEM particle hydrodynamic radii 
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Figure S11 Titration of the secondary amine by pH-metry and conductivity measurements 
 
Figure S12 Variation of the zeta potential of nanogels with pH 
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Figure S13 Images obtained on inverted IX81 microscope of fibroblast-like L929 cells after 72 h exposure to 
nanogel solutions 
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Figure S14 Measurement of isoelectric point of BSA by zetamety 
 
Table S1 NanoSight measurements on the nanogel solution, c = 4.7 mg/mL 
Dilution 
factor 
Cn measureda) 
[particles/mL] 
Cn calculatedb) 
[particles/mL] 
Measurement 
error min 
Measurement 
error max 
Comment 
10 2.25E+09 2.25E+10 1.91E+10 2.59E+10 Over concentrated 
50 6.23E+08 3.12E+10 2.65E+10 3.58E+10 Linear range 
100 4.30E+08 4.30E+10 3.66E+10 4.95E+10 Linear range 
1000 2.63E+08 2.63E+11 2.24E+11 3.03E+11 Not enough 
particles  
10000 1.03E+08 1.03E+12 8.73E+11 1.18E+12 Not enough 
particles  
a) Concentration measured by the NanoSight apparatus 
b) Concentration in the initial nanogel solutions calculated from Cn measured and the dilution factor 
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Appendix S1 - AFM procedure 
The distinct spread of particles onto the mica surface allowed the analysis of section dimensions. This 
spreading can be modelled as a disc-like structure. The radius of nanogels (RAFM) can then be estimated 
from the dimensions of the observed discs (diameter D radius R and height h), assuming that the volume 
of the discs (V) is equal to the volume of spherical nanogels (VAFM): 
Volume of spherical nanogels: 𝑉!"# = !!𝜋  𝑅!"#!  
Volume of disc: 𝑉 = 𝜋𝑅!ℎ 
Assuming V= VAFM, we obtained: 𝑅!"# = !!𝑅!ℎ !/! 
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